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The accession of Spain and Portugal to membership of the 
European Community in January 1985 not only brought new vitality to the 
European initiative, but served as a powerful reminder of the broader 
dimensions of the Spanish – and Portuguese-speaking worlds. A 
reinforcement of Europe’s natural and historical internationalism of 
outlook was particularly relevant in the context of biotechnology; for the 
sophisticated multi-disciplinary scientific base, and the several broad 
application areas, force on biotechnology an internationalism both for 
access to scientific capability, and for access to worldwide markets. 
Such was the rationale for SOBELA’: a Seminar on Biotechnology in 
Europe and Latin America’, which in April 1987 brought some 50 Latin 
American entrepreneurs, policy-makers and academic leaders to Europe and 
to Brussels. At the Commission’s Borschette Conference Centre, they heard 
presentations from eleven of the Community Member States, each 
emphasising its strengths in biotechnology and its interest in promoting 
industrial collaboration with firms in Latin America. 
The seminar was opened by speeches from Vice-President Karl-
Heinz Narjes on behalf of the Commission, and by His Excellency Luis 
Ramiro Alfonsin of Argentina, senior Latin American diplomat in Brussels. 
In the closing session, Directors-General Paolo Fasella (Science, Research 
and Development, DG XII) and Jean Durieux (External Relations, DG I) 
welcomed Their Excellencies the ambassadors from Argentina, Mexico, 
Brazil, Uruguay and Colombia.  
The conference itself was preceded and followed by visits to the leading 
centers in the various Member States. The fruits of these exchanges were 
shown through more than a hundred proposals for industrial collaboration 
which resulted, many of them now converted into ongoing relationships. The 
Commission through its Directorate-General for External Relations is 
continuing to promote such collaboration, helping firms in each continent to 
find useful partners for trade, investment, technical collaboration or marketing. 
The materials presented at the conference have been updated and 
edited, to give in this book an up-to-date picture of capabilities and common 
 
IV 
interests. Although inevitably any book on biotechnology is obsolete by the 
time it appears, there is nothing obsolescent about the dynamism now being 
displayed in the development of the bioindustries in both continents. We hope 
that the presentations assembled in this volume will testify to this dynamic 










Draft text of a speech by Vice-President Karl-Heinz Narjes, on 27 April 
1987, at the opening session of the ‘Seminar on Biotechnology in Europe 
and Latin America’, Conference Centre Albert Borschette, Brussels. 
Your Excellency, Mr. Chairman, Ladies and Gentlemen, 
It gives me great pleasure to welcome, on behalf of the Commission, 
the many distinguished visitors who have kindly accepted our invitation to 
this international gathering. There are present, representatives of some 
twenty different nations; but let me emphasise not our diversity, but our 
common interests. The European Community and its Member States have 
worked together to organise this seminar, and to offer to our guests from 
Latin America our hospitality; our friendship; our ideas; and our hopes for 
continuing and mutually beneficial collaboration. 
The subject on which our common interests will be focussed during 
this three-day seminar is biotechnology. Much can be said, much will be said, 
during these three busy days; but even if we talk all day, we shall not exhaust 
the range of topics covered by this broad subject. I speak with some 
confidence on this; the Commission has been talking about biotechnology, 
and developing its policies, for over ten years; some of our Member States for 
much longer. Whether we adopt a narrow or a broad definition, we have to 
recognise that ultimately the biological revolutions in progress will influence 
or transform every field of application of the life sciences – including 
agriculture and forestry, health care and pharmaceuticals, organic waste and 
water recycling, and the care of the environment. 
Initially, we saw biotechnology mainly as a research matter. Our first 
programme, the biomolecular engineering programme, ran from nineteen 
eighty-two to nineteen eighty-six, and was limited to the agriculture and agro-
food fields. It sought to remove obstacles to the transfer into practice of the 
advances in biological research. It was successful not only in scientific terms, 
but in catalysing trans-frontier collaboration within our community, through 
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transnational cooperation in research, and through training grants for 
researchers moving to laboratories outside their home country. 
Our current biotechnology research action programme runs until 
nineteen eighty-nine. It covers a wider range of subjects, including topics of 
importance to all the bioindustries, both in research, and in improving the 
infrastructure for research. We expect to expand the programme further in 
the near future. You will probably hear more about these activities during 
the course of the seminar. 
I should mention also that the breadth of biotechnology inevitably 
involves several other research areas, such as our agricultural research, our 
medical research, and (of particular relevance to this seminar), our 
programmes of science and technology for development. The first of these 
programmes concerned tropical agriculture, health and nutrition. It ended in 
December 1986; and we hope shortly to finalise a substantially larger effort 
in the same areas, including a greater involvement of laboratories in 
developing countries. 
We also plan a major new biotechnology-based initiative to 
stimulate innovative developments at the interfaces between industry and 
agriculture. The industrialist, the farmer and the scientist must work 
together to demonstrate and develop these innovations. This programme 
will seek to develop: 
 New crops, better adapted to market needs in both food and non-
food applications; 
 New processes for cultivating and harvesting crops, for splitting 
them into their constituent elements, and for transforming these 
into higher value products; 
 New approaches to the control of pests and diseases, and to the 
control of nutrition and metabolism in plants and animals. In this 
or in other programmes, we shall be continuing research on the 
assessment and management of any related risks. 
But our policies for biotechnology in Europe go beyond research. 
They interact with our plans for agricultural and industrial development, 
for safeguarding the environment, and for developing harmonised 
regulatory regimes in the Common Market. They include matters 
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ranging from price regimes for raw materials, to refinements of the laws 
on patents and on plant variety protection. 
In the context of this seminar, I want to emphasise the international, 
indeed the global, dimensions of biotechnology. The techniques, products 
and services of biotechnology are of central importance to countries rich 
or poor, at every stage or their economic development. Here in Europe, 
we believe we have major strengths and capabilities in biotechnology, and 
we want to talk about these with you during the coming days. We are also 
sure that we can learn from your experiences in your various countries. I 
recognise that we shall have some differences of opinion – that makes it 
all the more necessary to continue our dialogue, on occasions such as this, 
and to understand the basis for our differences. But above all, we believe 
that we have a common interest in learning together how to develop and 
use biotechnology for your needs and ours, whether we speak of social 
needs for health care and basic nutrition, or needs for commercial and 
competitive developments. 
Let me cite some practical examples. There is much fashionable 
talk about the hypothetical risks of biotechnology. When we talk about the 
needs for better vaccines, diagnostics and therapies, we are not talking 
hypothetically, but about real, current and continuing disasters; about 
hundreds of thousands of people round the world dying daily, to-day and 
every day, from avoidable causes, from starvation and preventable 
disease. We have the technology to produce the food; we have vaccines 
and therapies for many of the diseases that are still killing people. 
Through the methods of biotechnology, we have good prospects for 
developing vaccines against major diseases not yet curable, for example 
through our new ability to study the constituent parts of viruses, and to 
manufacture in large quantities and high purity their antigenic proteins. 
The development of monoclonal antibodies is providing precise and 
effective diagnostic tools, and the basis for delivering drugs to precisely 
targetted cells in the body. Such technologies are essential in the 
continuing battle against parasitic diseases such as Chagas’ or to combat 
the continuing and ever-changing challenges of malaria. They are equally 
needed to confront novel challenges such as the AIDS virus. The major 
risk to be avoided is the risk of unnecessary delay. 
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Concern is sometimes expressed about the impact of biotechnology 
on the environment. Around the world, some two hundred million people 
are engaged in ‘slash and burn’ agriculture. Of course, they are driven by 
their local necessities; but by their actions, they are destroying the 
remaining areas of tropical forest, with a loss of species estimated at several 
hundred per day. We are likely to lose half of all current species within 
twenty years; it is an environmental catastrophe, a species extinction of a 
magnitude unparalleled since the death of the dinosaurs. It is not 
hypothetical; it is happening now. Yet biotechnology can offer the means to 
feed the world’s whole population more than adequately, using far less land 
than we cultivate today. Further major gains in agricultural productivity are 
now seen to be possible. By pursuing these, we should be able to take the 
pressure off the environmentally sensitive areas, such as the uplands and the 
wetlands, the unique ecological habitats. We should be able to defend our 
forest, be it in temperate or in tropical zones, and restore our environment, 
replanting appropriate species in degraded areas such as, here in Europe, 
parts of our Mediterranean littoral. 
I do not want to be simplistic about the practical difficulties which 
inhibit the application of the new technologies to the problems of health care, 
agriculture and environment. The political and economic difficulties are often 
greater than those of science and technology. And above all, the application 
of new science demands adaptation to local conditions, and integration with 
local knowledge. Therefore collaboration and dialogue are essential, and our 
joint learning will inevitably have to proceed through trial and error. 
To put biotechnology to work requires men of action, bringing 
together managerial abilities, local knowledge, capital and science, and 
there must be a functioning system of trade. The successful application of 
biotechnology depends on appropriate exchanges, not only of the ideas and 
results of R&D, but also of the capital investment and trade in goods and 
services which follow from the success of such research. There is no 
alternative to progress in the liberalisation of world trade. The policy of the 
European Community, which is the largest trading bloc in the world, is to 
work seriously for the improvement of the current conditions of world 
trade, through the GATT framework. For we know, not least from our own 
experience within Europe, from Germany’s Zoll Verein in the nineteenth 
century to our community of to-day, that trade is a ‘non-zero-sum’ game, in 
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which all players can win. But this policy has to be accompanied by 
adequate measures in the same direction by the other important trading 
countries. We are happy to see the corresponding bilateral and multi-lateral 
agreements developing between countries within Latin America, and 
between Latin America and Europe. These developments provide the 
context within which biotechnology can thrive, encouraged by the prospect 
of global market opportunities, and driven by the social and economic 
needs to which biotechnology is relevant. 
A subject which must raise, in connection with world trading 
conditions, is that of intellectual property. As our world economy evolves 
more and more towards knowledge-based industries, an effective 
international system of respect for intellectual property is increasingly 
essential. It is a mistake to see patents or plant variety rights as systems 
defending the rich against the poor. Many biotechnology innovations may 
be realised by small enterprises. In order to encourage innovation, it is 
essential to provide adequate protection; and such protection facilitates 
technology transfer, where secrecy would inhibit it. As our biological 
science advances, the principles of protection for innovation are just as 
applicable to plants, foods and medicines as they have been to electrical or 
mechanical devices. 
We understand the strong desire of developing countries – indeed, of 
all countries – to have effective control of science and technology. But if 
we wish to enjoy the full benefits of science and technology, activities 
which are as international in their sources as in their applications, then we 
have to accept the fact of growing international exchanges. Recent 
historical experiences show that escape from economic and technological 
dependence is not through isolationism, but by increasing participation 
through new creative models of involvement of worldwide developments 
and consequent interdependence. The need again is to work together to 
define fair conditions for such interdependence. 
The scientists have delivered the goods, in terms of basic advances in 
understanding and techniques. In Europe, we have recognised their 
importance in the amendments to the treaty which are coming into effect: 
the Single Europe Act gives an explicit legal base for our science, 
technology and development activities. We have been debating with our 
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Member States the final details of our overall R&D programme, in which 
biotechnology is a major element. 
So if science and politics are playing their part well, they provide to 
the businessmen, the entrepreneurs, the means and the possibilities for 
innovation, investment and hence economic development. I hope that many 
contacts will be made at this seminar, and that seeds of awareness will be 
sown in these three days and in your visits to our Member States. We 
must develop greater awareness of one another’s needs and capabilities, 
and hence build co-operative and continuing relationships, which will 
help us to develop and to share our advances in biotechnology and to 





Remarks by Ms. Phili Viehoff, Member of the European Parliament and 
Rapporteur on Biotechnology for the Committee on Energy, Research and 
Technology, at the opening of the second day’s proceedings, Tuesday 28 
April 1987. 
Ladies and Gentlemen, 
Developments in biotechnology have been looked at on a number of 
occasions in recent years by the European Parliament. In the past, it was 
mainly the Committee on Energy, Research and Technology which was 
responsible for drawing up reports, but for my last report, entitled 
‘Biotechnology in Europe and the need for an integrated policy’, adopted in 
February by the European Parliament, a number of parliamentary 
committees were asked to deliver opinions; making specific policy 
recommendations for the medium and long term. 
I found it of utmost importance that this multidisciplinary 
technology, with such a wide range of applications was discussed not only 
in the Committee for Energy, Research and Technology. Now that the 
results of biotechnology research are rapidly finding their way into 
commercial applications in many sectors of industry, agriculture and health 
care, with far-reaching consequences, it is important to consider the various 
policy aspects more closely. 
I want to underline the fact that in a representative democracy, 
Parliaments, before users of future-oriented research work, are amongst the 
makers of the future. This is important to mention, because there is an 
increasing tendency in several European countries to forget or minimize the 
role of Parliament in advanced societies. The real decisions are too often 
taken by powerful interest groups.  
It is true that Parliaments are facing increasing difficulties to play 
their role to its full and legitimate scope in a more and more complex and 
fast changing society. 
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It is not easy to enact laws on fundamental issues of complex nature 
like, for instance, biotechnology. In many instances it implies a high degree 
of confidence in the assessment and monitoring of the long-term implications 
and consequences of the decisions taken today. 
This is not yet the case! The decisions taken today do have more than 
ever in the past far-reaching consequences for millions of people, whose 
daily life will be deeply affected in the future. In a modern representative 
democracy, it is a must that Parliament has the capability to legislate on the 
basis of honest attempts to forecast and assess the long-term implications 
and consequences of a given development; so that it is possible to monitor 
and direct the processes in such a way that the impact is for the benefit of 
mankind, not to its detriment. Since it has become clear that developments 
in biotechnology have an international-character, international cooperation, 
regulations and legislation are of great importance. Especially regulations in 
the field of deliberate release of manipulated micro-organisms, because 
they are not at all controlled by national borders. 
Important is also the democratization of the decision-making process. 
This means that more attention should be paid to the provision of balanced 





The Seminar on Biotechnology in Europe and Latin America 
(SOBELA) took place in Brussels, 27-29 April 1987. Unlike many recent 
meetings in biotechnology this was not an opportunity to display the latest 
developments, but more importantly a chance to exchange information and 
prepare commercial agreements based on the transfer of skills and 
technology in the biosciences. 
The meeting opened with important statements of interest and 
goodwill by key scientific and political figures from Europe and Latin 
America. Later, businessmen and scientists from the two sides of the 
Atlantic described the infrastructures that support biotechnology activities 
in their respective regions. It emerged that there was real scope for two way 
exchange of skills, materials and equipment. 
The Commission of the European Communities, CEC, and various 
multinational groupings in Latin America were able to compare and 
contrast the effectiveness of their enabling programmes. In both areas 
regulation and legislation raise barriers to the free exchange of skills and 
commodities resulting from biotechnology. In both areas collaborative 
ventures are breaking down such barriers, albeit too slowly. Both areas 
perceive the greatest competitive challenges to their biotechnology 
industries to come from the USA and Japan. 
Since April 1987 the stock market has become a less than safe 
investment and the US dollar is no longer a safe alternative to gold. These 
developments will have long lasting effects on the ease of raising capital 
and the success of exported products from Latin America. More pressure 
will be applied to Latin American governments to provide the means to 
enable the development of an internationally competitive industry. 
European biotechnology has moved rapidly from the position described in 
‘Industrial Biotechnology in Europe’, edited by Duncan Davies, (CEPS, CEE, 
1986) in which Europe was perceived to be failing to compete. In the past 
year there has been a flurry of supportive and concertation measures at both 




Europe and Latin America have social, cultural and linguistic ties, 
which for many years have supported significant commercial exchanges. 
The European Community is Latin America’s second biggest trading 
partner (after the USA) and the biggest supplier of development aid. 
The present problems of the Latin American economies lead many 
Europeans to ignore the wealth of natural resources and the size of potential 
markets. The good educational infrastructure and the presence of modern 
technology and science-based industry offer considerable scope for mutually 
profitable exchanges in the area of biotechnology. Despite sometimes being 
included amongst the nations of the ‘Third World’, Latin America has made 
significant contributions to developments in biotechnology and may have 
acted as a stimulus to action in European biotechnology. 
Existing training schemes funded by the European Community and 
its Member States do much to enable skilled management and senior 
scientific personnel to keep ahead of the latest technological developments. 
Biotechnology also depends on the availability of highly skilled technicians 
for whom fewer international training programmes are accessible. The 
absence of such personnel is a serious hindrance to the development of the 
biotechnology industry in Latin America. SOBELA participants meeting at 
informal events had the opportunity to discuss, without commitment, the 
nature of potential collaborations in this and other areas of interest to the 
biotechnology industry. 
In the absence of a formal biotechnology link between the European 
Community and Latin America, SOBELA provided a forum for dialogue. The 
presentations, summarised in the following pages, presented existing national 
initiatives in industry and in the public sector. It will be immediately 
noticeable that this was not a scientific seminar, but more importantly 
perhaps, an overture for collaboration in industry and the underlying science, 
mediated by diplomatic goodwill and influence. How can European/Latin 
American collaboration in biotechnology serve national priorities? 
The example of Brazil’s ambitious Gasohol programme so impressed 
France’s President Giscard d’Estaing during his 1977 visit, that he 
commissioned a report on French options in biotechnology. The report, 
Sciences de la Vie et Societé’ by Gros, Jacob and Royer (1979) initiated the 
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chain of events that lead to the first ‘Programme Mobilisateur’, designed to 
establish France as a leading contributor to the new technology, and 
participant in the markets of the emerging ‘bioindustries’. 
The United Kingdom and other European states in turn began the 
implementation of hastily contrived programmes, designed to salvage 
national position or pride in an emergent industry that seemed once again 
destined to be dominated by the USA and Japan. 
The example cited may in one case have acted as a spur to 
development in Europe, but in general the direction of technology transfer is 
predominantly in the opposite sense. What can Europe and Latin America do 
for each other? What are the perceived needs of these two widely different 
groups of nations? Firstly we shall examine what we mean by biotechnology. 
The Scope of Biotechnology 
Very broadly, biotechnology may be defined as the purposeful 
application of biological science, thus encapsulating most aspects of current 
and traditional agriculture, food production and health care, narrower 
definitions of phrases such as ‘new biotechnology’, forms specifically upon 
the more prominent modern techniques of genetic engineering, monoclonal 
antibodies, and their applications. 
Biotechnology has a prehistory, which predates the keeping of 
records or experimental details. Into this area must fall the first examples of 
cheesemaking, beer and wine manufacture and some aspects of traditional 
medicine. The transition from tradition to science took place around the end 
of the 18th century. At about that time the scientific method was becoming 
respected, the microscope was becoming a serious research instrument and 
the value of careful measurement was becoming realised. The quantitative 
approach saw fruits in the researches of Mendel and the flowering of 
organic chemistry, although a century was to pass before those disparate 
strands could be drawn together in the new biology. 
Until the second world war many basic organic chemicals were made 
by fermentation and subsequent purification. Glycerol, acetic acid, citric 
acid and many other solvents and acids were extracted from stirred tank 
fermenters using molasses as a raw material. In Japan monosodium 
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glutamate production from strains of aspergillus was the first pure product 
of the fermentation industry, other than alcohol. 
Microbiological development in the same period had been rapid as 
had the growth of medical genetics, but perhaps the most critical discovery 
for modern biotechnology was the discovery of penicillin action by Fleming 
in 1928. The stimulus of the second world war created a need for the large 
scale production of antibiotics. Because of the development of several 
different strands of appropriate technology it became possible to achieve 
the growth of moulds and filamentous bacteria in highly defined and 
controlled conditions. In 1940 Florey and Chain succeeded in isolating and 
purifying penicillin in a manner which allowed mass production. The 
development of downstream processing can be traced to this period. 
The perfection of the hybridoma technique for the production of 
monoclonal antibodies resulted from the work of an Argentine scientist 
carried out in a British laboratory. César Milstein with Georges Köhler 
went on to share the Nobel prize. 
In Latin America it is possible to say that much large scale use of 
biotechnology remains at roughly the stage reached in Europe by 1945. There 
are relatively sophisticated brewing and food technologies and increasingly a 
degree of competence in medical technologies such as vaccine manufacture. 
The inclusion of state of the art skills will hopefully be one of the results of 
some of the ambitious programmes described in this presentation. 
There is a real danger that biotechnology is being presented as a new 
industry. This is quite clearly not the case. Biotechnology is a set of 
enabling technologies which will find application in the existing 
bioindustries, i.e. the several sectors of activity based upon the applications 
of life sciences and/or the use of materials of organic origin. It is quite fair 
to say that some aspects of biotechnology have allowed the launch of new 
companies such as Genentech or Celltech, which rely exclusively on the 
new technology for their sales. The outlets for their products quite clearly 
label those companies as newcomers in the pharmaceutical industry, rather 
than harbingers of a completely new industrial sector. 
Modern biotechnology has the potential to change profoundly the 
nature of several major industrial sectors. This potential has as its 
foundations two very different sets of skills. Firstly, there exists an 
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assemblage of biological and engineering skills built up over centuries of 
experience in the fermentation industry. Secondly, and in the public eye, 
more prominently, modern molecular biology has allowed the tailoring of 
genomic material and cells to serve specific goals. The first biotechnology 
revolution occurred, not in the 1970s, but in the 1940s when the industrial 
scale production of antibiotics necessitated radically new developments in 
fermentation technology and downstream processing. 
In the course of the Seminar Professor Da Silva, working in Paris at 
the Pasteur Institute, used the example of vaccine production to identify 
four generations of biotechnology. 
Generation Vaccine Type Technology used 
Fist Traditional Eggs/in vivo extract 
Second Polio, Mumps, Rabies Cell culture isolation of virus 
Third Hepatitis Genetic manipulation 
Fourth AIDS? DNA/Peptide synthesis 
Europe is currently experimenting with Fourth Generation vaccine 
production, while Latin America is locked into the Second Generation. Can 
it become economically justifiable for Latin America to acquire its own 
Third and Fourth Generation capacity? 
From the viewpoint of a commercial entrepreneur, biotechnology 
serves to make money from biology. Growing public concern for the 
environment and public health risks, has in some cases limited the application 
of biotechnology. Such issues as the erosion of the earth’s ozone layer and 
CO2 build up in the atmosphere have sensitized the public to possible harmful 
effects of scientific and technological innovation. It is to the credit of the 
biotechnology industry in Europe and North America that their own policing 
standards have disarmed most critics. Biotechnology has succeeded in 
building up an environmentally responsible image, although as Mrs Viehoff 
emphasised, there is no room for complacency. The environmental record of 
the Latin American bioindustry will come under dose scrutiny if its products 
are to be launched on the European market. 
Like any innovative industrial activity, biotechnology is underpinned 
by an investment in Research and Development, R&D. The R&D financing 
comes either from the private sector, the public sector or a mixture of both. 
In the following chapters specific examples of European and Latin 
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American experiences will be presented, however certain general principles 
can be outlined here. Industry is concerned with making money in the 
medium or short term. R&D in biotechnology is very expensive and in 
industrial laboratories must be aimed at process improvement or product 
development, linked to astute market analysis if profits and long term 
success are to be achieved. In the case of modern genetics, applied 
industrial research is supported by the results of public sector research, 
published in open sources. 
To take a very obvious example. The structure of DNA, resolved by 
Watson and Crick in 1953, underpins the whole of modern molecular biology, 
which is one of the foundation stones of biotechnology. The discovery of DNA 
structure was made possible by public sector funding. The synthesis of human 
insulin by a yeast or bacteria would be unthinkable without knowledge of DNA 
structure. Human insulin is sold by many reputable companies, who could not 
dream of financing a research programme that might give commercial results 
only after 25 years. Yet it was only in 1988 that the first genetically engineered 
insulins appeared on the market. 
The European Commission has been deeply involved in discussions 
about the nature of fundamental research, precompetitive applied research 
and competitive industrial research, as applied to the biotechnology area. 
Fundamental research in Europe has historically been a matter for national 
funding programmes, while competitive research is quite properly the domain 
of industry. The middle ground is a difficult area in which all available 
goodwill must be coordinated so as to realise public sector/private sector 
collaboration. In Latin America collaboration in the Andean Pact states and 
between Argentina and Brazil is tackling specific goals perceived to be of 
regional benefit. The European Commission has attempted to tackle this 
middle ground through the Biotechnology Action Programme, BAP, which 
will be described later. Future European Community programmes will 
concentrate on providing enabling technology for the European bioindustry in 
order to enhance international competitiveness. The nature of European/Latin 
American collaborations may depend to some extent on the willingness to 
compromise such competitiveness in relations with the Latin American states. 
Ten years ago very few firms could think of a commercially 
justifiable reason for having molecular geneticists on their staffs. It would 
now be considered foolhardy for a European pharmaceutical company not 
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to employ such people. Later on, contributors to this volume will show why 
this is not always the case in Latin America. 
At present the agricultural industry is waking up to the promise of 
biotechnology. In ten years it will be unthinkable for a major seed supplier 
not to have a molecular genetics team. Dr Sargeant, working in the European 
Commission, showed that it is likely that the very nature of agriculture and 
land use may be changed by developments made possible by 
biotechnological research. Such consequences might be of more immediate 
relevance to agriculture in the developing world, including Latin America. 
In Western Europe, the United States and Japan, the main thrust of 
recent industrial activity in biotechnology has been orientated to the 
production of therapeutic products and diagnostics, both in the health 
sector. The public perception of biotechnology has been strongly influenced 
by issues as diverse as AIDS, the recent availability of highly publicised new 
wonder drugs, thrombolytic agents for heart attack victims and the dramatic 
application through forensic science of ‘genetic fingerprinting’. 
What can Biotechnology Offer? 
The first impact of biotechnology has been in the area of human 
health. The public has seen remarkable progress made in the treatment of 
viral diseases and cancer, using the twin technologies of molecular genetics 
and cell fusion. Molecular genetics gave rise to genetic manipulation and 
cell fusion gave rise to the ‘magic bullets’ of monoclonal antibodies. 
Products resulting from DNA cloning and expression in micro-
organisms include: insulin, lymphokines, clotting factors and thrombolytic 
agents. Monoclonal antibodies have been the basis for simplified diagnostic 
tests and the hope of a cure for several cancers. Monoclonal antibodies can 
be used as guided missiles, carrying a ‘warhead’ of toxin or radioactive 
element to a specific target, such as the cells of a malignant tumour. 
There is a great deal more to biotechnology than the health care 
sector. As a set of technologies it is poised to offer benefits to a number of 
industrial sectors including: Food, Environment, Agriculture and Animal 
Health, Chemicals, Mining, Energy and, of course, Human Health. 
Despite the conspicuous successes of some health care applications, 
some goals have proved unexpectedly difficult to realise. Plant 
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biotechnology, for long the Cinderella of the biosciences is hastily 
constructing a carriage to get to the ball! Despite the early delays, the pace 
of discovery in this area is now remarkable. 
The prospects of controlled nitrogen fixation by incorporating the 
genes of bacteria into flowering plants have proved difficult to realise. The 
complexity of the problem was underestimated by the naively phrased 
publicity which portrayed molecular biology as a universal solution in 
search of problems to attack. The hopes for alcohol from wood have also 
evaporated as enzymatic means of lignocellulose degradation have proved 
impracticable as a commercial process. Responsible scientists had always 
pointed out the difficulties involved, but the media, conditioned to a science 
which realised the impossible, would not accept such stark realism. 
Political pressures are also significant. Debate has raged on the 
introduction of an EEC sponsored bio-alcohol programme, portrayed as an 
alternative to adding lead to petrol. Backed by several agricultural and 
fermentation companies, but strongly opposed by producers of industrial 
alcohol and more cost-effective lead substitutes, the ultimate decision looks 
set to be made as much on political grounds as on economic: finally, the 
argument was resolved by the decline in the price of oil and the 
strengthened Community commitment to budget discipline. 
The Latin American countries with their vast genetic resources could 
well harbour microbiological resources that might offer solutions to some 
industrial process problems. Screening and identification of natural resources 
is an aspect of biotechnology that is often overlooked in Europe and North 
America. The potential reward in terms of useful biological activities is 
immense. Microbial screening using fairly traditional technologies is a key 
area in which Latin America can make a contribution to European 
biotechnology. A recent expedition to Brazil by staff of the Cranfield Institute 
of Technology, UK, underlined the importance of resources held in 
developing countries. The expedition hoped to collect samples from the 
Amazonian forest, with a view to understanding the rapid turnover of 
vegetable life on a very thin topsoil. Genes locked in Amazonian organisms 
could play an important role in the energy and environmental industries in 
years to come. Obvious applications in the environment sector include 
sewage treatment. The growing problem of urban sprawl in the developing 
world, makes sewage control a major issue in environment and public health. 
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Mining has received comparatively little attention from the public, 
but micro-organisms have been developed that are capable of concentrating 
minerals of commercial value from normally unworkable deposits. The 
same techniques could scavenge environmentally dangerous elements such 
as Cadmium or Mercury. 
Biotechnology can do more than exploit existing markets. As old 
markets are eroded biotechnology has the potential to create new markets 
and revenues. In the context of SOBELA we must address the question of 
how biotechnology can serve the common interests of Latin America and 
Europe. Cynics will find it easy to say that major European companies will 
exploit Latin America. Collaboration should be approached with caution so 
as to distribute the benefits equitably between partners. The contributions of 
the following chapters show that indeed we do have something to learn 
from each other in terms both of science and models of cooperation. 
European Biotechnology 
Most European states have taken action at government level to 
improve competitiveness in the area of biotechnology. National programmes 
and coordinating bodies have until recently had little interchange of views. 
Even the European Commission has had comparatively little success in 
coordinating national strategies in biotechnology. Despite thirty years of 
community it is not generally appreciated among European governments, to 
what extent the European Commission works on their behalf in the 
harmonisation of regulations and the elimination of barriers to trade and free 
movement of personnel and skills. The probable impact of the 1992 target 
date for the removal of internal barriers to trade is gradually being 
appreciated by European industrialists, thanks to an information campaign 
orchestrated at national levels. 
Total public sector biotechnology spending in the EEC member states 
may not be far short of that spent in the USA – estimated at $2.7 billion in 
1987 by a report from the Congressional Office of Technology Assessment. 
Partly because of duplication and fragmentation of effort and largely 
because of differences of commercial opportunism and the absence of a real 
Common Market, Europe nonetheless lags behind both the USA and Japan 
in the commercial exploitation of biotechnology. 
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The funding of new ventures has been easier in the USA than in 
Europe. Seedcorn capital, venture capital, tax concessions and the 
entrepreneurial tradition are particularly North American attributes. Europe 
however has less often had to write off investments in failed ventures. The 
most conspicuous examples of failure in Europe have involved US 
companies operating without a tightly defined business plan. In the past two 
years European entrepreneurs have established a substantial pool of venture 
capital, with several specialist funds able to evaluate ventures in 
biotechnology. The United Kingdom has Europe’s most sophisticated venture 
capital market, modelled on the USA, but characterised also by European 
conservatism. Some analysts now say that there are more new funds in 
Europe than the USA, although the pool of American funds, especially in the 
area of seedcorn capital will continue to be larger for the foreseeable future. 
Europe probably has much to offer Latin America by way of advice 
on business start up schemes. If this can be integrated with some of the 
existing programmes and experience, it may be possible to fund suitably 
targeted biotechnology start-ups in Latin America. 
In Europe two very different types of company have played a role 
in the new biotechnology. In the first instance medium to large 
companies, with diverse products and a long established tradition in 
product sectors ranging from engineering and chemicals to ethical 
products, have adopted the new technologies as a logical extension to 
their portfolios. More recently a second kind of company has emerged, 
backed by risk capital, small to medium sized, with a very few but very 
high technology products. Whereas in the USA such small companies 
dominate the biotechnology sector, in Europe it is the old, traditional, 
medium to large companies that dominate. 
The larger companies in Europe, such as Elf-Aquitaine, Hoechst, ICI, 
Unilever etc. have added rDNA technology to their research programmes in 
health care and agriculture. In the UK and Netherlands university/industry 
partnership has played a major role in transferring appropriate technologies. 
Many of the resulting small firms, which succeed by attracting investment, 
become in turn targets for acquisition by the larger companies with a more 
conservative approach to new technology. Large companies are often 
unwilling to gamble on untested technology, but happy to pay the going 
price for proven products. 
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Even for the largest companies the regulatory and legislative barriers 
that exist in Europe are a major headache. A large company will have a 
regulatory affairs department far larger and more expensive than a USA 
company of the same size that focuses only on the internal USA market. 
Latin American Biotechnology 
In Latin America as in Europe, manufacturers of ethical products 
have had to face a number of different regulatory regimes. The cost of 
overcoming different national requirements has proved prohibitive for 
many smaller companies. In Europe as in Latin America, multi-national 
negotiations are moving ahead with the desire to provide a unified 
regulatory system. SOBELA might prove a launch point for European/Latin 
American negotiations in this area. 
The SOBELA meeting demonstrated the steps taken by Latin 
American countries to rationalise, regroup and pool skills in this 
important area of high technology. Biotechnology has been the focus of 
an almost unprecedented dialogue between the Latin American states. 
Typical results of this dialogue include Argentinean/ Brazil collaborations, 
Andean Pact collaborations and an increasing Mexican involvement in 
South American biotechnology. 
Whereas there are a number of interesting biotechnology start-ups 
funded by private or state organisations, it is notable that the local market is 
already being assaulted by the established multinationals. Many middle 
sized European, Japanese and N American firms are establishing marketing 
structures in Latin America. Several are contemplating the establishment of 
manufacturing and R&D facilities. These companies in particular must be 
encouraged to enter into a constructive dialogue with the nascent domestic 
biotechnology companies. This route might also be the most appropriate if 
European companies are to avoid the pitfalls of inadequate patent 
protection. It is difficult for companies to defend their intellectual property 
rights if they are far away from the market or competition concerned – even 
where such protection is legally guaranteed. Several small European 
companies have lacked the financial resources to defend infringements of 
their intellectual property rights in the USA. 
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The SOBELA Meeting 
Introductions by several distinguished speakers confirmed the extent 
of goodwill among the participating states. The subsequent presentations 
gave an overview of the status of biotechnology in Europe and Latin 
America. Speakers from both sides of the Atlantic affirmed their 
governments’ commitments to collaboration and several presenters were 
able to speak of specific examples. 
Dr Pereira da Silva explained that biotechnology cannot be regarded 
as a panacea for the problems of a developing economy, although its 
application to well defined problems could yield very significant benefits. 
Many of his recommendations could be summarised by saying that what 
Latin America, and other developing countries, need is the establishment of 
bilateral accords with developed nations which permit training and the 
creation of a domestic infrastructure capable of supporting the benefits to be 
wrought by biotechnology. 
The following chapters consider the state of biotechnology in 
Europe and Latin America. To what extent are the goals of collaboration 
likely to bring tangible benefits to participants? 
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SECTION ONE  
 
BIOTECHNOLOGY IN EUROPE 
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1.0. OVERVIEW OF EUROPEAN ACTIVITIES IN BIOTECHNOLOGY 
Karl Simpson 
European administrations and industrial organisations have realised 
that they cannot afford to miss out on the exploitation of biotechnology. 
European scientists working in industrial and university laboratories have 
made decisive contributions to the methodology of this ‘New 
Biotechnology’. The first University Chair in biotechnology was 
established in Lyngby, Denmark in 1905 and the world enzymes market is 
dominated by two European companies; Novo, Denmark and Gist-
Brocades, Netherlands. 
Although total European industrial spending on biotechnology is 
approaching that of the USA, it is in the USA and increasingly Japan, that 
new commercial opportunities are being exploited. The funding of new 
ventures has been far more difficult in Europe. The USA offers important 
tax concessions for new ventures and there is ready availability of seedcorn 
and venture capital. Perhaps most importantly the USA has an 
entrepreneurial tradition that respects the risk taker. 
The most important disadvantages facing Europe are those of internal 
language and trade barriers. Despite the activities of the European Commission 
there are still separate markets in the European Community, with different 
regulatory practices, legislatures and languages. rDNA regulations vary widely 
in the community. In Denmark draconian legislation is driving R&D out of the 
country to more hospitable locations. The same may soon happen in Germany 
where a strong, but uninformed Green movement has considerable influence. 
Surveys have revealed that opposition to rDNA is most deeply rooted where the 
public perceives itself to be uninformed. 
The harmonisation of Community regulations, aimed at creating a 
single market ready for January 1st 1993, is expected to improve this state 
of affairs, although much work will have to be done. The European 
Community has adopted a number of research and training programmes to 
stimulate and strengthen biotechnology in Europe. Proposals from the 
Commission from the mid-1970s were finally adopted by the Member States 
in 1981, launching the Biomolecular Engineering Programme, SEP’: 15 
MECU, 1982-86. This addressed specific bottlenecks, applying the results of 
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modern genetics and enzymology in the agro-food sector. The larger 
Biotechnology Action Programme, ‘BAP’: 75 MECU, 1985-89, embraced a 
wider range of biotechnology topics, including topics of interest to a wider 
range of industries, an expanded safety programme, and projects on 
‘infrastructure’ to strengthen cell- and micro-organism collections and 
databanks. At the time of going to press, a 100 MECU programme, 
Biotechnology Research and Innovation for Development and Growth in 
Europe, ‘BRIDGE’, 1990-94 is before Council and Parliament. 
In addition to the research and training programmes, the Commission 
has recognised since 1983 the value of a coherent strategy for biotechnology, 
embracing not only the programmes mentioned above, but five other action 
priorities: 
 new regimes for sugar and starch, to make these raw materials 
available at a competitive price to Community industry; 
 new regulations, to provide in the context of the developing 
Common Market a common regulatory framework for 
biotechnology and its products; 
 new regulations for the protection of intellectual property (patents 
and plant varieties), to ensure in the field of biotechnology clarity 
of legislation and adequate protection to maintain the incentive for 
research and innovation; 
 demonstration projects, to stimulate the transfer of new 
technology towards commercialisation, in particular across the 
intersectoral and inter-disciplinary boundaries between science, 
industry and agriculture. The 80 MECU European Collaborative 
Linkage of Agriculture and Industry through Research, ‘ECLAIR’, 
was a result launched in 1989; 
 a ‘concertation’ action, for monitoring and awareness of emerging 
opportunities and challenges, and in order to improve co-ordination 
in biotechnology relevant policies between the several Commission 
services involved, and between Community and Member States. 
With the strong support of the European Parliament, this multi-
dimensional response enabled the Commission to develop an 
integrated response to the challenges of biotechnology. 
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One of the most desirable consequences of Community and National 
activities in biotechnology has been the move to enhance communication 
between nations, industry, universities and ministries. Inter-national 
consultation has been a feature of newly established biotechnology 
programmes such as those of Greece and Spain. 
The European Biotechnology Industry 
In the USA the biotechnology industry is dominated by small high 
tech companies with few products, brought into existence with venture 
funding. In Europe medium to large companies with a long established 
pedigree and a diverse range of products from fertilisers to DNA probes are 
dominant. Until very recently only in the UK, and to a much lesser extent 
the Netherlands, has venture capital allowed the emergence of significant 
numbers of small to medium US style ventures. In 1988 and 1989 new 
venture capital companies are seeking business in all parts of the 
community. Significantly there is some real seed corn capital available. 
All of Europe’s traditional chemical and pharmaceutical giants have 
now invested heavily in rDNA technology, adding it to their mainstream 
programmes in the health care and agriculture sectors. University/Industry 
partnerships have played a major rle in transfer-ring the appropriate 
technologies. In the UK this is typified by the ICI/University of Leicester 
relationship. Leicester, where Alec Jeffreys invented DNA fingerprinting, is 
one of Europe’s leading centres of rDNA research. In W Germany Hoechst 
(still in disfavour with the government after its decision to invest in 
Massachusetts General Hospital) has a number of collaborative ventures 
with university laboratories. 
What Are Europe’s Strengths? 
The fragmentation of Europe has paradoxically provided a major asset. 
Firms have grown up in an environment that requires export earnings. 
Knowledge of export regulations and a lack of dependence upon internal 
markets are in sharp contrast to many US firms who have the world’s largest 
single market at their doorstep. The old colonial powers of Europe have left 
their languages as a permanent monument to occupation. Language thus 
provides privileged access to markets such as Latin America and Africa. 
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Several areas of biotechnology are dominated by European science or 
companies including: enzyme production, agro-biotechnology, biosensors, 
waste treatment and speciality chemicals. 
European firms are generally willing to contemplate participation in 
joint ventures, both within and outside the Community. There is some 
apprehension about the loss of European proprietary knowledge to the USA 
and Japan through mismanagement of joint venture activity. 
A Summary of National Activities in the EEC 
BELGIUM 
The governments of the Flemish and French speaking areas have 
both implemented support programmes for biotechnology. Large companies 
Solvay and Smith Kline Rit have moved firmly into biotech. Small 
companies including Plant Genetic Systems and Phytotec, with good 
university contacts are making rapid progress to success internationally. 
DENMARK 
Despite a tough attitude to biotech legislation, the government has 
committed another US$60 million in the next four years. A small country, 
but strong in enzymes and gene technology. Novo has been active in protein 
engineering and European collaboration. Rationalisation in the domestic 
biotechnology industry is exemplified by the merger of Novo and Nordisk, 
both major insulin producers with rDNA technology. 
FRANCE 
In 1987 the conservative government overturned spending committed by 
the departed socialists, but the biotechnology Mobilisation Programme 
continued in weakened form. May 1988 saw the Socialists return under Rocard, 
and Minister Curien almost immediately instituted massive new investment in 
biotechnology. France has major strengths in bioreactors centred on Daniel 
Thomas in the University of Compiègne. Agro biotechnology is another strong 
field, Limagrain has developed artificial seeds and Moet-Hennessy is looking at 
the micropropagation of woody plants. Club Agri has a 4 year, US$3 million 
programme of club sponsored research. 
Sanofi, an Elf Aquitaine subsidiary with major health-care biotech 
commitments had turnover of more than US$600 million last year. 
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Transgène, the rDNA and cell biology firm works in collaboration with 
several major French companies and is starting to be a candidate for entry 
into the international league. 
FEDERAL REPUBLIC OF GERMANY 
One of Europe’s biggest biotech spenders. Major public expenditure 
by both central (US$700 million over 5 years in latest programme) and 
regional governments. Central government is being forced by Green 
movement to enact restrictive legislation. Some companies may look 
elsewhere for new R&D activity. Biotechnology Centre in Braunschweig is 
world class for fermentation development and general biotech activity. 
Companies such as Hoechst, Bayer, BASF have bought in all the new skills, 
but are very secretive about R&D. Hoechst is far advanced in yeast 
expression systems, but information about future products is mostly 
rumour. BASF is the latest giant to earn government disapproval as it sites 
its major molecular biology facility in the USA. The Bissendorf 
Biotechnology Group have come from nowhere to being an exciting group 
of companies with international connections and major investments. 
Venture capital is opening up and a number of new firms are taking off. 
Middle sized companies such as Biotest have gone public to fund new 
biotech activities. 
GREECE 
Not really a biotech power, but the Institute for Molecular Biology 
and Biotechnology, Heraklion, is a major new institute devoted to keeping 
Greece in the picture. Vioryl is important in flavours, pheromones and plant 
tissue culture. Biohellas is first biotech company to exploit new legislation 
to create high tech enterprises. Old pharmaceutical companies such as PN 
Gerolymatos are entering the area of biotechnology. 
REPUBLIC OF IRELAND 
Weak economy undermines the very strong university system which 
offers top class skills. Small biotech companies have arisen to exploit 
Ireland’s Import Substitution Programme. Guinness has major bio-tech 
investment with top class rDNA facilities and skills in yeast biotech. The 
Agricultural Institute in Dublin funds animal and plant biotech studies. 




Has come rather late into the arena, but is putting money into a major 
national initiative to support industry in a range of mission-orientated 
projects. The government has talked of an Italian Human Genome project. 
Major companies are in acquisition moods and have got hold of biotech 
skills. Farmitalia, Ferruzzi and the ENI group (including Sclavo) are 
leading firms. Major academic industrial collaboration is being encouraged. 
THE NETHERLANDS 
Small country, but host to several multinationals. Biotechnology is of 
great importance with 7% of world turnover. The government restructured 
biology six years ago and most university research is now partly industry 
sponsored. After uncomfortable start, applied research is stronger in 
Netherlands than anywhere else in Europe. National skills include enzymes, 
yeast, dairy biotech, protein engineering. Major companies include: 
Unilever, Philips, Shell, Akzo, Gist-Brocades. Many small companies are 
university or institute based and enjoy good relations with big brothers. 
Government encourages foreign biotech investment. 
PORTUGAL 
Newly arrived in the EEC, Portugal has little biotech. A national 
Biotechnology Centre is now proposed. Companies include: Cipan 
(antibiotics) and Franco-Farmaceutica (immunology, vaccines). The 21 
renowned Gulbenkian foundation is not interested in commercial spin off 
operations. 
SPAIN 
Spain until recently had no significant biotechnology industry, although 
it has first class university facilities. A major Mobilisation Programme is 
intended to put Spain on the biotech map. Built at a cost of US$3 million the 
new Biotechnology Centre with a British head, Dr Michael Parkhouse, will 
house more than 100 scientists. Biotechnology active companies include: 
Atom, Laboratoris Girfols, Laboratoris Knickerbocker and Processos 
Enzimaticos. University/ industry collaboration is in its infancy. 
UNITED KINGDOM 
Government spending in biotech is lower than that of Germany, but 
UK has arguably the most healthy biotech industry in Europe. UK firms 
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pioneered access to venture capital, about half European venture funding in 
biotech is British (although as much as 70% is invested in USA). Despite 
cut-backs in fundamental research, applied research is receiving support 
from the biotech programmes of several ministries. Giants like ICI, 
Unilever, as well as smaller firms work with university departments. 
Celltech is now in profit situation as world’s largest monoclonals 
producer. It will be the first British start up to make the transition from 
small high tech to tomorrow’s new style middle size pharmaceutical firm. 
Although overall spending is limited the UK actually has competence in a 
wider range of biotech activities than the USA. Strong points include 
biosensors and protein engineering, PE. The Inmos transputers are being 
assembled in parallel to give enormous real time power for PE applications 
in the hands of companies like British Biotechnology, which in addition is 
perhaps the only firm to offer routine gene synthesis. The UK has pioneered 




Adapted from speech made by Mr C. de Wispelaere 
In 1980 the state of Belgium agreed to a substantial devolution of 
power to the two regions of French and Dutch speaking peoples. This move 
was to have profound consequences on all aspects of Belgian 
administration, including science and industrial policy. 
National and Regional funds are administered separately, but despite 
the potential for conflict, pragmatic administrators make the system work. 
Biotechnology has long been regarded as a strategic technology, 
and as such has received strong support from both state and regions. In 
practical terms the regions have placed greater emphasis on industrial 
biotechnology, while the state has emphasised fundamental or 
precompetitive research and international collaboration programmes of 
both academic and industrial nature. 
The Role of the State 
Belgium has a highly developed university system and a 
distinguished record of achievement in the life sciences. In 1984 the state 
made available funds of US$125 million for life science research of which 
US$50 million was designated for biology and biotechnology. 
Funds are administered by a number of bodies: 
 The Ministry of Education which funds the day to day running of 
the universities. 
 The Belgian Science Policy Office which carries out three 
different initiatives 
• concerted actions Centres of excellence are identified and 
supported with grants over a six year period. 
• impulse programmes fund applied research tools such as 
microbial culture collections and strategic studies aimed to 
optimise the performance of Belgian biotechnology. 
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• interuniversity attraction poles for high technology aim to 
further increase the efficiency of university biotechnology by 
‘networking’. 
 The National Fund for Scientific Research (NFWO IFURS) financed 
by the Ministry of Education provides grants for research. 
 The Institute for the Encouragement of Scientific Research in 
Industry and Agriculture (IWONL IIRSIA) is funded by the 
Ministries of Economic Affairs and Agriculture. It provides grants 
for applied research. 
 The Regional Authorities also allocate funds to university research 
in biotechnology. 
Some Prominent Research Groups in the Areas of Agriculture and 
Medicine 
AGRICULTURE 
Professors Van Montagu and Schell from Rijksuniversiteit Gent are 
active in plant molecular genetics and Agrobacterium. 
Professor Briquet at the Université Catholique de Louvain is 
renowned for his work on cytoplasmic male sterility. 
Professors Bernier, Université de l’Etat à Liège, and Jacobs, Vrije 
Universiteit Brussel, work in the area of molecular physiology of plants. 
Professors Boxus and Semal, Faculté des Sciences Agronomiques de 
Gembloux, are known for excellence in micropropagation. 
MEDICINE AND HEALTH 
Excellence is found in many centres. Those with broad based 
competence include: 
The Institute of Molecular and Cellular Pathology (ICP), associated 
with the Catholic University of Louvain, was founded in 1975 by Nobel 





The Institute of Molecular Biology, at the Free University of Brussels 
(VUB/ULB) carries out basic research in prokaryote and eukaryote genetic 
manipulation, developmental biology and immunology. 
The REGA institute of the Catholic University of Louvain, founded by 
Professor de Somer is a centre for applied research in medical microbiology 
and immunology. Excellent work in lymphokines, cytokines and interferons 
has been carried out.  
Smaller centres of excellence include: 
 
32 
Professor Ghuysen’s group at the State University of Liège, which 
studies the molecular basis of enzyme activity. 
Professor Fiers at the University of Ghent elucidated the complete 
primary structure of a gene in 1972. He is now active in the cloning and 
expression of interferons and lymphokines. 
Professor Collen of the Catholic University, Louvain isolated Tissue 
Plasminogen Activator, TPA, currently at the focus of attention as a 
treatment for heart attack and thrombosis. 
Professor Martial’s group at Liège has studied the expression of 
genes for prolactin, growth hormone and placental lactogen. 
Many other excellent teams exist, suffice it to say that the quality of 
precompetitive research in Belgium is high. Twenty six Belgian research 
teams participate in the European Commission’s Biotechnology Action 
Programme, BAP. 
In the industrial sector, involvement in biotechnology is keen, 
although Belgian firms are active predominantly in traditional 
biotechnologies in the food, pharmaceutical and agricultural areas. 
Involvement in the new biotechnologies of gene manipulation and advanced 
bioprocessing is concentrated in the pharmaceutical industry, although 
exceptions such as Plant Genetic Systems have achieved world renown. 
Biotechnology in Flanders 
Flanders is the Flemish (or Dutch) speaking part of Belgium. Flemish 
policy concentrates on the stimulation of contact between industrial and 
institutional laboratories with a view to augmenting regional 
competitiveness. Co-operation models such as Limited Research 
Partnerships are implemented when appropriate. 
Third Industrial Revolution in Flanders, DIRV, is the title of the 
regional action plan for high technology, designed to stimulate businessmen 
looking for new technologies and markets and foreign investors looking for 
high tech locations for production sites. Biotechnology is identified as one 
of the strategic technologies. 
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Nearly 60 companies in Flanders are in some way exploiting 
biotechnology. The whole spectrum of biotechnological applications is 
covered, but there is an emphasis on food and agricultural activities (2/3 of 
Belgian agro-food companies are in Flanders). 
Table 1. Companies in Flanders involved in applications of biotechnology. 
 Flanders Belgium 
Food industry 19 26 
Diagnostics and therapeutics 7 31 
Agriculture and horticulture 13 21 
Environment 10 18 
Chemistry 2 10 
Aquaculture 1 2 
Engineering 9 12 
Total 60 120 
Agro-food applications include refinements of traditional 
fermentations of milk products, beer, bread, meat products and sugar. 
CEBOBA is a research centre founded by the agriculturalists 
association, AVEVE and the Artois brewery. Adding value to starch and 
lignocellulose substrates is the focus of activity. 
Amylurn in Aalst is studying the fermentation of starch and sugars, 
and with Plant Genetic Systems, PGS, participates in a Limited Research 
Partnership on protein engineering of saccharide enzymes. 
Plant Genetic Systems merits further attention as the ‘Jewel in the 
Crown’ of Belgian biotechnology. Founded in 1982 as a joint venture 
funded by: Tienen Sugar Refinery, Radar, Hilleshög (a Volvo subsidiary) 
and the Regional Investment Company of Flanders. PGS has attracted 
attention in the international press for its achievements in developing 
herbicide resistant plants by gene manipulation. Further work includes new 
developments in Plant Engineering, Microbial Engineering and Protein 
Engineering. Close links with Professor Marc van Montagu in the 
university of Gent and Professor Shoshana Wodak in the University of 
Brussels assure excellence in genetics and computer aided protein design. 
Medical Sector developments are underrepresented in Flanders with 
only 25% of the Belgian biomedical companies. Those companies have 
however been active in exploiting the advances of the regional universities. 
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Special emphasis has been placed on the development of diagnostics and 
the production of biological substances. Two companies illustrate the 
situation in Flanders: 
Innogenetics was established in 1985 to develop and market diagnostic 
and therapeutic products for the human and animal health care market using 
recombinant DNA, cell culture, monoclonal antibodies and other advanced 
biotechnologies. The company has its own R&D competence and a number of 
collaborative ventures both in Belgium and abroad. 
Biogent was established in 1982 as a division of Biogen US. It 
operates in dose association with Professor Fiers at the Laboratory of 
Molecular Biology. rDNA technology is used to develop products for cancer 
treatment, immunological anomalies, viral infections, cardiovascular and 
other diseases. 
Biotechnology in Wallonia 
The Walloon region (French speaking) has aimed to establish itself as 
a pole of excellence, essentially orientated towards the outside world. 
Several measures have been taken to expedite this aim: 
Direct support to universities for applied industrially orientated 
research. Examples include development of a vaccine against swine 
plague, development of antibiotics by protein engineering and the 
improvement of plant species by in vitro culture. 
Support to and co-operation with industry. Essentially to support 
innovation for example by making available ‘Technology Innovation 
Consultants’ (in French – Responsable d’Innovation Technologique) and 
by funding sectorial analyses so as to tailor a competitive strategy. In 
1982 the Walloon Regional Investment Company launched a holding 
company, Companie de Dévelopment de l’Agro-industrie et des 
Biotechnologies. 
Intra and extraregional actions. Operation Athena is designed to 
alert companies to the possibilities of new technology. It aims to: 
inform, incite, support, fund and communicate. Launched in 1982 this 
venture is increasingly successful and has produced a journal; ‘Athena’ a 
meeting programme; ‘Journées Athena’ and a annual award for 
innovation, the ‘Golden Owl’. 
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Co-operation is strongly directed to foreign partners, including 
companies in the USA, Japan, Europe, Latin America and elsewhere. 
Number of University Labs Number of Enterprises 
     
  42 Agriculture/Sylv. 6  
     
  24 Agro-Food 8  
     
  15 Chemistry 5  
     
 113 Health Care 19  
     
  12 Environment/Energy 4  
     
 6 Equipment 2  
     
  10 Others 9  
     
Fig. 2. Biotechnology in Wallonia 
The Biotechnology Scene in Wallonia 
Fifty companies and more than 250 French speaking university 
laboratories are active in biotechnology. The large university contribution 
emphasise that prospects for industrial/university collaboration are by no 
means exhausted. More than half of the active companies were satisfied 
with their university partners. Universities have gone to great lengths to 
present a hospitable infrastructure by creating science parks, pilot 
laboratories and R&D interfaces. 
Particular regional strengths include: in vitro plant multiplication (6 
companies), vaccines, therapeutics and diagnostics (9 companies), 
environmental applications (6 companies) and extraction and purification of 
natural products (5 companies). Notable new companies include: 
 Phytotec, a joint venture of Native Plant Institute, USA, and the 
Belgian company, Société Européenne de Sémences, devoted to 
plant development. 
 IRE-Celltarg, is involved in the use of monoclonal antibodies as 
targeting agents for cytotoxic agents, such as radio-isotopes. 
 
36 
Partners in this project include, the Liposome Company, USA, and 
the Institut des Radioéléments (IRE) of the Catholic University of 
Louvain. 
 IRE-Medgenix, manufactures in vitro diagnostic agents and 
involves partners, IRE and Bioassay Ltd. 
In addition Wallonia is host to many Belgian and foreign multinational 
companies including: Monsanto, Smith Kline Rit, Hybritech, NPI, Sanofi, 
Noorden, Lederle-Cyanamid etc. The Walloon authorities have stated that per 






Biotechnology has a long tradition in Denmark. Substantial funds have 
been devoted to research in both private and public sectors. Modern 
biotechnology is used in many different areas of industry and in the public sector. 
The following review emphasises applications of the latest 
developments in biotechnology in the following sectors. 
1. Manpower in molecular biology and biotechnology; 
2. Public institutions including universities performing research in 
molecular biology and biotechnology; 
3. Biotechnological industries and their research; 
4. Government funded research programmes in molecular biology and 
biotechnology; 
5. International collaboration; 
6. Legislation concerning control of research and production.  
Manpower in Molecular Biology and Biotechnology 
Graduates in molecular biology are produced at the universities of 
Copenhagen, Aarhus and Odense, but most workers in the field are 
graduates from other institutions which have a molecular biological 









Universities of  Copenhagen, Aarhus, Odense:  
graduating in molecular biology, biochemistry, biology and 
chemistry 
215 
graduating in medicine 560 
Danish Technical University: 
graduates in chemical engineering 
70 
Royal Danish School of Pharmacy 70 
graduates in pharmacology 
Royal Danish Veterinary and Agricultural University 
275 graduates I veterinary science, agronomy, food technology, 
horticulture, dairy science 
Total 1190 
Clearly the total is large enough to support a considerable expansion 
of Denmark’s biotechnology activity. All of the above institutes also offer 
advanced training and degrees, but a lack of training grants and facilities 
has limited intake. 
The bottlenecks have been identified as limited facilities and staff at 
senior level, but the enthusiastic response of Denmark’s scientific community 
to the new biotechnology indicates considerable scope for expansion. 
The new biotechnology programme aims to substantially increase 
research training in biotechnology. The scientific manpower available to 
support the programme has a broad base of appropriate competence. The 
tendency of Danish scientists to have spent time in foreign laboratories adds 
further to the experience base of Danish biotechnology. 
Public Institutions Including Universities Performing Research in 
Molecular Biology and Biotechnology 
UNIVERSITIES 
As mentioned above all of the institutions shown in Table 1 carry out 




Basic operating funding for university linked institutes and 
laboratories comes from the university research budget, which is almost 
entirely provided by the government. To supplement the government funds 
there is competition for funds from agencies which include research 
councils, private foundations, government research initiatives and 
international initiatives such as the European Commission’s Biotechnology 
Action Programme.  
Almost all of the universities are involved in active collaboration, 
either with other universities and institutes at home and abroad or with 
industry both at home and abroad. 
GOVERNMENT RESEARCH INSTITUTES ETC. 
Ministry of Interior Affairs: At the Government Serum Institute, high 
level research is dedicated to the production of diagnostics, sera and 
vaccines. The University Hospital in Copenhagen works in close co-
operation with the medical faculty at the University and with other 
hospitals especially those in university cities. 
Ministry of Agriculture: Gives support to several institutes active in 
biotechnology, notably the Veterinary Serum Laboratory in 
Copenhagen, The Institute for Veterinary Virus Research at Lindholm 
and the Research Institute for Animal Husbandry at Foulum. 
Ministry of Fisheries: The Institute for Fish Research at Lyngby and 
Hirtshals and the Fishery and Sea Investigations at Hirtshals are both 
active in aspects of aquatic biotechnology. 
Ministry of Energy: At the Research Establishment in Riso plant 
biotechnology and especially protoplast technology is the focus of effort. 
Ministry of Environmental Affairs: Has a largely supervisory role. 
Research funding is not a primary objective. 
Ministry of Labour: At the National Institute of Occupational Health, 
steps have been taken to initiate a programme in gene technology and 
health care problems in related to modern biotechnological procedures. 
Ministry of Industry: Several programmes support R&D in 
biotechnology. Support is given to Technological Service Institutes, 
independent, non-profit institutes working in co-operation with 
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industry and in some fields with the public sector. Several such 
institutes are active in biotechnology, especially those sponsored by 
the Academy for Technical Services, ATV. Notable are, the Gene 
Technology Laboratory, Lyngby, the Danish Aquaculture Institute, 
Horsholm and the Institute for Biotechnology, Kolding. 
Biotechnological Industries and Their Research 
Alfred Benzon A/S 
A small highly specialised company operating in the molecular 
biology and active peptide sector. Major R&D commitment. 
Danisco A/S 
Investing heavily in biotechnology, Danisco and its subsidiaries are 
involved in the production of enzymes, emulsifiers food additives 
and sewage treatment. 
De Danske Sukkerfabrikker A/S 
Active in plant genetics and membrane technology. Passage of new 
rDNA regulations has prevented field trials (in Denmark) of 
genetically modified sugar beet. 
Chr Hansens Laboratorium A/S 
Involved in production of chymosin and lactic acid bacteria cultures. 
Novo Industry A/S 
Novo is a major producer of insulin and industrial enzymes. With 
about 4.000 employees in Denmark, Novo is by Danish standards a big 
company. Almost all biotechnological activities are undertaken by 
Novo, and R&D represents a very large proportion of total turnover. 
Nordisk Gentofte 
Is also involved in Insulin production. Other products include peptide 
and protein pharmaceuticals including human growth hormone, 
serum albumin and factor VIII. 
United Breweries 
Include the Carlsberg Research Centre and Carlbiotech. This 
company has a long tradition of innovation and investment in 
biotechnology. Products and interests include: enzymes, hormones, 




Include; Aarhus Oliefabrik, Convex Biotechnology, Dansk 
Sojaakagefabrik, L Dxhnfeldt, Ferrosan, Fredericia Cellulosefabrik, 
Kobenhavns Pektinfabrik, Lundbeck. 
Almost all Danish biotechnology companies are involved in formal or 
informal relationships with universities and government research institutes. 
Personal contact plays an important role in establishing these important 
networks. Expensive instrumentation is often shared. 
Government Funded Research Programmes in Molecular Biology and 
Technology 
In a well established pattern, the research councils have provided 
funds for scientific research in many areas including molecular biology and 
biotechnology. Applications for such funds are competitive. 
The Ministry of Industry through its Agency of Technology has 
supported biotechnology through a number of programmes. Two in 
particular were specifically designed to support biotechnology. 
THE RESEARCH PROGRAMME FOR BIOMOLECULAR TECHNIQUE 
Approved in June 1984 Parliament voted DKr33.6 million for a five 





Table 2. The following appropriations have been made so far. 
   DKr 1000   
 1984 1985 1986 1987 1988 
Biorganic chemistry 880 741 770 870 870 
Biostructural chemistry 400 818 850 850 850 
Genetic stability 775 767 860 1010 1010 
Purification 150 460 690 840 840 
Plant cells 400 511 679 680 680 
Plant genes 0 1022 1158 1160 1160 
Reproductive biology 300 734 884 1035 1035 
Reagents and vaccines 0 460 901 1150 1150 
Total 2905 5513 6792 7595 7595 
RESEARCH AS A BASIS FOR TECHNOLOGICAL DEVELOPMENT 
Approved by parliament in 1985, this five year programme totals 
DKr300 million, with biotechnology getting DKr 60 million. The research 
councils administer the funds. 
THE NEW BIOTECHNOLOGY PROGRAMME 
Proposed by the government in 1986, funds were approved in 
principle in 1987, but at the time of writing final programme approval has 
not been given, and the following outline is necessarily provisional. 
THE DANISH PROGRAMME FOR BIOTECHNOLOGY 1987-1990 
Introduction 
The recent advances in biological sciences have profound implications 
for applied biology and for Danish production and export, as well as for the 
environment, health care and nutrition. 
Denmark must secure an independent competence in biotechnology, 
characterised by an intensified national effort. The proposed national 
programme has three main elements: 
 Biotechnology Research Centres 
 Education 
 Information and technology assessment 
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The programme will have a broad based steering committee with 
representatives from the ministries, universities and industry. 
Biotechnology Research Centres will form the core of the programme. 
The establishment of 6-10 centres is visualised. A centre would not be a 
physical structure, but the formalised association of research groups in 
institutes and industry. For a country which until recently had a clear rift 
between universities and industry this is a major step. The achievement of an 
intellectual critical mass is one of the objectives of such centres. 
Technology transfer from university to industry would be facilitated 
by the centres leading to rapid commercialisation of research work. 
A call for applications for grants was distributed. Applications 
contain information on the qualifications of participating scientists, the 
nature of the projects and proposed budgets. The biotechnology programme 
is intended to supply only part of the costs, essential infrastructure being 
provided by the participants. Grants would be given for the whole funding 
period, and holders would have considerable flexibility to target fund 
according to changing project requirements. This requires a radical change 
away from closely monitored research funds. 
The centres will concentrate on disciplines such as: biochemistry, 
molecular genetics, immunology, growth physiology, microbiology, bioindustrial 
processing technology and research must be directed to optimisation of micro-
organism, cell cultures and molecular biology applications. 
Each centre will focus upon a large area and funding will depend 
upon the quality and distribution of the applicants. It is intended that the 
following areas be covered: 
 Molecular biology, biotechnological methods and processes 
 Fermentation and down stream processing 
 Plant production 
 Animal production 
 Marine biology, fish farming, use of aquatic resources 
 Food production 
 Environmental protection, ecology, use of waste products 
 Health care 
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At the time of writing more than 50 applications had been received, 
covering the whole target area. 
Education 
There must be an increase in the supply of biotechnologists. Part of 
the programme appropriation is aimed at increasing the output of MS level 
graduates in relevant subjects. 
DKr60 million has been budgeted for education in the programme to 
be used in the following way: 
  DKr million  
1987 1988 1989 1990 
Final year undergraduate stipends 6.0 8.0 8.0 8.0 
Bottleneck courses 2.0 2.0 2.0 2.0 
Curriculum development 3.5 2.5 1.0 1.0 
Retraining 4.5 4.5 2.0 2.0 
Instrumentation for education 4.0 3.0 2.0 2.0 
Total 20.0 20.0 15.0 15.0 
The aim of the funding described above is to increase the production of 
relevant graduates to a level of 150-200 per year, increasing to 300 by 1990. 
Ph.D. level research will take place in research centres, which will be 
obliged to have a number of graduate students on their staffs. The centres 
will also have to arrange courses, workshops etc for other scientists. 
Information and Technology Assessment 
There has been much concern in Denmark over the risks and ethical 
concerns involved in biotechnology. Public information is a key need. 
Research must also be undertaken to evaluate the implications of 
biotechnology for the economy, the environment, public health and nutrition. 
The information programme will focus on providing the public with 
more and better material on molecular biology and biotechnology. This 
should not take the form of ‘official information’. Translation of key 
literature into Danish could play a part of the programme. Existing 
information channels, including schools, public libraries etc. will be used 
for distribution. Access to international studies on technology assessment 




Overall Programme Budget 
The following appropriation has been made for the National 
Biotechnology Programme: 
 DKr million 
 1987 1988 1989 1990 Total 
Research centres 50 100 130 130 410 
Education 20 20 15 15 70 
Information and 
technology assessment 
5 5 5 5 20 
Totals 75 125 150 150 500 
International Collaboration 
Several Danish institutions and companies participate in the EEC 
Biotechnology Action Programme 1985-1989. Denmark is also a member of 
the European Molecular Biology Laboratory, EMBL, and is playing an 
active role in the EUREKA programme. A Nordic collaborative programme 
in biotechnology is being considered, and is seeing first fruits in agreements 
on protein engineering. Co-ordination of international co-operation and 
national programmes is a high priority. 
Legislation Concerning the Control of Research and Production 
In 1986 Denmark was the first country to enact legislation to regulate 
genetic manipulation (an official English translation is available). The law 
is wide reaching and precise details of interpretation will depend upon 







France has a long and distinguished history in the domain of 
biotechnology. The lasting legacy of Pasteur continues to be a world class 
centre of excellence in many areas of biotechnological relevance. 
While the early history of biotechnology was distinguished the recent 
past has been less so. The Pasteur Institute represented the only focus of 
modern biotechnology in France. Many universities and industrial 
laboratories were working in relevant areas, but no overall aims or objectives 
integrated the obvious potential for excellence (Institut Pasteur excepted). 
Moved by the growing impact of the ‘new biotechnology’ of gene 
manipulation and monoclonal antibody production, France decided to assert 
its competence on the world stage. To a large extent this initiative was the 
result of President Mitterand’s personal will to achieve French preeminence. 
The ‘Programme Mobilisateur’ 
Accordingly in 1982 the ‘Programme Mobilisateur’ was launched 
under the aegis of the Ministry of Technology, to cover a mobilisation in 
seven strategic areas of technology, including biotechnology. The original aim 
of the programme was to give France’s biotechnology industry 10% of the 
world market by 1995. Spending in biotechnology by industry and government 
was quadrupled from about FF250 million in 1981 to FF1 billion in 1982. 
Professor Daniel Thomas of the university of Compiègne was put in 
overall charge of the biotechnology programme. Provided with considerable 
means, both financial and political, the programme had an immediate 
rejuvenating and integrating effect on France’s biotechnology endeavour. 
Special importance was given to the agriculture and agro-food sectors, vital 
for long term global strategies. Of great and lasting value has been the 
building of bridges between the industrial and academic research sectors. 
This process is gaining momentum. 
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France has not failed to see the importance of international co-
operation and the programme is specifically orientated to maximising the 
benefits obtainable from such collaboration. No fewer than 60 countries 
have sought French help in relevant areas of application and France has 
much to learn from EEC partners and the USA. 
PRIORITIES OF THE PROGRAMME MOBILISATEUR 
1. to assure logistical support for biotechnology 
2. by consultation with the research administrations, CEA, CNRS, 
INSERM and INRA, involve the scientific community in 
determination of themes and priorities 
3. intervene directly to initiate applied research projects that involve 
industrial/academic collaboration. 
4. the provision of a training programme so as to meet the needs of a 
growing biotechnology industry 
5. break down France’s traditional isolation by forging international 
collaborations. 
I. ELEMENTS OF LOGISTICAL SUPPORT 
France is moving rapidly to establish the infrastructure necessary for 
a dynamic national biotechnology enterprise. Aspects of the infrastructure 
requirement include: 
Establishment of competence in bioinformatics, to include 
nucleic acid sequence data banks, crystallographic data banks, 
Microbial data banks etc. There is a real need to develop a French 
competence in molecular graphics. In many cases existing European 
resources (EMBL for example) imply the formation of regional 
nodes and will offer valuable opportunities for French participation. 
II. THEMES AND PRIORITIES 
Five theme areas have been defined, including molecular biology, 
microbiology, enzymology/protein structure, plants and immunology. 
Gene manipulation is but a means to an end and it should be made 
routinely available to all those with a requirement. 
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Microbial diversity presents a range of untapped potential. 
Classification and studies in microbial physiology and genetics hold 
out the prospect of valuable new products and processes. Anaerobes 
in particular have been largely ignored. 
Enzymes/Protein structure. With the increased capability for 
tailoring genes, it is necessary to develop those tools which make 
protein engineering a possibility. X-Ray diffraction, molecular 
graphics, NMR determinations and the tools of molecular genetics 
form an integrated package for protein design and modification. 
Plant molecular biology has been recognised as a weak link in the 
economic growth of biotechnology. France defined this priority area 
even before the EEC. Government institutes, especially INRA (Institut 
National pour la Recherche Agronomique) have international 
standing. The main requirement is increased manpower. 
Immunology has been the key to dramatic changes in diagnosis. 
Monoclonal antibodies resulting from hybridoma technology have 
created a new industry in rapid diagnosis, from pregnancy to swine 
fever. French industry has moved fast to remain competitive, but 
investment in basic research and training is essential. 
III. INITIATION OF PROJECTS 
The first area for action is the agro-food sector and the six following 
projects have been designated as being of industrial priority. Research in 
these areas will have direct economic benefits to French competitiveness. 
Identification and classification of micro-organisms, development 
of fast diagnostic tools. 
Development of competence in mixed or sequential culture 
methodology in the dairy and brewing industries. 
The optimisation of enzymes in media of economic importance: 
complex media, heterogeneous media, non-aqueous media. 
Special emphasis on R&D of milk related bacteria in all sectors of 
the French food industry. 
Optimisation of fermentation processes, both traditional and modern. 
 
49 
Improvements in the understanding and control of the vinification 
process. 
At the end of 1985 FF35 million had been set aside for these priority 
areas. 
The second area for action is health, where France has a number of 
internationally competitive companies. Priority is to be given to the early 
recognition of disease states. Biotechnology has enormous scope for 
applications in preventative medicine: vaccines, diagnostics etc. for both 
human and veterinary applications. The fate of proteins from expression, 
through extraction and purification in commercial cultures is a priority. This 
will be linked to structural studies. 
IV. TRAINING 
Centres of excellence, ‘Poles’ in the French nomenclature will meet 
the training requirements of the scientists and engineers needed to steer 
France’s biotechnology industry towards the future. Centres at Compiègne 
and Toulouse are being followed by several others. 
V. INTERNATIONAL COLLABORATION 
The ‘Programme Mobilisateur’ is committed to close collaboration 
with European initiatives such as the BAP and BRIDGE programmes of the 
EEC and the EUREKA programme. The contribution of industry to these 
collaborative ventures will be critical. The Versailles Summit in 1986 
defined the need for an international biotechnology network. France already 
contributes to model structures such as EMBL (France contributes 22% of 
operating funds). 
France has recognised the potential of collaboration with Latin 
America. A French delegation visited Argentina in 1986 and Brazil in 1987. 
Mexico has an established collaboration with France in the field of 
fermentation in the solid phase. ORSTOM, concerned with French overseas 
relations with the 3rd world is concerned with the potential of 
biotechnology to add value to marginal agriculture. 
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Public Institutions in Biotechnology 
France has an established tradition of excellence in many fields of 
fundamental and applied research. The ‘Programme Mobilisateur’ referred 
to above rectifies an omission in the case of biotechnology. The research 
organisations active in biotechnology include the following: Centre des 
Etudes Nucleaire, CEA; Centre National de la Recherche Scientifique, CNRS; 
Institute National de la Recherche Agronomique, INRA; Institut National de 
la Santé et de la Recherche Medicale, INSERM; Institut Pasteur and the 
universities. 
All of these organisations now have a structure which permits 
academic-industrial technology transfer. The Pasteur Institute is now a 
hybrid organisation with commercial and basic research activities. 
The CEA, rather like equivalent institutions in W Germany and the 
United Kingdom has peripheral, but significant interests in 
biotechnology. These range from the obvious association of radio-
labelling and diagnostics, through to the development of an 
independent competence in much of the relevant molecular biology 
and immunology. 
The CNRS is France’s leading agency for the funding of 
fundamental research. It has many institutes and employs a large 
number of France’s fundamental research workers. Increasingly the 
CNRS is responding to the call for more applied research trends. The 
CNRS has played a major role in developing molecular biology and 
immunology in France. 
INRA has always had a strong commitment to applied agricultural 
research. In recent years it has made determined moves to be at the 
forefront of biotechnology. Research on animal vaccines and 
immunogenicity is world class. INRA has several exclusive licencing 
deals with French companies, particularly in the area of diagnostics 
development. 
INSERM, with its responsibility for medical research has always 
had applied research as a major part of its portfolio of work. 
Immunology research is one of INSERM’s foci of excellence. INSERM 
is moving towards a clearer interpretation of its role in a scientific 
climate that increasingly heeds the call of economic necessity. 
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INSERM has close relations with the newly founded company 
Immunotech, which commercialises the results of research. This 
involves a far greater degree of communication with other 
institutions and industry. Other areas of activity include the 
development of new bioactive agents, lymphokines and artificial 
vaccines. 
The Institut Pasteur has a purely commercial division, Pasteur 
Production, a classic example of government privatisation. It is 
responsible for vaccine production and therapeutics. Its cell culture 
facilities are outstanding as are the basic biology support services. 
Research in the government sponsored Institute proper is supported by a 
number of funding agencies and covers areas as diverse as chromosome 
structure, microbial physiology and AIDS. Government funds of FF100 
million are targeted at the disease, much of the spending is on the 
Pasteur facilities, which have developed sensitive tests. 
The universities also make a contribution to biotechnological 
research. The university of Compiègne and certain other facilities are 
developing strong industrial and institutional links. 
The Biotechnology Industry 
The French biotechnology industry is dominated by three large 
pharmaceutical companies, Rhône-Poulenc, Roussel-Uclaf and Sanofi with 
in addition a much less significant ‘second division’ including both agro-
food and pharmaceutical companies such as Bertin, Mérieux, Lafarge-
Coppée, Limagrain, Moet-Hennessey, Serono. 
Unlike the USA France has not seen a wave of opportunistic start ups 
in biotechnology. There have however been a number of company launches 
from the public sector and from big industry. Companies such as 
Immunotech, Transia and Transgène would fall into this category. 
Transgéne is a start up funded by predominantly government originated 
funds. An increasing proportion of the ownership has been acquired by 
private investors. Transia is a genetic engineering company set up by a 
consortium of agro-food industry. Biosys is a university of Compiègne spin 




A fourth category of biotechnology companies would be the large 
agro-food companies with a small activity in the field. Such companies are 
typified by Fromageries Bel, Moet Hennessey, Gervais-Danone. 
The interest level and commitment to biotechnology varies from 
Sanofi’s state of the art competence in rDNA and expression systems, to a 
straightforward requirement for better process control in the cheese industry. 
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1.4. THE FEDERAL REPUBLIC OF GERMANY 
Helmut Zeittrager 
Introduction 
The government of the FRG was one of the first to recognise the 
strategic significance of biotechnology. By 1974 the BMFT 
(Bundesministerium für Forschung und Technologie) had already begun the 
promotion of biotechnology. Dechema (Deutsche Gesellschaft für Chemisches 
Apparatwesen), an industrial representative body for the chemical industry 
played a role in dissemination of information and in 1978 was instrumental 
in founding EFB, European Federation of Biotechnology. 
The German Biotechnology Co-ordinating Committee, 
Arbeitsgemeinschaft Biotechnologie, was founded in 1978 and acts to 
integrate biotechnology activities in both industry and academie sectors. 
The first German biotechnology programme, the ‘Leistungsplan’ 
(Performance Plan) was launched in 1979. It incorporated many of the key 
proposals made by Dechema in collaboration with the BMFT. In the period 
1979-84 a total of US$350 million was allocated to biotechnology. 
Other government departments supporting research in biotechnology 
include: 
 Deutsche Forschungsgemeinschaft, DFG, who focus on basic 
research. In 1984 bioscience funding accounted for US$107 million, 
one third of the total funding. DFG is an association of universities 
funded by local and federal government. 
 BMWi, Federal Ministry for the Economy. 
 BML, Federal Ministry for Agriculture. 
The BMFT is keenly aware of both the opportunities and risks 
presented by biotechnology. Their position is summarised in a booklet 
obtainable from the BMFT in Bonn, FRG. 
In a major policy speech in May 1983, the Chancellor defined the 
government position with regard to biotechnology: 
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Our society needs technical progress. Globally, developments are 
taking place at a furious pace, in the information and communications 
technologies, in new production techniques, in biotechnology and in 
the development of new materials. These offer opportunities, but also 
carry with them dangers. We know that not everything that is humanly 
possible is suitable for mankind. This is the challenge which we have 
to face. We must seek to remain master of the technology. 
The Federal government subsequently drew up a programme for 
applied biological and biotechnological research for the period 1985-88. 
Biotechnology was given a central innovative role among the applied 
sciences. The following research objectives were defined: 
 to promote top quality science in areas relevant to the future 
competitiveness of the state. 
 to evaluate opportunities and hazards, introducing appropriate 
safety regulations and debating ethical considerations at an early 
stage of progress. 
 to promote the training of a new generation of biotechnologists. 
FEDERAL FUNDING 
At the beginning of 1986 it was announced that the total Federal 
funding for the period 1984 to 1989 would be increased to DM 1.14 billion. 
Roughly 1/3 was targeted to institutions and another 1/3 to four new gene 
centres, other centres of excellence and infrastructure, including support for 
new biotech ventures. The bulk of the remaining money is designated for 
development of facilities in ‘bottleneck’ areas such as cell culture 
technology, fermentation, enzymology, plant biotechnology etc. 
One of the essential components of the present funding is a generous 
investment in the essential enabling science for biotechnology. The federal 
government has accepted that this is essential if the commercial focus of 




Table 1. Federal Spending on Biotechnology, in millions of DM. 
 1984 1985 1986 1987 1988 1989 Total 
Institutional funding        
EMBL, EMBC, GBF etc.  37,4 45,2 59,2 69,2 67,1 58,1 336,2 
Gene centres and 
strategic projects 
14,3 19,0 24,0 26,0 32,0 37,0 152,3 
Indirect support of 
industry, databanks etc. 
2,0 2,0 15,0 27,0 35,0 40,0 121,0 
Support for essential 
technology 
0,7 2,0 3,2 3,8 3,8 2,5 16,0 
Technology Theme 
Support 
11,3 13,0 14,0 16,8 20,4 24,6 100,1 
Microbial technology/ 
gene technology 




10,6 14,0 18,3 21,8 33,5 42,2 140,4 
New technology/ inter-
disciplinary activity 
12,4 2,3 2,0 6,5 9,2 13,0 45,4 
Plant and Animal 
Research 
       
Plant culture and raw 
materials 
3,2 5,5 5,0 6,0 7,0 8,0 34,7 
Alternatives to animal 
research/ biological 
safety 
5,6 10,0 18,6 19,9 20,4 22,6 97,1 
Totals 111,4 132,3 175,3 213,2 244,9 264,6 1141,7 
To achieve these ends the BMFT has instituted a process of consultation 
with Deutschen Forschungsgemeinschaft, DFG, the federal science research 
funding body; Max-Planck-Gesellschaft, the very wealthy research foundation 
with institutes both in Germany and abroad; and the Verband der Chemischen 
Industrie, VCI, the German Chemical Industries Association. 
In addition to the broad themes outlined earlier, the BMFT has 
identified several specific objectives, some of which are detailed in Table 1, 
above. Many of these ‘bottlenecks’ require commitment of new manpower 
resources, available only education at high school and university level is 
appropriately orientated. 
Already mentioned are: 
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 Genetic manipulation 
 Bioprocessing 
 Enzymology 
 Interdisciplinary measures 
At the forefront of much of this work will be the university sector 
and government research centres, most notably, GBF, Gesselschaft für 
Biotechnologische Forschung, in Braunschweig and the Kernforschungsanlage, 
KFA, Julich. These two centres backed by both federal and regional funds 
have become showpiece institutes. The GBF went through a difficult period 
in the early 1980s and there was even question of closure. Appointment of 
the Present Director, Professor Joachim Klein preceded a dramatic turn 
around in the fortunes of GBF. Strong backing from the regional government 
of Lower Saxony has been a major spur to success. Like GBF, KFA is 
strongly backed by local government, North Rhine Westphalia. Dialogue 
with industry will be an essential component of long terra project planning 
for both Centres. Most untypically, the BMFT is prepared to consider the 
funding of projects over a period of up to 15 years. 
THE BIOTECHNOLOGY INDUSTRY IN GERMANY 
Approximately 100 companies in Germany have a significant 
involvement in modern biotechnology. Many other companies, notably in 
the food and beverages sector, have a peripheral involvement. The scope of 
involvement is very large. Giant firms such as Hoechst are interested in 
biotechnology in a number of areas from insulin production to insecticide 
resistance. Small companies such as Biosyntech can offer services such as 
custom nucleotide or peptide synthesis. On the technical side engineering 
based companies can supply fermentor and bioprocess technology. 
Total industrial biotechnology R&D expenditure in FRG for 1985 (last 
year for which results are available) amounts to about DM 700 million, 
based on biotechnology related sales of DM 20 billion. 
To date it is true that the bulk of investment and production has been in 
the pharmaceuticals and diagnostics sectors. In the long term there will be a 
gradual increase in the emphasis of agricultural applications and plant genetic 
engineering. The strong Green movement is a force to be reckoned with, even 
by the strongest companies. One embarrassing incident involving the 
Heidelberg based firm Gen-Bio-Tec occurred when they failed to notify the 
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Safety Commission of their work on expression of anti-clotting agents in 
bacteria. Gen-Bio-Tec was at the time in receipt of major Federal and 
regional support. For weeks the future of that support was placed in doubt. 
Facilities to enable new biotechnology start-ups are becoming more 
available. Venture Capital, in particular, is becoming readily available to 
firms with a sound technology. Unlike the USA, genuinely high risk 
investment is unavailable. In the past five years almost thirty significant 
new start-ups have been established in FRG. 
Dechema plays a central role in representing the interests of German 
biotechnology companies and provides a forum for discussion and debate in 
the famous Achema congress series. Held every three years Achema is one 
of Europe’s most important shop windows on chemical engineering and 
biotechnology. Themes treated include sociological issues arising from 
public concern at issues such as genetic engineering. 
The Hannover Biotechnica series of fairs, held annually was 
launched in 1985 and is already rivalling Achema for prestige in the field of 
biotechnology. Although backed by Lower Saxony, the Hannover fair has 
no direct relation with the GBF, although GBF and other local enterprises are 
given very prominent pavillions. 
SECTORIAL CONTRIBUTION OF BIOTECHNOLOGY 
Pharmaceuticals is a major business area in FRG, with companies 
such as Hoechst, Bayer and BASF as giants in the first rank. Medium sized 
companies include Boehringer-Mannheim, Boehringer-Ingelheim and its 
pharmaceutical subsidiary Thomae. Henkel, Merck and Schering. All of 
these have involvements beyond pharmaceuticals. Specialist pharmaceutical 
companies of medium size would include Behring, Biotest and Knoll. Many 
of the new start-ups are active in pharmaceuticals and have staffing levels 
of 5 to 100. Examples of these include Bioferon and the Bissendorf Bio 
technology Group. 
There is a strong emphasis on the latest developments in biotechnology. 
Pharmaceuticals in trials and production include, insulins, coagulation factors, 
monoclonal antibodies, urokinase, antiviral agents, interferons, lymphokines, 
interleukines, TPA, TNF, recombinant vaccines. Market projections for 1995 
show a domination by products based on the new technology. 
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Agriculture is receiving more attention now. Both the Federal and 
regional governments are defining this as a priority area. Action by the 
European Commission is helping to focus attention on the prospects for a 
post subsidy agriculture. The creation of genetically engineered plants is a 
delicate issue in the FRG. Field release of such plants is subject to fiercely 
critical scrutiny by both ecologist groups and the governments. The incentive 
for carrying out such work in Germany is accordingly very small. In 
university departments, such as Hannover and Bielefeld and at the Max-
Planck Institute for Plant Breeding in Min, work nonetheless continues into 
such vital goals as increased nitrogen uptake by cereals and other crop plants. 
Unless there is a campaign to stimulate awareness of the value of 
biotechnology for agriculture, it is likely that the industrial contribution to 
research in Germany will be limited. 
Chemical Industry. The application of enzymes to the cost effective 
production of both raw materials and speciality chemicals in stable 
bioreactors is receiving dose attention. Centres such as GBF are 
collaborating with industrial laboratories so as to engineer temperature 
stable enzymes, capable of working effectively in both aqueous and non-
aqueous solvent systems. Microbial leaching and concentration of high 
value elements and compounds is receiving attention from the metal 
extraction industry. Many of the large chemical companies are moving into 
more biological applications areas as the potential of biotechnology 
becomes apparent. Such activities would include applications of microbial 
polysaccharides and crude oil recovery. 
ENVIRONMENTAL PROTECTION 
The microbial breakdown of waste figures largely in a number of 
sewage specialist companies. The strong ecological groups in the FRG make 
it politically expedient for the government of the day to make considerable 
moves to meet their demands. Biological treatment of effluents with 
engineered microbes remains unlikely in the present anti-release climate. 
University joint ventures are in favour with the government and there 
is considerable pressure on industry to participate. The new Gene Centres 
have been founded partly with industrial support. 
The University Sector, including the Max-Planck Institutes and state 
funded institutes still carries out the bulk of research in biotechnology, 
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particularly at the precompetitive level. As intimated earlier strategic 
collaborations with industry are increasing in number and quality, although 
fears about industrial confidentiality may cause some concern. With 
government support, general excellence in over 300 departments of 
biological sciences has crystallised into the formation of four Gene Centres 
located at Min, München, Heidelberg and Berlin. These centres were 
established around existing centres of excellence, but the inflow of central 
funds has allowed the elaboration of new building and equipment. 
One of the central weaknesses in the FRG’s biotechnology has been the 
traditional University/Industry divide. The FRG has jealously dung onto the 
demarcation, well after its abandonment by many other European states. 
Among academics pure research still has enormous ‘cache’ compared with 
applied industrial research. Salary differentials, while significant, do not 
mean the difference between a bearable and good standard of living. In the 
FRG academics earn a comfortable living. Biotechnology itself is one of the 
forces bringing about a reappraisal of the situation as fundamental rapidly 
becomes applicable. Unfortunately industrial support of ‘academic research is 
concentrated on institutes such as GBF, Braunschweig or KFA Julich, rather 
than universities ‘per se’. Institutes such as the German Cancer Research 
Centre in Heidelberg have played a useful role in creating a respectable 
image for applied research. EMBL, the prestigious international laboratory, 
also in Heidelberg, is also strengthening this consensus by establishing more 
links with industrial ventures, including the licensing of know-how. 
The road to a doctoral level qualification is very long. A diplom 
awarded at age 25 or 26 must be followed by up to five years research 
before the award of a doctorate. There is much opposition to changing the 
system, although many percieve it to be overdue. 
CONSEQUENCES OF THE BMFT BIOTECHNOLOGY INITIATIVE 
In the context of enabling technology for biotechnology, the BMFT 
initiative has provided substantial funds for universities to do work in 
bottleneck areas such as: bacterial physiology, plant physiology and 
biochemistry and bioprocessing technology (see Table 1). 
The Gene Centres are designed to radically upgrade German 
competence in the field by giving substantial funds and prestige to already 
recognised centres of excellence. The research aims of these groups are: 
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 elucidation of genetic structures; 
 action and interactions of genes; 
 control of gene expression. 
The Köln Centre based on the Max-Planck Institute for plant culture 
research and the University Genetics Institute is concerned with plant 
genetics and the use of plants for the expression of foreign genes, plant cell 
culture and micropropagation, the genetic basis for nitrogen fixation. Other 
work focuses on viral genetics and general aspects of cell biology and 
biochemistry. 
The Heidelberg Centre, located at the university with input from the 
Cancer Research Centre focuses on microbial genetics, virology and 
Immunology. Work is targeted at medical problems: diagnosis, therapy, 
neurobiology etc. 
The Munich Centre links the University and the Max-Planck Institute 
for Biochemistry. Work focuses on the development of sequencing 
technology and chemical synthesis of genes. Ancillary work in immunology 
and cell biology builds upon this competence. Plant cell biology focuses on 
gene transfer. 
The Berlin Centre continues the thrust of excellence in gene 
technology and draws upon the skills of the Max-Planck Institute for 
Molecular Genetics, which is world renowned. Analogous to the Gene 
Centres are two BMFT designated Centres of Excellence in bioprocessing 
technology. These centres are designed to provide a skill and knowledge 
base for the fundamental skills which underpin commercial processing 
technology. The first centre has been established in Lower Saxony and 
receives input from the universities of Braunschweig, Göttingen and 
Hannover, and the GBF, Braunschweig. GBF is the leading German centre 
for process and fermentation technology. Its diversification into other areas 
of biotechnology has secured a status unparalleled. 
The Lower Saxony Centre will have its centre of gravity in 
Braunschweig and will concentrate on the enzymatic and microbial 
processing of carbohydrates. Antibiotic production processes, animal cell 
processes, culture development, cell reactions and measuring methodology. 
Computer and information systems research will support control system 
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development and data treatment. Bioreactor development will be an almost 
automatic consequence of the skill base in Lower Saxony. 
The second centre, associated with the University of Stuttgart started 
work in 1987 and 1988 and consists of five institutes focusing on Bioprocess 
Engineering, Biochemical Engineering, Applied Microbiology, Applied 
Genetics and Mammalian Cell Culture. 
OTHER STRATEGIC PROJECTS 
The development of biotechnology worldwide demands a flexibility 
of response from the German research base so as to maintain competitivity. 
Interdisciplinary fertilisation (electronics/enzyme technology) is seen as 
critical. New centres could and will be designated as appropriate. Topics 
under consideration include biocatalysis, chemical synthesis of peptides and 
genes, protein engineering, etc. New centres will include both institutional 
and industrial representation to a greater extent than is presently the case for 
the Gene Centres. GBF has broken this ground by establishing a healthy 
portfolio of industrially funded projects. 
INDIRECT MEASURES 
Might include the financing of studies on aspects of regulation, or the 
provision of training funds for specific problem areas. The provision of 
funds in this category is deliberately flexible. 
ENCOURAGEMENT OF ENTERPRISE 
The BMFT is keen not to lose the innovative potential of academic staff 
and especially staff in small and medium scale enterprises in the 
pharmaceutical and chemical industries, in the food industry. Such 
innovations could have applications in sectors such as plant biology, 
industrial scale production, commercial microbiology etc. Bioreactor 
technology could be encouraged by stimulating joint venture activity between 
equipment, engineering and research activities. To meet such need funds shall 
be available to encourage product orientated innovation in biotechnology. 
ENCOURAGEMENT OF THE BIOTECHNOLOGY INDUSTRY 
Industrial potential in the biotechnology industry is to be reinforced by 
targeted BMFT support. The basis of support is the provision of training and 
support for acquisition of the latest in biotechnological methodology. Such 
support should cushion the risk undertaken by industry active in these areas. 
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AREAS TO BE TARGETED FOR SUPPORT 
 Cell culture 
 Gene manipulation 
 Process technology using plant animal and human cells and 
manipulated micro-organisms. 
 Enzyme technology for medical and food applications 
 Apparatus and equipment development 
 Bioreactor development, measurement and control systems 
All independent enterprises with an interest in the above areas should 
be eligible for support up to the level of 40% of costs to a maximum of 
DM600 thousand per enterprise. Other funds for personnel, equipment etc 
are available. Total budget for this programme was fixed at DM100 million 
over four years from January 1986. 
TRAINING FUNDS 
To provide the manpower necessary to sustain growth, the Federal 
government has designated training as being a major priority and 
accordingly has provide substantial funds. Training funds are targeted at 
three areas: 
 International scientific collaboration 
 Biological chemistry 
 Biotechnology further training 
Generally speaking the training is orientated towards the areas 
previously defined as important. 
ENCOURAGEMENT OF ACADEMIC/INDUSTRIAL COLLABORATION 
Particularly in the area of precompetitive research it is seen that a 
dose relationship between factory and university could be beneficial for the 
Federal Republic. Areas of particular interest in this context would be 
environmental projects and risk assessment projects that could take place 
without any threat to industrial security. The work in this area could be 
chosen on the basis of national and international importance. Flexibility in 
approach and execution of such projects is seen as essential. To this end the 
normally detailed and frequent review procedures will give way to a less 
tightly controlled assessment procedure. The basic project areas could lie in 
the same theme regions as previously outlined: 
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 Microbiology and microbial genetic techniques; 
 Cell culture and cell fusion technology; 
 Enzyme technology; 
 Biological processing (including food technology); 
 Plant and animal research; 
 Safety research. 
Other areas may be defined with the growth of knowledge and 
experience. The dialogue between science and industry will in itself achieve 
further definitions. Many areas of development essential to long term industrial 
competitivity could be developed. In some cases collaborations similar in 
concept to the British and French club themes would be used to provide 
enabling technology to a number of client companies and universities. 
To identify just a few project areas noted by the BMFT. 
Microbial Technology 
Gene transfer technology to improve microbial cell culture yields etc. 
Genetic stability, ecology and toxicology of mixed microbial cultures. 
Possible applications of mixed culture techniques. 
Cell Culture 
Development, control, standardisation of bioindustrially interesting cell 
lines 
Development of cell storage techniques 
Enzymology 
Biocatalysis, stability and characterisation of immobilised and carrier 
associated enzymes, enzyme complexes and cells. 
Bioprocessing 
Bioreactor mechanics, construction and applications 
Evolution of biosensors for process monitoring 
Plant and Animal Biology 
Development of plants for food, raw material and environmental 
applications 
Diagnosis, prophylaxis and treatment of animal disease. 
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Safety and Technology Monitoring 
Development of safer fermentation and bioprocessing technologies for 
genetically manipulated organisms and their products. Socio-economic 
aspects of biotechnological developments 
New Areas of Applied Biology 
Fusion of biomolecular and microelectronic technologies Enzyme 
design and protein engineering, gene synthesis 
Other areas of significance include: microbial screening, effluent 
microbiology, microbial collections, gene technology projects, human and 
animal cell potential, plant cell evaluation, biocatalysis, enzyme production, 
biocatalyst based production, new bioreactor systems, upstream processing, 
control technology, plant breeding and raw materials, natural product 
screening, alternatives to animal research, ecological impact of genetically 
modified organisms, safety and genetically modified organisms. 
INTERNATIONAL COLLABORATION 
The BMFT places great importance on collaboration with other EEC 
member states, especially within the framework of EEC mediated 
collaborative programmes such as BEP (Biomolecular Engineering 
Programme), BAP (Biotechnology Action Programme) and projects such as 
ECLAIR which seek to study alternative, bioindustrial, applications for 
Europe’s agricultural potential. 
The OECD initiative in determining regulating principals for 
molecular genetics is welcomed by the FRG. Collaboration with the OECD is 
a valuable aspect of international collaboration in biotechnology. 
Collaboration with industrial nations is largely focused on Europe 
and to a lesser extent the United States. Realisation of the Japanese 
Human Frontiers Programme may well involve German groups. 
Collaboration with developing nations is a theme of several recent 
initiatives. Notably, the GBF Braunschweig has initiated a programme 




The Role of the GBF, Braunschweig 
The GBF was Europe’s first dedicated centre for research and 
development in biotechnology. After a period of uncertainty, the 
appointment of the present director, Dr Klein has given GBF a powerful and 
widely appreciated authority in many areas of biotechnology. 
Originally founded by the Volkswagen foundation, the GBF has since 
1976 been cofunded by the Federal government (90%) and the regional 
government of Lower Saxony (10%). 
The main research areas of the GBF are: 
 Microbial products of synthesis and biotransformation; 
 Molecular and cell biology of biologically active proteins;  
 Industrial enzymes and protein design; 
 Development of bioprocessing. 
In addition the GBF has played host to the German Collection of Micro-
organisms, DSM, since 1979. A separate legal entity, DSM is poised for 
commercial exploitation as one of the world’s foci of microbial strain 
deposition. 
In addition to precompetitive applied research, the GBF has a number 
of confidential collaborative projects in hand. While GBF can not be as 
secure as an industrial laboratory, the industrial partners in such contract 
research have been well satisfied with the GBF’s role in such collaborations. 
Protein Design was launched as an interest in 1985. In the past year 
development of hardware and software components of the system has 
matured and this area looks set to become one of GBF’s principal activities. 
Potential for partnerships with industry and commercial exploitation of this 
growing know-how is large. The pharmaceutical industry is particularly 
interested in the prospect of exploiting protein engineering for the 
production of new or modified biologically active peptides. 
The fermentation and bioprocessing facilities of GBF are first rate and 
already act as a focus for industrial development and pilot studies. The 
‘Biotechnikum’ is equipped with fermenters up to 5.000 liters capacity. 
Down stream processing facilities can be used to model processes up to 
semi-industrial scale – a valuable national resource. The ‘Biotechnikum 
Service Unit’ gives back-up to process engineering when no commercially 
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obtainable support is available. Such back-up might include the production 
and isolation of materials not available on the market. 
Sophisticated computing and spectrographic facilities back up all 
aspects of development work, and contribute to a growing excellence in the 
understanding and implementation of novel process control systems. 
Licensing of GBF technology is possible, although offered preferentially to 
German firms. 
Almost all of the FRG’s major chemical and bioscience companies 
have entered into collaboration with the GBF in at least one project over the 
past ten years. Roughly 1/3 of GBF’s industrial partners are foreign, the 
majority from Europe. The opening up of new industrial contacts and 
ventures is facilitated by an outward looking attitude characterised by 
seminars and invitations in both industrial and institutional laboratories. 
The German Chemical Industries Association has created a GBF support 
group to strengthen industrial appreciation of the resource. 
GBF has about 425 staff of whom 160 are scientists. The 1987 budget 
amounted to almost 70 million DM, including a large 61 element of new 
building support, which should do much to alleviate the recent 
overcrowding problems. 
GBF has noted the potential of developing countries to benefit from 
several biotechnological advances. Without adequate training and local 
expertise such advances cannot be applied. The provision of trained 
scientists is a choke point which GBF aims to remedy by an in-house 
training programme. Already three course have sent 60 third world 
scientists back to their home countries with an appreciation of the modern 
technologies and their applicability in a third world environment. 
Of 250 applicants for the first course the 20 selected included five 
from Latin America. All costs, including air fare, were born by the GBF. 
Lower Saxony has made clear its intention to become the foremost 
region for German biotechnology. Recently it became committed to 
supporting three biocentres collaborating with the GBF, Braunschweig 
Technical University, the University of Hannover and the University of 
Göttingen. This structure will give the area a solid mass of excellence. The 
only problem foreseen is that of staff recruitment. 
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Growth in biotechnology is characterised by the rapid expansion of the 
Bissendorf Biotechnology group. Next to GBF they have launched a major 




Presentations by Drs Tzotzos and Dourtouglou 
Presentation by George Tzotzos  
INTRODUCTION 
Greece’s economy has several similarities with that of Latin 
America. Emphasis is placed on services and traditional agri-industries, 
while Greece’s chemical industry was heavy commodity and obsolescent; 
unable to incorporate biotechnological advances. 
In Greece as a whole the worldwide trend, of movement away from 
manufacturing to service industries, is being observed. The Greek scientific 
community has two components, a small domestic element and a large and 
conspicuously successful international element. 
To encourage the development of an infrastructure capable of 
supporting a Greek biotechnology industry the government launched 
incentives for the repatriation of Greek scientists. These took the form of 
two international centres of excellence 
 The Institute of Molecular Biology and Biotechnology, IMBB, at 
Heraklion, Crete and: 
 The Hellenic Institute Pasteur launched a hybridoma and 
monoclonal antibody facility. 
Participation of Greek scientists and laboratories in European and 
EEC ventures such as EMBL/EMBO and the BEP and BAP programmes has 
increased the flow of knowledge and awareness in biotechnology. 
With the support of the government the first Greek biotechnology 
company, Biohellas, has recently been launched. 
These measures have provided a solid basis for encouraging the 
repatriation of Greek scientists working overseas. 
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WHAT EXPERIENCE HAS BEEN GAINED IN THE PAST FOUR YEARS? 
1. Finance, management and marketing are integral parts of the 
biotechnology process. Small economies cannot meet demand for 
these skills at an adequate level. 
2. R&D scale-up is investment intensive, making redundant the 
notion that biotechnology is cheap.  
3. Expertise in microbial physiology and fermentation is embryonic 
in Greece and probably elsewhere too. Training in biochemical 
sciences is no panacea. 
In the light of the above it appears unlikely that transfer of 
technology and strengthening of the biotechnology industry can be achieved 
without a coherent policy focusing on target definition, commitment of 
resources and openness to the scientific and entrepreneurial communities 
beyond national borders. The latter is of paramount importance particularly 
in cases where national economies are unable to sustain technological 
growth at the required pace. Greece’s efforts to overcome the problems, 
briefly outlined above, is presented in Dr Dourtouglou’s paper. 
Presentation by Dr V. Dourtouglou 
Greece has come to appreciate the potential of modern 
biotechnological innovations. Interest in government circles was first 
stimulated at the beginning of the 1980s, when a national support policy for 
both private and public sector involvement in biotechnology was outlined. 
Of primordial importance in assisting Greek biotechnological 
development is the provision of training. In the medium term such training 
should be geared to industrially relevant aspects of biotechnology such as: 
 enzyme engineering; 
 bioreactor use and development; 
 diagnostic kit development; 
 agricultural biotechnology, micropropagation etc. 
With no advanced industrial base available to assist the development of 
biotechnology and no suitable funding structures in Greek financial markets, 
it must be assumed that only by 1994 will Greek biotechnology enter a 
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positive cash-flow situation. The role of state intervention is therefore critical 
to the development of a domestic biotechnology enterprise. 
ROLE OF THE STATE 
A number of ministries have interests in biotechnology and the 
following all have a budgetary allocation for biotechnology. 
 Ministry of Energy, Industry and Technology, General Secretariat 
for Research and Technology; 
 Agricultural Ministry; 
 Health and Social Security Ministry; 
 Ministry of Environment and Urban Planning; 
 Ministry of the National Economy. 
As yet there is no formal interministerial co-ordination, but the 
Research and Technology Secretariat has drawn up a plan which considers 
other ministries and research interests in biotechnology. 
The Research and Technology Secretariat may gain the authority to 
steer national biotechnology policy with the approval of all ministries. 
Three laboratories in Greece can be considered to have significant 
resources in biotechnology. These are: 
 IMBB Heraklion 
 Centre for Biological Research of the National Research Foundation 
 Hellenic Institute Pasteur, Athens 
Since 1979, university research work has received government 
backing, but as explained elsewhere, Greek universities are viewed 
primarily as training, not research, establishments. 
Despite the identification of biotechnology as a national priority, the 
production capacity of existing related industry has limited both project 
development and proposals. 
With the support of the government, two investment banks a the 
Pharmaceutical Producers Association of Greece launched the first Greek 
biotechnology company, Biohellas, in 1984. Today two companies in Greece 
have a significant biotechnology commitment, the second being Vioryl. 
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Having manifest the industrial application of biotechnology as a 
priority, the government passed legislation to aid investment in advanced 
technology. Guidance was given to universities and secondary education so 
as to achieve an output of graduates able to support commitment to high 
technology. The universities have responded by organising training 
programmes in rDNA and other aspects of biotechnology. 
With 20% of the national workforce in agriculture, it was logical to 
place emphasis on agro-biotechnology, including the support of small 
companies active in micropropagation and biomass. Other areas include 
waste treatment and diagnostics of agricultural relevance. 
To obtain a redeployment of skills, retraining and reorientation 
towards high technology is perceived to be of importance. 
FINANCING BIOTECHNOLOGY 
A rapidly growing slice of the total R&D budget of 15.56 billion 
drachma is being spent on biotechnology. 




A relatively large percentage of biotechnology spending is being 
devoted to agricultural applications, centred on a number of sites and institutes. 
Healthcare biotechnology is an important area and relevant research 
is focused on the IMBB and the Hellenic Institute Pasteur. It is still too early 
to see the consequences of spending in health care and agriculture. In 
industry the first concrete manifestation of progress is Biohellas, but here 
too many projects are in development rather than commercial exploitation. 
Biohellas has a privileged relationship with IMBB, with a licence to 
commercialise IMBB developed innovations. 
Vioryl is more independent of government support and has 
successfully commercialised pheromone technology. It is now trying to 
master monoclonal antibody production. Other interests include biocatalysis. 
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A number of small firms are commercialising agricultural aspects of 
biotechnology, in vitro technology and micropropagation. The Ministry of 
agriculture should be approached for information on these firms. 
EEC support is helping both industrial and academic laboratories to 
build fruitful relationships with other biotechnology laboratories operating in 
the EEC. These ventures will make a large contribution to the Greek 
knowledge base in precompetitive research relevant to biotechnology industry. 
There is, in conclusion, much in the Greek experience of 
biotechnology that could be of direct relevance to developing countries 
interested in the possible benefits of biotechnology based industrial ventures. 
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1.6. THE REPUBLIC OF IRELAND 
Brendan Finucane and Staff of BioResearch Ireland, Dublin 
Prepared by the biotechnology group, National Board for Science and 
Technology (now replaced by BioResearch Ireland), presented by Brendan 
Finucane 
Introduction 
An Irish National Biotechnology Programme was initiated in 1983 by 
the National Board for Science and Technology, and the Industrial 
Development Authority. The programme’s objective is to promote and 
assist the application of biotechnology in Irish industry, agriculture and 
other areas of social and economic development. 
The major areas of application in Ireland are in agriculture/food, and in 
the healthcare and pharmaceutical industries. Agriculture occupies 15% of the 
Irish workforce directly, and the food and drink industry employs 26% of the 
industrial workforce. Exports in 1986 of food and drink were worth over 
US$3.2 billion or 23% of total exports. It is thus a very important sector and 
one in which biotechnology can play an important role. 
The healthcare and pharmaceutical sector is also important for 
Ireland and has undergone considerable growth in recent years. The 
Industrial Development Authority, IDA, has been very successful in its 
efforts to attract pharmaceutical and healthcare companies to Ireland. Over 
100 overseas companies in this sector now have Ireland based production 
plants, including 10 of the world’s top 15 pharmaceutical companies. 
Exports totalled IR£ 1.5 billion in 1985 and are growing at 40% per annum. 
There has been a particularly encouraging growth in the Medical 
Diagnostics area of the healthcare industry. Among indigenous companies, 
Biocon, Bioprep and Noctech Ltd are manufacturing a range of products 
based on enzyme immunoassays, while Beckman, Technicon, Organon and 
Flemming GmbH are examples of transnational companies which produce 
diagnostic products in Ireland. The industrial strength of this sector and the 
fact that biotechnology has great immediate application made it an obvious 
area for national development. 
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There is also activity in other sectors, eg Biocon Ltd manufactures 
enzymes and other speciality chemicals for the food industry. Interbio 
Laboratories also manufacture microbial cultures for water and waste 
treatment and other purposes. A number of chemical and food firms are also 
using biotechnological processes in their manufacturing. These include 
Pfizer Chemical Corporation (Citric acid manufacture), Wheat Industries 
Ltd (Glucose/Dextrose Plant) and Carberry Milk Products (Alcohol 
production from by-product whey). 
Biotechnology Research Centres 
As in many countries, much of Ireland’s expertise in biotechnology is 
located in universities and other higher level colleges. 
Because almost half of the Irish population is under 25, Ireland has 
invested heavily in scientific and technical education. In line with our policy 
to develop Ireland as a centre for high technology industry, new colleges and 
new laboratories have been built to cater for technical education. Science, 
engineering and other technical graduates are an increasing proportion of the 
output of these colleges. They represent 41% of the primary degrees and 45% 
of higher degrees awarded by Irish colleges in 1985. The research facilities in 
biotechnology have also been improved and individual colleges have agreed 
on specific priority areas for biotechnology research. 
Other centres of expertise include the following government funded 
agencies: 
 Institute for Industrial Research and Standards, which performs 
research on fermentation process scale up, enzyme technology and 
monoclonal antibodies. 
 The Agricultural Institute, which has a staff of 1300 in 7 major 
research centres throughout the country, is also involved in research 
and application of biotechnology in food and agriculture.  
Areas of Biotechnology Expertise 
The major areas of expertise in Ireland are: 
 Genetic Engineering 
 Diagnostic Technology 
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 Specialty Chemicals and Pharmaceuticals 
 Biopharmacology 
 Mammalian Reproductive Technology 
 Plant Biotechnology 
GENETIC ENGINEERING 
Research is conducted in 6 of our 7 colleges; but particularly in 
Trinity College, Dublin and the University Colleges of Cork and Galway. 
Microbial Genetics is the main area of interest at the Dept. of Genetics, 
Trinity College Dublin, where the research team of Prof. David McConnell 
have performed work for many companies, including Arthur Guinness and 
Co., Biocon Ltd., and ICI. This Group have recently signed a research 
agreement with the Agricultural University of Beijing to jointly done the gene 
for Porcine Growth Hormone. The research for Arthur Guinness was to done 
the gene for glucanase into brewing yeast strains. Guinness have recently 
located all their corporate research in a new centre in Dublin. 
Another interesting area in Trinity College is in vaccine development 
at the department of microbiology. Among other projects is one with the 
objective of developing a vaccine for mastitis. 
In animal genetics research is in progress at University College, 
Galway, in collaboration with the Agricultural Institute to develop transgenic 
animals including fish. This work is funded by the EEC in association with 
French researchers. 
The Dairy Microbiology Dept., at University College Cork, and the 
Agricultural Institute at Fermoy, have developed considerable expertise in the 
genetics of dairy starter culture organisms: Strains of bacteriophage resistant 
bacteria developed by this group are now used to produce almost all of the 
50.000 tonnes of cheddar cheese produced in Ireland. Further work on the 
genetic manipulation of other important dairy micro-organisms is under way. 
DIAGNOSTIC TECHNOLOGY 
Ireland has much expertise in this area. The dose contacts between 
the biological and clinical scientists in Ireland has been an important factor 
in the development of this area of technology. 
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The major centre for research on diagnostics is in University College 
Galway, where work is ongoing on solid phase immunodiagnostic 
technology, and on the development of kits for various human and animal 
hormone indicators. 
Veterinary diagnostics is an area of particular interest because of our 
large livestock population. Work at University College Galway resulted in 
the development of the first animal progesterone assay to be put on the 
market. This was the progesterone measuring system from Noctech Ltd. This 
Irish company has produced Reprostrip, a rapid assay for progesterone. 
Ireland also has a very important thoroughbred horse industry. 
Research on behalf of this sector is conducted by the Irish Equine Centre, a 
privately funded organisation, in association with university researchers. 
This centre is currently researching indicators of stress, eg travel stress, in 
performance horses with a view to developing diagnostic kits for equine 
health. Diagnostic kits are also in preparation in other centres for Epstein 
Barr Virus, Chlamydia and others. 
BIOPHARMACOLOGY 
Ireland has a large pharmaceutical and healthcare industry. To service 
the needs of this industry, both for technical services and for trained staff, 
Irish colleges have developed centres of expertise in several relevant areas. 
Of particular interest are: 
Development of in-vitro tests for pharmaceutical screening and for 
toxic effects. Among the projects in progress at the moment are in-
vitro assays for detection of drug-related specific neural tube defects, 
eg spina bifida and also an assay for assessing efficiency and toxic 
effects of cancer chemotherapeutic drugs. Development of novel drug 
delivery methods. 
MAMMALIAN REPRODUCTIVE PHYSIOLOGY 
Ireland is one of the major milk and meat exporting countries in 
the world and breeding of sheep and cattle is therefore of great 
importance. Both the universities and the Agricultural Institute perform 
research on many topics of relevance to the breeding and production of 
cattle and other livestock. A topic which is of relevance to 
biotechnology is the area of mammalian reproductive physiology. The 
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research group of Prof. Ian Gordon at University College Dublin, was 
among the pioneers of Embryo transplantation. 
Work by this group and the associated group of Dr J Sreenan at the 
Agricultural Institute at Beldare, Co Galway continues on areas such as 
immunological control of reproduction, embryo sex determination, oestrus 
control and in-vitro fertilisation. 
PLANT BIOTECHNOLOGY 
The major crops of interest to Irish biotechnologists are potato, 
cereals and ornamentals. Ireland has a large seed potato industry based on 
exports to Mediterranean and N African countries. The majority of these 
exports are two varieties which were bred at the Agricultural Institute, 
Oakpark. 
Forestry research focuses on the use of mycorrhizae to assist the 
reafforestation of our marginal lands. Research on inoculation of 
seedlings with candidate strains of mycorrhizae is underway in the Forest 
and Wildlife Research Laboratory and at University College, Dublin. 
Biotechnology Infrastructure 
The major agencies responsible for the various elements of the Irish 





National Board for Science and 
Technology NBST, until late 1987 
*National S & T policy and programme 
formulation: advice to government: 
promotion of specific technologies, 
including biotechnology and 
coordination of research 
From beginning of 1988 
Bio research Ireland 
Biotech activities of NBST have been 
privatized. BioResearch functions as a 
contract research and technology transfer 
organization. Staff and mandate similar 
to that of NBST. 
Industrial Development Authority, IDA  
Attraction of overseas investment, 
support for Irish enterprise 
The Agricultural Institute – An Foras 
Taluntais, AFT 
Agriculture and agricultural product R&D 
Institute for Industrial Research and 
Standard, IIRS 
*Industrial Research and services; 
Establishment of national standards 
*These two agencies were merged in January 1988 to form EOLAS, the Irish Science & 
Technology Agency. 
The Irish National Programme for Biotechnology was jointly 
developed by the NBST and the IDA. 
The NBST’s role within the Irish National programme was primarily 
to develop national biotechnology expertise and facilities and to maximise 
its application to Irish industrial and economic development. 
The NBST achieved this end by: 
 Funding basic and precompetitive research in universities. 
 Promoting and assisting university-industry research co-operation. 
 Promoting and assisting international research co-operation. 
A very important part of the programme is the improvement of 
linkages between industry and researchers in Irish universities and the 
development of international linkages. Irish researchers are actively 
encouraged to perform research for industry in other countries, and also to 




The process of linking university researchers and industry has been 
one of the major activities of the NBST. To this end a newsletter, Irish 
Biotech News’ was published and distributed widely in Ireland and abroad. 
Mechanisms for Biotechnology Promotion 
As mechanisms for co-operation are of specific interest to participants 
in SOBELA, it may be useful to point out some of those used in Ireland: 
1. Publication of a newsletter – Irish Biotech News, which is 
distributed free of charge to both industry and researchers and 
highlights co-operative opportunities. 
2. Running of seminars and workshops on topics of common interest. 
For each chosen topic both researchers and relevant industry 
representatives are specifically invited so as to encourage contacts. 
3. Grants of up to 50% of the cost of university/industry co-operative 
research, are made available. 
4. Funding assistance is given towards the employment of scientists and 
technologists by companies with a low level of technical employees. 
NBST put a very high priority on international co-operation in 
research. Irish researchers have a particular problem in that our island 
position makes the travel necessary for co-operation more costly than on 
mainland Europe. To alleviate this, the NBST provide assistance towards 
visits by researchers to other research centres. This mechanism proved 
highly successful in developing collaborative research teams for 
applications to EEC research programmes. NBST also strongly promoted 
involvement in EEC and in other international programmes as a means of 
developing contacts and collaboration. We have also formed scientific and 
cultural exchange agreements with many countries. 
Regulation of Biotechnology 
A National Recombinant DNA Committee advises planning authorities and 
others on the safety of genetically engineered organisms used in the state. The 
committee is composed of experts, and representatives of the public, unions, 
industry and government. The guidelines of the National Institute of Health, NIH, 




In 1988 many of the activities of the NBST were merged with those of 
the IIRS to from EOLAS – the Irish Science and Technology Agency. EOLAS 
is geared to generating income for the state. BioResearch Ireland represents 
biotechnology activities within EOLAS, and is focused on three national 
centres: 
 National Cell & Tissue Culture Centre 
 National Food Biotechnology Centre 
 National Diagnostics Centre 
The National Cell and Tissue Culture Centre is located in the 
National Institute for Higher Education, Dublin, which was set up in 1980. 
The focus of work is monoclonal antibody production and all aspects of 
animal cell culture, including toxicity testing applications. Contract 
research is going on with a number of companies in Europe and elsewhere. 
The National Food Biotechnology Centre is located in University 
College Cork. Genetically manipulated organisms are developed to enhance 
food bioprocessing and flavours. Cheese microbiology is a particular strength. 
The National Diagnostics Centre, located at University College, 
Galway joins many skill bases to develop innovative diagnostics, including 
DNA probes. Custom synthesis of oligonucleotides is a feature of this 




Recently there have been major changes in the organisation of Italian 
biotechnology. In 1985 biotechnology R&D was fragmented without real 
direction or co-ordination. No national priorities had been defined.
Most of the nation’s biotechnology programmes were at that time focused 
on human health and supported by the National Research Council, 
Table 1. Finalised Biotechnology Projects 1985 National Research Council




Improvement of agricultural production 
Fine and secondary chemistry 
This initial set of projects gave rise to competence in several
aspects of biotechnology, such as monoclonal antibody production and 
molecular recognition. Significant short term advances were made in the 
area of gene manipulation and the production of recombinant products.
In the context of the fine chemistry projects several advances in 
enzymology were funded, and in the domain of agriculture some 












The investment made in this first round of funding was judged 
inadequate, but none the less it demonstrated Italy’s commitment to meeting 
the levels of R&D expenditure sustained by other developed countries. 
Figure 1 compares the rate of growth of R&D expenditure as a 
%age of GNP up to 1984. The data are derived from a report of the Italian 
Chemistry Federation, Federichimica, on biotechnology entitled ‘Le 
Biotecnologie in Italia: un opportunita di sviluppo industriale’. Milano 1986. 
In 1985 a National Biotechnology Committee had been created, 
supported by the Committee for Development and Innovation in the 
Chemical Industry Federation. These bodies recommended the pursual of a 
National Biotechnology Policy, charged with organising, funding and 
directing programmes. 
The National Programme represented a logical development, for 
24% of Italy’s revenues are based on organic or biological products with 
a 1984 value of 112 billion US$ (see Figure 2). This percentage is higher 
than for other countries and illustrates why biotechnology is of such keen 
interest; several key market areas of relevance to Italian industry are affected. 
The areas illustrated in the following diagrams have several 
common features:  
 They are big markets with potential for large expenditure; 
 They are characterised by imported products; 
 SMEs have a high profile in this market. They need a common 
development policy. 
The Italian health care market was worth US$6 billion in 1984, about 
35% of that spending going on diagnostics, pharmaceuticals and biomedicals. 
By 1990 this area could be 25-35% dependent on biotechnology products. 
Agriculture accounts for total invoices of US$32 billion, spent mostly 
on animal breeding, cereals and vegetables. Consumption increases are 
causing an import boom. The animal feed sector in particular, worth US$26 




% of production from organic sources in respect to the global internal product (1984) 
Countries % Close-up of sectors in Italy (1984) 
   Sectors % 






















U.K  22% 
U.S.A  20% 
France  19% 
Germany  18% 
*24% = 112,000 million US$ 
 
Fig. 2. Comparison between various industrialized countries concerning their percentual 
production from organic sources. From the report of Italian Chemistry Federation 
‘FEDERCHIMICA’ on Biotechnology ‘Le Biotechnologie in Italia: un’opportunità di 
sviluppo industriale’, Milano 1986. 
Several factors influence this: 
 Feed habits orient towards a strong feed industrialisation (with low 
cost); 
 Trend to ‘natural feed’ with high quality food from direct agricultural 
sources and wide availability throughout the year (with high cost). 
Biotechnology might solve the problem by providing high quality 
food at low prices. Production and storage technologies might also be 
favourably influenced. 
Ecological considerations will play an increasingly important role in 
the industrialised nations. The processing and recovery of industrial and 
agricultural wastes is a market worth perhaps US$15 billion within a decade. 
Lack of ecological surveillance could precipitate high costs in both social 
and economic terms. 
Ecologically relevant companies have increased by more than 75% in 
number since 1980. 
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In the Chemicals sector the global market for Italian products was 
estimated at US$26 billion. This potential is compromised however, by a 
massive dependence on imported products. 
All sectors of industrial activity are therefore open to the influence of 
biotechnology. An industrial representative committee has considered the 
following theoretical areas of application. 
 40% of biotech products would be new, not realisable by existing 
technologies. 
 60% of biotech products could represent the consequence of 
improvements to existing processes. 
 70% of ideas generated could be realised in the short to medium 
term that is up to 5 years from now. 
In 1985, in response to these ideas the National Research Council, 
CNR, created a Task Force to mobilise activity in well focused research 
areas. Focused on CNR and university laboratories the resulting programme: 
Strategic Project, Advanced Technology in Biology, was divided into three 
major subprogrammes: 
 Biotechnologies 
 Agro-industrial technologies 
 Aquaculture 
Table 2. National Research Council:  
Strategic Project Innovative Technologies in Biology’ (1986-1987) 
Funding: US$2.1 million 
Subprojects: 
1. Biotechnologies 
 Enzymology, natural or modified enzymes 
 Agro-industrial biotechnologies 
 Oligonucleotide synthesis and molecular probes 
 Cellular carriers 
 Biosensors 
2. Agrotechnologies 
 Cultivated plant technologies 
 Molecular and biological control of parasites and abiotic stresses 
 Models of agroecosystem productivity 
3. Aquaculture 
 Artificial reproduction and genetic improvement in fish breeding 
 Reproduction and breeding of new fish species 
 Breeding of molluscs 
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In the first two years the budget for this programme was low, only 
US$2.1 million, but the idea was to orientate a number of research groups to just 
a few well defined technologies. 
Following on from this programme is the: Special Project: 
Biotechnology and Bioinstrumentation, with funding of US$68 million over 
the five year period, 1987-1991. This programme will focus on precompetitive 
aspects of biomedical and chemical areas. Addition of important new 
subprogrammes in vaccines, cell culture and transplantation biology is a 
feature. The CNR will involve universities and research institutes in the 
programme. 
Table 3. National Research Council:  
Special Project ‘Biotechnology and Bioinstrumentation’ (1987-1991) 
Funding: US$68 million/5 years 
Subprojects 
1. Molecular and Cellular Engineering 
2. Innovative vaccines and bio-diagnostics 
3. Biosensors, cellular bioreactors 





Table 4. Ministry of Scientific and Technology:  
National Project Advanced Biotechnologies’ (1988-1992) 
Funding: US$308 million/5 years 
1. Medicine and veterinary areas 
 Diagnostics 
 Plasma proteins 
 Fibrinolytics enzymes  
 Biological response modulators 
 Immunotherapeutics 
2. Chemistry, Energy and Environment 
 Biocatalysis 
 Biopolymers 
 Biological control of pollution 
3. Agriculture and Food 
 New plants 
 Micro-organisms 
 Animal husbandry 
 Food bio-conversion 
 Food diagnosis 
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A third major programme designed to stimulate industrial 
competitivity and innovation through government support, is entitled: 
National Programme, ‘Advanced Biotechnologies’, funded by the Ministry 
of Scientific Research and Technology. This programme envisages 
expenditure totaling US$308 million over the five year period to 1992. 
Table 5. Nonmedical applications of biotechnology.  
Chemistry, energy and environment 
A) New enzymes 
B) Innovation on bio-conversion and enzyme catalysis 
C) Polysaccharides from natural sources 
D) Control and recovery of environments 
E) Bioprocessing of minerals 
Agriculture and Feed 
A) In vitro plant generation 
B) Introduction and expression in plants of exogenous genes 
C) Plant nitrogen metabolism 
D) Biological defence of plants 
E) Improvement of growth and nutritional properties of breeding animals 
F) Enzymes for feed industry 
G) Treatment of agricultural wastes 
H) Control of food safety 
In Table 5, two of the areas considered above are examined in closer 
detail. There is broad accord with the aims expressed by the European 
Commission, particularly with regard to the stimulation of agro-industrial 
development. 
The Italian response to the recent Commission ‘Call for Expressions 
of Interest’ on the theme, ‘Stimulation of Agro-Industrial Development’, 
was most encouraging (see Fig 3). Some 70% of the Italian ‘expressions’ 
were from industrial organisations (see Fig 4). 
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Agro-industrial development – Results of call for interest
Fig. 3. Results of call for interest concerning the ‘Stimulation of Agro
Development’ from EEC expressed as national percentual of the total responses. From 
EEC document CUBE-XII/233/87. 
Industry Interest 
Fig. 4. Industry interest for stimulation of agro-industrial development. Results are 









Total = 856 interest forms
Cost + 580 millions U.S. $
Total = 266 (31%) forms













Other public programmes with an element of biotechnology are 
summarised in Table 6. 
In the planning stage is an agricultural programme with a provisional 
budget of several hundred million US$. Focus will be on crop production, 
animal breeding and adding value to agricultural by-products. 








Biologically active products  
rDNA technology vs genetic disease 
18 
23 





Technology in oncology Monoclonal antibodies and DNA
probes 
14 
Pharmaceuticals: Targeting of cytotoxic drugs 4 
In Figure 5 the present state of national funding programmes in 
biotechnology is recapitulated. The overall commitment of funds is seen to 
exceed US$430 million over the present five year period. This major funding 
is intended to bridge the gap between industrial innovation and academic 
research, so strengthening the Italian presence in this key area of technology. 
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Public fundings for Biotechnologies 
 
Fig. 5. Comparison between two periods of public fundings to 
biotechnology in Italy. PN MRST: National Program from Ministry of 
Scientific Research and Technology. CNR PF: Finalized Project from 
National Research Council. 
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1.8. THE NETHERLANDS 
Henk C. van der Plas 
In September 1984 Professor Schilperport, then Chairman of the 
Programme Committee on Biotechnology, PCB, suggested that in the 1990s the 
Netherlands might be the biotechnology delta of Europe. Is that fiction or reality? 
The Netherlands posses an industrial base of about 100 biotechnology 
firms, together providing an R&D potential of 1,100 manyears (in 1985). 
Sales of traditional biotechnology products in the dairy, brewery and 
antibiotics industries accounted for sales of about US$4 billion. New 
products such as recombinant vaccines and diagnostics based on 
monoclonal antibody technology are contributing to 1987 sales of about 
US$40 million. 
A few major companies dominate biotechnology in the Netherlands. 
These have a base in traditional biotechnology and have rapidly included 
new technology in their ranges of competence. Many, much smaller 
companies have emerged recently, partly because of the relatively easy 
access to investment capital. 
Figure 1 summarises the scope for biotechnology R&D in the 
Netherlands. The role of the major companies is clear. 
Because of the small size of the country and the initiative of the 
government in pushing activities in biotechnology, there exists a solid 
network of contact and communication among all Dutch biotechnologists, 
in industrial, university or government laboratories. 
The standard of excellence in Dutch universities is among the highest 
in Europe, and although there was considerable displeasure some 7 years 
ago when the government first sought to stimulate a productive orientation, 




DSM, CCA, Avebe, 
Heineken, Naarden carry 
out 7-30 man-years R&D 
the middle group
90 companies carrying 
out R&D constitute the 
rest
GIST, BROCADES, AKZO, 
Unilever- The big 4 
contribute 100-400 
manyear each, 
representing 80% of 
industrial R&D
Fig. 1. Scope for biotechnology R&D in the Netherlands 
The small size of the country cannot hide the fact that it plays host to 
some of the more prominent multinationals. The financial power of big 
companies, combined with experience and marketing know how has made 
it possible to exploit the opportunities in biotechnology. 
Small is effective for the Netherlands. Communications are no 
problem as all locations are geographically close. 
The government has made biotechnology a priority area, not only 
because of the solid industrial base, but also because biotechnology 
provides fast growing market opportunities in many industrial sectors.  
The Role of the Government 
The government launched its Innovation-Oriented Biotechnology 
Research Programme in 1981. This formed part of a series of similar such 
Composition of industrial base 1985 a total of 1100 
manyears was commited to biotechnology R&D 
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programmes in a number of strategically critical areas including: 
membranes, polymers, composites, carbohydrates, engineering ceramics 
etc. The primary goal of these innovation oriented research programmes, 
IOPs, is to stimulate research in universities and institutes. The goal is three 
pronged, seeking: 
 to stimulate research. 
 to structure the knowledge infrastructure through division of tasks, 
co-operation and market orientation. 
 to set up a communications network. 
Let me explain these three points. Stimulation of biotechnological 
research at universities and institutes is being accomplished by provision of 
an extra US$20 million between 1981 and 1990. The money is shared out by 
a high level body, the Advisory Committee on Biotechnology, ACB, which, 
although government appointed, works at arm’s length from the 
government. Its membership includes representatives of both industry and 
research institutes. The indirect, co-ordinating, effect of this extra financial 
stimulation is, in my opinion, even greater than the direct impact. 
The Advisory Committee on Biotechnology seeks to realise the entire 
threefold goal simultaneously. As in some countries, government funded 
university research in the Netherlands is being trimmed, owing to budget 
constraints. The division of tasks is therefore an indispensable element for 
structuring the knowledge infrastructure (e.g. to avoid overlap). 
Biotechnology is a multidisciplinary science. Co-operation between 
research teams is a sheer necessity, because only integration of knowledge 
can produce practical applications. The third element of restructuring the 
knowledge infrastructure, finally, is more market orientation. Extensive 
consultation with industry was found to be a simple and effective way of 
learning exactly what the market needs. 
An inventory of the wishes and needs of industry, as regards both research 
objectives and research teams, served as a basis for this industrial orientation. The 
inventory was made through confidential interviews, the results of which were 
generalised. This guaranteed an open industrial orientation. 
The third goal, that of building up a communications network, is vital 
for the rapid growth of a new technology, which cannot develop without 
dose co-operation between everyone concerned. 
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Central to the IOP network is the Advisory Committee on 
Biotechnology, ACB, which co-ordinates the overall stimulation of the four 
sub-programmes on Biotechnology under the supervision of four separate 
Programme Committees, PCs. Each of the four PCs receives money from 
the Ministry most closely involved. 
The ACB together with the four Programme Committees has also 
succeeded in creating the conditions for good fines of communication 
between research institutes, industry (including investors) and government. 
In the first stage of the IOP, from 1981 through to 1984, financial 
stimulation was used to raise the level of biotechnological research on a broad 
scale, while building up a communications network. At the same time inventories 
were taken to determine the direction of the infrastructure structuring. 
In the second stage from 1985 to 1990, structuring is being selectively 
programmed and anchored in the infrastructure, so that industry will be able 
to continue making optimal use of the government funded knowledge 
infrastructure after the programme has ended. 
The following tables show the range of activities encountered in 




Table 1. The Major University Biotechnology Centres in the Netherlands. 
Centre Activity 
BDL, Biotechnology Delft-Leiden 
(Technical University Delft & State 
University Leiden) 
Incomplete oxidations 
Plant cell biotechnology 
Yeast physiology/genetics 
Environmental biotechnology control 
Bioreactor design and downstream 
processing 
Agricultural University Wageningen Biocatalysts 
Food and animal feeds 
Waste and environment 
Plant cells 
Animal cells 
BCA, Biotechnolog Centre 
Amsterdan (Free Universit 
Amsterdam & University of 
Amsterdam) 
Opimisation of product formation by 
micro-organisms 
(yeast & prokaryotes) 
Plant biotechnology 
Monoclonal antibody production 
Enzymology 
State University Utrecht Vaccines 
Peptide and polypeptide hormones 
Monoclonal antibodies 
State University Groningen Fine chemicals and stereo specific 
reactions 
Development of host-vector systems for 
industrial micro-organisms 
Biological oxidation, biodegradation of 
waste 





Table 2 Some of the Important Biotechnology Research Institutes in the 
Netherlands 
Institute Activity 
Plant Biotechnology  
Wageningen: SVP, ITAL Genetic engineering for plant breeding 
ITAL 
Secondary metabolite production for high grade 
chemicals 
IVT Horticulture 
IPO, IVT Disease and pest resistance 
Baarn:                        CBS Central Bureau for Mycology 
Agroprocess Biotechnology  
Wageningen: Sprengen-IBVL Processing of waste flows  
IMAG Treatment of manure 
Ede:                          NIZO Dairy production and processing 
Groningen:              NIKO Carbohydrates 
Zeist:                         TNO 
Food and animal feeds (incl. biocatalysus and 
bioprocess technology) 
Animal Cell Technology  
Lelystad:                     CDI Vaccine and diagnostics development 
IVVO Livestock feeding/nutrition 
Wageningen:            ITAL Malaria control by insect genectics 
Zeist:                          IVO Animal production 
Medical Biotechnology  
Amsterdam:               CLB Blood/blood factor research tissue culture 
NKI Cancer research 
Bilthoven:               RIVM Human vaccines and other biological 
Rijswijk:                    TNO 
Monoclonal antibodies for 
diagnosis/therapy/research rDNA technology 
Environmental Biotechnology  
Amsterdam/Delft:     TNO 
Fermentation and bioprocessing recycling, 
purification, membrane technology 
Bilthoven:               RIVM Microbiological soil and water treatment 




INDUSTRIAL BIOTECHNOLOGY POLICY 
Since 1983 the Dutch government has encouraged industry to 
participate in ambitious R&D programmes. Two forms of subsidy have 
backed up this encouragement. 
 the INSTIR subsidy scheme 
 case by case assessment 
INovation STImulation Regulation, is a scheme which offers wage 
support for R&D. Given the massive cost of wages in modern industry this 
incentive dramatically lowers cost thresholds and has been provided for a 
number of promising technologies, including biotechnology. 
Although university collaboration was not a precondition of these 
subsidies, it is a testimony to the establishment of the communications 
infrastructure that, in practice most projects were carried out in 
collaboration with universities or institutes. 
The recent economic upturn has made R&D financing much easier for 
companies, who are now less in need of government support. Since 1987 the 
Dutch government provides incentives only for technologies in which the 
support policy results in the highest added value. 
Biotechnology is one of the four high tech areas that continues to 
benefit from public support. The technology policy enabling the knowledge 
infrastructure through the IOP is being followed up in the form of a 
programme policy concerned directly with industry. 
At this stage the goal is to increase the number of firms engaged in 
new biotechnology operations from 10 or 20 to 100! More than 100 
potentially promising firms that we now have are being prevented from 
achieving high-tech production in the near future, not so much by lack of 
money, but by a low level of in-house research activity. 
Subsidies do not play major role in the government’s programme 
policy, although they do perform a valuable supportive role. The 
programme for the 100 companies target covers a number of synergic and 
mutually complementary activities. 
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INFORMATION AND CONTACT 
A vital factor in pulling firms across the threshold towards new 
technologies is information. This part of the programme is already in full 
swing, with the publication of booklets and a biotechnology magazine in 
Dutch. Printed information does not suffice. Personal contacts through 
consultants paid for by the Economic Affairs Ministry often produce better 
results. The consultant acts as a broker between industry, the knowledge 
infrastructure and government. 
IOP BIOTECHNOLOGY 
Already discussed in the earlier part of this presentation. 
STIMULATION OF INDUSTRIAL R&D PROJECTS 
An important criterium for selection is co-operation with a university 
or institutional research group. This industrial stimulation is therefore 
closely linked with the IOP stimulation. 
ESTABLISHMENT OF NEW COMPANIES 
Can foreign companies be persuaded to set up in the Netherlands, as 
a consequence of providing the appropriate infrastructure? We have been 
successful, as the establishment of subsidiaries of the American 
biotechnology firms, Centocor, Mogen International, Promega and recently 
EuroCetus demonstrates. 
EDUCATION 
Without suitably skilled manpower, no innovation is possible. We are 
busy setting up a postgraduate training facility for biotechnology engineers, 
a joint initiative of Delft and Leiden. 
INTERNATIONAL CO-OPERATION 
For a small country like the Netherlands, cross frontier co-operation is 
important, particularly within the context of the European Community, EC, 
and EUREKA. Non-European collaboration also receives dose attention from 
the government, particularly the third world countries. The Netherlands have 
initiated biotechnology collaborations with Indonesia, India and Thailand. 
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OPTIMISING THE CHANCES FOR SUCCESS 
General policy actions relating to the approval of biotechnology 
products, patent matters, supplies of cheap raw materials for the 
fermentation industry and last but not least – social acceptance. 
The Dutch government is working for industrial innovation in 
biotechnology along these lines. 
WHAT HAS BEEN ACHIEVED? 
A number of products have emerged from the Dutch Biotechnology 
initiatives. The following are just a sample that illustrates the breadth and 
potential of the Dutch biotechnology enterprise. 
 Anaerobic purification of waste water: a co-operation between 
universities, TNO and Gist-Brocades 
 Development of a vaccine against diarrhea in calves and piglets: a 
co-operation between RIVM and Amsterdam University. 
 Pregnancy test using monoclonal antibodies: Organon 
 Preparation of D I L amino acids by enzymatic separation of D, L 
mixtures: Dutch States Mines, DSM. 
 Production of aspartame: DSM, Toyo Soda 
 Biofilters for air filtration, production of chymosin with rDNA 
technology: Gist-Brocades, NIZO 
Many other products and processes are well on the way to realisation. 
The last table gives evidence to support the assertion that growth in 
biotechnology will be gradual, but steady. At this point I return to the claim 
that The Netherlands might become a Biotechnology Delta in the 1990s. It 
is still premature to say that this is more than fiction, but we are working 
hard to create a really strong base for industrial biotechnology in the next 
decade. We are full of confidence and so far, if I may say so, we have not 
been unsuccessful! 
I hope this introduction to Dutch biotechnology has roused your 
interest and that it may lead to the next step of entering into dose co-
operation with Dutch partners. The Netherlands is ready for it. 
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For anyone wishing to learn more about Dutch biotechnology, a 
highly informative and illustrative brochure can be ordered, as well as a list 
of names and addresses of Dutch firms and institutes active in the field. 
Table 3 Biotechnology Sales for Various Industries: (figures in millions of Guilders) 
Industrial sector 
Total Biotechnology sales 
1982 1985 1990 1995 
Fine Chemicals Human & Veterinary 6500 460 555 655 
Health Care 2500 750 1000 1350 
Food and Beverages 64000 8500 9400 10800 
Equipments and Instrumentation 13000 275 310 350 






In Portugal, biotechnology has become integrated into the traditional 
biology dependent industries. Microbiology and enzymology are now 
finding new applications. Many scientists have returned from training and 
employment overseas. This new resource of largely European trained scientists 
is now helping to create new poles of academic and industrial excellence. 
The promise of biotechnology is being hindered in Portugal by the 
lack of entrepreneurial tradition. Human potential and favourable political 
conditions do not alone create new industries and economic development. 
The government is sympathetic and started the implementation of a 
Mobilisation Programme in 1987. Funding levels for biotechnology have 
increased each year and are being complemented by funds from the 
European Commission and with A.I.D. 
This presentation attempts to identify the impact of biotechnology 
on Portuguese industry and agriculture as well as its potential in 
research and education. 
INDUSTRY 
The industries involving biotechnology can be divided into two 
sectors, one more traditional and the other of a more modern kind which 
can be situated in the post antibiotic era. 
In the first case, it is justifiable to start by referring to the wine 
industry, which has acquired great importance both internally and for export 
income. Port, Madeira and some Rosé wines contribute most. 
The fruits of yeast research are now being enjoyed. Strain selection 
and slow fermentation conditions are being optimised so as to minimise 
undesirable contamination or side products. The sparkling wine industry is 




In the cheese industry microbial enzymes are used in large scale 
production, but the best cheeses, called Serra, are still produced 
traditionally. Cardoon flowers are immersed in sheeps milk, a process prone 
to contamination and quality variation. Family production methods are 
being studied in the laboratory so as to identify proteases. It is hoped that it 
may be possible to produce cheese ‘in vitro’ with suspended and 
immobilised cardoon cells. 
The old olive oil industry could be improved with better extraction 
processes and regeneration of the older plantations. New technologies such 
as micropropagation could play a useful role. 
The beer industry has achieved a sophisticated understanding and 
control of the processes of malting and fermentation. 
Antibiotic production is a significant export earner, with more than 
90% exported. The major products include: penicillin, tetracycline, 
oxytetracycline, erythromycin, gentamycin and ampicillin. 
A new ampicillin process was developed in Portugal, whereby 6- 
aminopenicillinic acid was formed by passing penicillin through novel 
bioreactors containing immobilised penicillin acylase. The technology has 
been successfully exported. 
The fine chemicals industry carries out R&D, often in collaboration 
with university laboratories. Products have included steroids and some 
diagnostic kits. 
Baker’s yeast is produced at two locations, while glucose and 
glucose/fructose syrups are obtained with enzymatic processes. 
Alcohol factories depend upon imported molasses (some 15% 
produced domestically). This traditional industry is now moving towards an 
incorporation of the new biotechnologies. 
Environmental considerations have not been overlooked. Several 
wastewater treatment plants have been constructed using a variety of 
technologies: activated sludge, percolating filters and a variety of ponds. Several 
cattle and poultry raising installations have built tanks for anaerobic digestion, 




Portuguese agriculture is a very traditional discipline and the only 
biotechnological input has been from classical genetics. In the future 
biotechnology will affect agriculture in two ways. Firstly, the fruits of 
research will influence the growth and multiplication of plants, possibly by 
species improvement by gene transfer and classical hybridisation etc. The 
sum of many developments in Nitrogen fixation, in vitro propagation and so 
on might radically modify the culture of a given region. Already some 
hybrid cereals have dramatically improved the productivity of some 
regions. In vitro propagation has so far been applied only to high value 
decorative plants and exotic fruits. Many technologies are unexploited, for 
example the knowledge of coffee developed in former colonies. 
The second major influence may come about when agriculture is in a 
position to provide industrial raw materiais. The introduction of new 
cultures or the modification of old ones may bring about changes. At the 
moment trials are underway with an inulin producing Jerusalem artichoke. 
Suitable for fructose, or by fermentation, alcohol production this could 
become both a food and energy source. 
Native biological resources are not overlooked. Plants of the semi 
arid interior might be used to produce commercial quantities of lipids from 
marginal lands. Euphorbia is presently being studied as a candidate for 
exploitation. 
RESEARCH 
In recent years there has been an important increase in biotechnology 
research. Little has yet emerged from this new development. In traditional 
areas such as yeast physiology and fermentation, Portuguese scientists have 
established a high standard of excellence. Fields of application would 
include yield improvement and alternative methods of fermentation product 
extraction, so as to reduce the energy costs of distillation. 
Immobilised enzymes and micro-organisms are quite routine 




Plant cell culture has yielded important developments in the areas of 
callus production, micropropagation and suspended cell culture. Other 
applications are in development. 
In the area of environmental biotechnology a town of 13.000 
population is successfully demonstrating the use of high photosynthetic rate 
ponds for sewage treatment. 
At least three of the nation’s research centres have been looking at 
the technologies of fermentation and down stream processing. Purification 
and separation of fermentation products using ultrafiltration membranes, 
and supercritical extraction of natural products exemplify this interest. 
The bio-conversion of energy is being studied by groups whose focus 
is on energy mediating enzymes such as the hydrogenases. In vitro 
reconstitution of such activity could yield commercial benefits. 
Other small groups are looking at genetic engineering, immunology, 
virology, monoclonal antibodies, etc. 
Most research is carried out in university laboratories and public and 
private institutes. Industrial concerns only rarely have established an R&D 
competence, relying instead on outside agencies. This must change if 
industry is to face a sound future. 
An Institute of Chemical and Biological Technologies is being 
commissioned with the purpose of establishing links between 
biotechnology, agriculture and the agro-food industries. 
EDUCATION 
Several new courses have been inaugurated to train graduates in the 
skills required by tomorrow’s institutional and industrial needs. The New 
University of Lisbon launched an Applied Chemistry course with a strong 
biotechnology component. In the Technical University of Lisbon, the 
Instituto Superior Técnico, a biotechnology course is taught during the five 
year Chemical Engineering degree. In Oporto a food engineering course 
was started four years ago within a Faculty of Biotechnology. 
At postgraduate level two courses exist, at the New University of 




LINKS WITH LATIN AMERICA 
Portugal has a long standing tradition of openness to the outside world, a 
consequence of the past colonial tradition and associated migrations. 
Brazil and Portugal have particularly dose ties, resulting from a 
common history over several centuries and a common language. At present 
high level talks are aimed specifically at creating a collaborative 
relationship in the field of biotechnology. Joint workshops have been held, 
with a view to establishing common programmes. 
One type of link that may develop between Portugal and Latin 
America involves technology transfer from biotechnology using industries. 
A new antibiotics factory in Brazil, CIBRAN was designed in Portugal and 
at least initially was dependent upon Portuguese technology. 
Portugal's interest in fermentation and downstream processing, 
alcohol and biocatalysis may be of particular interest. Support for 
developing these technologies has come from the European Commission. 
Tropical agriculture, pest control and disease are points of common 
interest and expertise with a potential for fruitful co-operation. 
Educational links are particularly favoured with Brazil. Portuguese 
universities receive many Brazilian students onto their M.Sc. courses and 
are willing to accept Spanish or Portuguese speakers onto Ph.D. degrees. 
Both Latin American and Portuguese workers have shown the willingness 
to travei so as to learn or teach new technology. 
The mobility of research workers and teachers seems of fundamental 
importance if Portugal and Latin America are to keep pace with modern 
developments. It is essential to create bridges between Europe and Latin 








Soc. Port. Leveduras Selecionadas 
Fine Chemicals: Quatrum 
Hovione 
France-Farmaceutica 
Baker’s Yeast: Propam 




Plant Micropropagation In Vitro Plants 
Research  
Yeasts: Instituto Gulbenkian de Ciencia, IGC 
Universidade do Minho 
Alcohol Fermentation: Instituto Superior Técnico, IST 
Faculdade de Engenharia da Universidade do Porto 
Laboratório Nacional de Engenharia e Tecnologia 
Industrial, LNETI 
Environmental Biotechnology: Universidade Nova de Lisboa, UNL 
IST 
Universidade de Aveiro 
LNETI 
Immobilised Biotacalysts: IST 
Universidade de Coimbra 
Algal Biotechnology: Instituto Nacional de Investigação das Pescas, INIP 
LNETI 
IST 
Energy from Biomass: LNETI 





Hydrogen and Methane Production: UNL 
Genetic Engineering IGC 
Instituto de Ciencias Biomedicas, ICBAS 
Plant Cell Biotechnology Faculdade de Ciencias Lisboa, FCL 
Estação Agronômica Nacional, EAN 




Plant Genetics: EAN 
Estação de Melhoramento de Plantas de Elvas 
IGC 
Universidade de Tras-Os-Montes e Alto Douro 
Fine Chemicals, Diagnostic kits: LNETI 
IST 
Food Biotechnology: LNETI 
Escola Superior de Biotechnologia, Porto 
Instituto Superior de Agronomia 
Wine Research: ISA 
Estação Vitivinícola Nacional 
Aqualculture: ICBAS 
INIP 
Monoclonal Antibodies: IGC 
ICBAS 
Lignocellulose degradation: ISA 
LNETI 
Biogas Production: LNETI 
UNL 
Virology: IGC 
Human Biotechnolgy: Instituto Nacional de Saúde Pública 
Animal Biotechnology: Escola Superior de Medicina Veterinária 
Laboratório Nacional de Investigação Veterinária 
Immunology: Universidade de Coimbra 
Further information on Portuguese biotechnology centres can be 
obtained from the speaker or from the following institutions: 
JNICT – Junta Nacional de Investigação Científica e Tecnológica, Av. D, 
Carlos I, 126-1o, 1200 LISBOA, PORTUGAL 
Sociedade Portuguesa de Biotecnologia, c/o Instituto Superior Técnico, 





Biotechnology, understood as the application of the principles of science 
and engineering to the treatment of materials by means of biological agents, for 
the production of goods and services, comprises a wide field of study. 
The economic and social importance is now unquestionable, 
especially if it is understood that in our country the production value of the 
potential users amounts to some 15% of the Gross Domestic Product. 
Mobilising Programme 
Spain has a scientific community capable of incorporating 
biotechnology into its production systems, and into an improvement of its 
services. For this a series of objectives have been defined and the 
necessary economic resources for the Biotechnology Mobilising 
Programme have been made available. This Programme was initiated by 
the government in response to the perceived gap in the organisation and 
execution of biotechnology research and application. The situation was 
explained in the volume: ‘Programa Movilizador de Biotecnologia’, 
published by the Ministry of Science and Education in Rine 1985. 
So far the execution of the Mobilising Programme has been 
satisfactory, with objectives being attained. The state has made funds 
available and no major contradictions in proposals and financial realities 
have emerged. 
Present Situation of the Biotechnology Sector 
More than 250 groups are working on biotechnology in the public 
sector (universities and government research laboratories) and nearly 50 
firms have expressed an interest in biotechnology R&D. The situation 
indicates sufficient activity to generate a biotechnological ‘critical mass’ in 
the near future. The response to the Mobilising Programme has been 




Spain supports over 100 research fellows. A further 80 + fellows have 
spent at least one year in foreign centres. 
CENTRO NACIONAL DE BIOTECNOLOGIA, CNB 
Initiated in 1987 this centre should become fully operational this year, 
representing a total investment of about us$25 million. Director, Michael 
Parkhouse has been appointed and recruitment of other senior staff is going on. 
Fifty research projects are being financed in public sector 
laboratories, and a further 10 projects involving companies, with a total 
budget of about US$8 million. 
The research projects fall into the area of application orientated basic 
research. 18 studies are ongoing, 8 in genetic engineering, 9 in human and 
animal health, 9 in chemical and agro-food industry, 9 in Agriculture and 5 
in biomass and pollution control. 
Industrial projects focus upon aspects of human and animal health, 
the chemical industry and the food industry. The Centre for the 
Development of Industrial Technology, CDTI, has taken up the 
responsibility of supporting 20 R&D programmes with a total value of about 
US$30 million. 
The conclusion of the Mobilising Programme has stimulated the view 
that it is necessary to continue and increase efforts in this area with a R&D 
National Programme in Biotechnology, along the lines indicated below. 
Planned Actions 
The following major themes encapsulate the National Programme. 
1. Human Resources – Staff Training 
The Mobilisation Programme confirmed the need to increase efforts 
in training. During the five year period of the National Programme it is 
proposed to train a further 225 biotechnology PhDs, and to send 100 to 150 
scientists to foreign centres of excellence, with a view to covering 
deficiencies in areas such as: biochemical engineering, downstream 
processing, cell culture, etc. 
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This effort must be accompanied by the establishment of relevant 
courses for specialist engineers and technicians. It is anticipated that the 
National Biotechnology Centre will play a decisive role in this training effort. 
At least 100 scientists are going to be recruited into the public sector 
so as to reinforce Spanish biotechnology. At least 35 of these new posts will 
be in the CNB. 
2. Instrumentation and Utilities 
This part of the programme will concentrate on two actions: 
Support for the acquisition of equipment and instruments of middle 
to high price for the CNB and other public sector laboratories. 
Creation of regional centres of excellence in biotechnology, 
associated with the CNB and other public institutes in their scientific 
environment. Financing is expected to be a mixture of national and 
regional. The creation of at least five such regional centres is foreseen. 
3. Financing of R&D Projects 
According to needs identified and the scientific and technological 
possibilities, research and technology development will be supported, with 
emphasis on the following priority areas: 
a) basic research in biotechnology (3 areas) 
b) agro food and agro-industrial aspects (6 areas) 
c) health (4 areas) 
d) industrial technology (5 areas) 
e) biodegradation and pollution control (3 areas) 
Ninety projects in universities and public laboratories, and between 
35 and 40 concerted R&D projects are expected to be partly financed by 
industry, over a three year period within the five years of the programme. 
4. International Relations 
The participation of public research centres in European Community 
programmes will be actively supported. Special fellowship programmes 
will be established for graduates speaking Spanish or from the same 
geographical area. In the CITED-D, the Research Programme related to the 
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500th anniversary of the discovery of America, a number of projects in 
biotechnology have been established with Latin American collaborators. 
5. National Biotechnology Centre 
The creation of a National Biotechnology Centre was one of the 
specific objectives of the Biotechnology Mobilising Programme. Designed 
to house some 300-350 scientists this Centre of Excellence will require solid 
support during the launch phase. Such support will be provided by the 
Mobilising Programme. 
Such is the significance of this venture that it is best considered apart 
from other aspects of the Mobilising Programme, although of course it will 
interact with all parts of that Programme. Staff Training 
STAFF TRAINING 
The Centre should be able to commence training of high calibre staff 
by the middle of 1989, through the organisation of courses and specialised 
workshops. A graduate fellowship programme will be initiated at the outset, 
with due regard to the specific needs that must be met in Spain. In accordance 
with its international interest the National Centre of Biotechnology will have 
a specific programme of scholarships for graduates from Latin American and 
African countries. About 15 such scholarship places are envisaged. 
In the early stages it is envisaged that senior staff will be supported by 
4 Visiting Professors, 15 graduate technicians and engineers, 20 laboratory 
technicians and some 20 young postdoctoral scientists. 
EQUIPMENT AND UTILITIES 
During the launch phase some 400 million ptas will be required.  
PROJECT FINANCING AND COLLABORATIVE RESEARCH WITH INDUSTRY 
The National Biotechnology Centre is expected to participate on a 
competitive basis for projects and funds managed by either government or 
industry. 
Management 
The Mobilising Programme is to be managed by a Programme 
Committee consisting of scientists and technologists. They will take the 
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responsibility of making proposals according to scientific merit, technological 
interest and economic practicability in the following areas: 
1. Personnel selection for their training in Spain and in foreign centres 
of excellence; 
2. Infrastructure endowment (utilities and equipment); 
3. Selection and funding of research projects and contracts with 
industry after appropriate peer review procedures; 
4. Evaluation and follow up of results obtained; 
5. Modifications to the Programme in consultation with both academia 
and industry; 
6. Temporary programming of the aforementioned actions and co-
ordination with related programmes, especially those of the CDTI; 
7. Direct promotion of R&D programmes of special interest not 
covered by existing recommendations. 
Priorities 
In accordance with the needs identified by the Programme 
Committee, taking into account the scientific and technological competence 
available in Spain the following fields will be promoted by the Programme: 
General Interest: 
 Development of systems for genetic manipulation in organisms of 
interest for biotechnology; 
 Development of animal and plant cell cultures related to their 
potential applications in biotechnology; 
 Development of enzymatic and other biochemical processes with 
potential biotechnological application. 
Agriculture and Food Area: 
 Genetic improvement in plant breeding; 
 Nitrogen fixation; 
 Improvement of fermentation processes (wines, dairy products, 
fermented drinks); 
 Improved microbial starter cultures; 
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 Bioconversion of lignocellulose materials  
 Pesticides. 
Health Area: 
 New generation antibiotics; 
 Immunology: vaccines, diagnostics, antigens, allergens; 
 Blood proteins; 
 Peptides, proteins and enzymes. 
Industrial Area: 
 Microbial mining; 
 Recovery of heavy metals; 
 Organic acids; 
 Bioconversion-bioreactors. 
Biodegradation and Pollution Control: 
 Residue and effluent biotransformation; 
 Microbial ponds for water purification; 
 Microbial purification of metal contaminated waters 
PREDICTED COST OF THE PROGRAMME 
Item Millions of pesetas Millions of ECU % of total cost 
Staff training 1 622 11.2 18 
Researchers and contracted personnel 1 380 9.5 15 
Infrastructure 2 000 13.8 22 
Projects 1 600 11.0 17.5 
R&D industrial concertation 2 240 15.5 24.5 
Business plan, other expenses 270 1.9 3 
Totals 9 112 62.9 100 




1.11. THE UNITED KINGDOM 
Roy Smither 
Introduction 
During the last half century biotechnology has undergone radical 
changes. Historically British scientists and technologists have played a key 
role in this development. 
Table 1. A few dates in the history of UK biotechnology 
1796 Smallpox vaccination, Jenner 
1843 World’s first agricultural research station founded at Rothamsted 
1923 Isolation of insulin, Macleod e al 
1928 Discovery of penicillin, Fleming 
1946 Large scale penicillin production, Glaxo 
1950 Food preservative antibiotic, nisi, NIRD 
1950s Modified penicillins, Beecham 
1953 
Cephalosporins, Oxford 
DNA structure, Crick, Wilkins and Watson 
1957 Interferon, NIMR, London 
1958 Insulin structure, Sanger 
1961 Foot and mouth disease vaccine, ARC 
1967 Marek’s disease vaccine, ARC 
1975 Monoclonal antibodies, Milstein 
1980 Pruteen, ICI 
1980s Fungal protein for human consumption, RHM 
1980s Cloned oil palm trees, Unilever 
1984 Monoclonal antibodies for purification of gamma interferon, Celltech 
Government Spearhead 
In 1980 the Spinks Report paved the way for accelerated development 
in both industrial and academic biotechnology. More than 20 
recommendations were made, of which most have been implemented. The 
Department of Trade and Industry, DTI, took over the lead responsibility for 
biotechnology and in 1982 the Secretary of State launched a campaign to 
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foster the development of biotechnology in industry with the objectives 
shown in Table 2. 
Table 2. Five key objectives of DTI support 
– Raise awareness of opportunities for biotechnology – consultancy support 
– Raise level of industrial research & development – innovation support 
– Improve biotechnology infrastructure – culture collective, information services 
– Identify and tackle strategic weaknesses – expensive agricultural raw materials 
– Identify and promote sectors of biotechnology that represent particularly 
important opportunities for UK 
To implement these priorities the Government Chemist established a 
Biotechnology Unit, BTU, staffed by civil servants and secondees from 
industry. With eight staff the BTU has been effective in ensuring the proper 
appraisal of proposals for support from industry. The BTU has also been 
pro-active in identifying and promoting biotechnology sectors of industrial 
significance, described in more detail later. 
Key Objectives 
1. Awareness 
The Department’s initiative in supporting biotechnology is part of a 
wider scheme known as Support for Business’, which also embraces other 
key technologies. Various levels of support were available to companies 
(ranging from large multinational to the novice, one man start-up) to 
employ a consultant to provide specialist skills that the company did not 
possess. The BTU had more than 100 candidate consultants which it could 
call upon. Discontinued now, largely because of its success, the DTI 
provided almost £0.64 million for consultancy support. Waste treatment 
proved to be a surprisingly interesting sector. Consultancy support was 
followed up to assess the impact achieved. A high level of success was 
achieved as judged by further development within a company, according to 
the follow-up studies. 
Other awareness raising activities include the launch of a pilot 
scheme to provide fermenters to secondary schools, support to the Open 
University to produce a series of videos, and the publication in 1984 of the 
Directory of British Biotechnology. A second edition was produced by a 
private company at the end of 1986. 
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2. Research and Development 
Support for innovative research encourages companies to spend more 
on high risk projects that would not have proceeded otherwise. This 
involves the largest element of spending to date. A grant of up to 25°/0 of 
eligible costs is payable to a single company, but no single project has 
received support for more than three years. About half the 200 proposals 
received have been funded. Company support for the projects outlined is 
estimated at around £50 million (April 1987 figures) with DTI support at 
£13.179 million. Additional support for collaborative research exceeded 
£10.323 million. 
Although biotechnology is moving at a fast pace, it is too soon to see 
any commercial benefits, although some R&D projects are beginning to bear 
fruit. Two examples of the fruits of R&D support are (i) ICI Agricultural 
Division – production of polyhydroxybutyrate, PHB, from micro-organisms. 
(ii) Amersham International – the development of the Amerlite, 
luminescent immunoassay system. 
3. Infrastructure 
Although the DTI takes the central role in supporting industrial 
biotechnology, many other Departments are concerned with aspects of 
health, agriculture, environment, energy etc. Co-ordination is maintained by 
the Interdepartmental Committee on Biotechnology, ICBT, for which the 
BTU supplies the secretariat. This co-ordinating activity has resulted in the 
production of a simple guide to UK regulations and regulatory bodies, a 
document of particular value for companies new to biotechnology. The BTU 
also provides the secretariat to the Industrial Consultative Committee on 
Biotechnology, chaired by a DTI Minister and consisting of senior 
industrialists. Its terms of reference are to identify and recommend to 
government, priorities and policies that encourage the exploitation of 
biotechnology by UK industry. 
The BTU underpins certain strategic technologies by major funding of 
two public sector laboratories, widely regarded as centres of excellence: 
Harwell and the Centre for Applied Microbiological Research, Porton. 
To facilitate access to data from the UK’s 9 microbial culture 
collections, the BTU has instigated the formation of MiCIS, the 
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Microbiological Information Culture Service. MiCIS went ‘on line’ in March 
1987 and enables subscribers to make cost savings on microbial selection. It 
is hoped that MiCIS might eventually become part of a pan-European data 
bank. 
A DTI survey on regulation revealed that the UK regime is regarded as 
sensible, pragmatic and generally preferable to other national regimes. It 
allows innovation to flourish, while offering adequate safeguards to the 
worker and consumer. Patenting has produced problems, particularly with 
regard to the basic patentability of biological innovations. Plants cannot be 
patented in the UK, although the DTI’s view is that the protection offered 
under the Plant Varieties Act is no longer adequate. The ICBT is of the view 
that UK law on patents should be harmonised with the European Patent 
Convention in restricting access to cultures deposited for patent purposes. 
The DTI feels that UK law must change to harmonise it with the situation in 
the USA and elsewhere. 
With regard to control of genetic manipulation, the DTI is concerned 
to avoid the imposition of new controls on industry, except where clearly 
justified. In view of the anticipated large increase in type and frequency of 
environmental release, it is likely that the existing Advisory Committee for 
Genetic Manipulation case-by-case review system may need revision. The 
OECD report of 1986 provides a framework for new controls. The DTI has 
recommended to the European Commission, EC, that risk assessment should 
figure largely in new biotechnology programmes. 
The DTI is prepared to co-ordinate UK industrial input into the EC risk 
assessment programme and assist in making links with European and other 
countries. It is keen to stimulate interest in an awareness campaign about 
biotechnology aimed at the general public, to dispel any ill-formed public 
perceptions, especially with reference to planned release. 
Most organisations active in biotechnology have representation on 
appropriate committees. Two bodies stand out at present, the British Co-
ordinating Committee for Biotechnology, BCCB, representing professional 
bodies and the Association for the Advancement of British Biotechnology, 




4. Priority Sectors 
Because the scope of biotechnology is so broad, the BTU has analysed 
the technology on a sectoral basis, taking into account the following aspects: 
market characteristics, UK sectoral characteristics, technology development 
characteristics, the relevant UK technology base and a suggested strategy for 
future development. An action plan gives five sectors a priority status: 
 Enzymes (biotransformations) 
 Diagnostics (biosensors) 
 Agriculture 
 Food 
 Process plant/instrumentation 
It is believed that these sectors, taking into account UK strengths 
and weaknesses, will afford the country major opportunities in future. 
Gradually the major biotechnology firms are agreeing with the 
notion that collaborative research, particularly at the precompetitive stage, 
is a sensible and viable solution to very costly research, especially when 
the DTI is prepared to fund up to 50% of programme costs. Successful 
ventures include the development of biosensors by Amersham 
International, Thorn EMI and the National Institute of Medical Research 
and also the development of the novel food, mycoprotein developed in 
collaboration by Rank Hovis McDougal and ICI. Examples of the larger 
consortia are listed in Table 3, below. The largest of these, the Plant Gene 
Tool Kit’ is a £3million/3 year programme involving 11 companies, 2 
universities and 2 research institutes, which will develop routine methods 
for  the transfer of genes into plant material. Each participant has free 




Table 3. DTI Sponsored consortia 
Consortium Objective Members 
rDNA and antibiotics To improve understanding 
and control of antibiotic 
production 




To extend useful life of 
immobilised biocatalysts 
in bioreactors 
7 firms at 3 universities 
Leicester Biocentre To improve expression of 
foreign proteins in yeast 
5 firms at 1 university 
Plant gene tool kit To develop gene 
manipulation techniques 
for crop plants 
11 firms at 2 universities 
and 2 institutes 
Enzyme supplementation 
of animal feeds 
Make low grade animal 
feeds suitable for non-
rumants 
7 firms at 2 research 
organisations 
Rapid microbiology using 
ATP bioluminescence 
Development rapid 
detection and enumeration 
systems for bacteria in 
industrial situations 
5 research organisations 
and many firms 
Even when 5 or 6 firms collaborate, large research programmes are 
expensive. This expense can be reduced if a university or research 
organisation is used as the focus for the establishment of a club with a 
specific research activity. This situation allows members to tackle problems 
of general interest, producing state of the art reports for the benefit of 
members. It is expected that membership fees cover at least 50% of the 
costs so that viability is ultimately linked to industrial interest. The BIOSEP 
club focusing on downstream processing and separation technology 
involves over 50 companies, some foreign. The DTI supports a number of 
clubs and could consider the support of others. 
The organisations that can be supported are listed in Table 4. 
Training 
The universities and Research Councils undertake most of the basic 
research and provide the kernel of trained manpower for industrial 
biotechnology. The quality of basic research in the UK is high and arguably 
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second only to the USA, with its huge resources. Generally the UK provides 
the right blend of talent for its industrial needs, although there may be 
shortfalls in specific areas such as immunology. The education system in 
the UK is flexible enough to be able to respond rapidly and redress any 
adverse trends. Education is thus in a state of dynamic equilibrium, 
carefully pivoted to cope with the increasing demands of industry. 
Table 4. Who Does the DTI Support? 





Companies Research organisations 
 Educational establishment 
 Hospitals 
Consortia of companies (and other organisations) 
Clubs 
Centres of Excellence 
Certain public bodies 
Certain foreign companies wishing to research and manufacture in the UK 
Clearly to achieve the right blend of academic and industrial talent 
requires large resources and a co-ordinated approach from government. To 
this end the BTU, along with a strong DTI Regional office network, works 
closely with the four relevant Department of Education and Science (DES) 
Research Councils. Significant liaison is maintained with the Biotechnology 
Directorate of the Science and Engineering Research Council, SERC, set up 
in 1981 with separate resources for funding research. The emphasis of the 
Directorate’s support is for high quality science and technology in the 
university sector, which, while addressing basic problems, will also provide 
information from which industry would benefit in the short or long term. Its 
priority sectors listed below, Table 5, sensibly complement those of the 
BTU. Much of SERC supported research is also through the medium of club 
or collaborative activities. 
To ensure that the UK does not miss out on some of the exciting work 
conducted at the AFRC and MRC research institutes, each research council 
has spawned a company, backed by city investment, which has exclusive 
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rights to certain areas of work conducted in their respective institutes. 
Celltech, which exploits much of the MRC monoclonal antibody 
developments is now the world leader in bulk monoclonal production. 
Agricultural Genetics Company, AGC, unlike Celltech, does not have its 
own laboratories, but acts in a venture capital role to ensure exploitation 
with industry of high calibre research in certain AFRC institutes. 
Table 5. SERC biotechnology directorate, priority sectors. 
Process engineering 
Bioconversions 
Animal cell biotechnology 
Plant cell culture 
Whole plant biotechnology 
Host-vector systems 
Biosensors and bioelectronics 
Protein engineering 
Public Sector Funding of Biotechnology 
Since the definition of biotechnology, as used by different funding bodies 
is variable, it is difficult to estimate precisely how funds have been allocated. 
Table 6. Government R&D funding of biotechnology in the UK 
Source Commitment £million 
Medical Research Council, MRC 27 
Agricultural and Food Research Council, AFRC 21 
Natural Environmental Research Council, NERC 1 
Science and Engineering Research Council,, SERC 3 
University Grants Committee, UGC 3* 
Ministry of Agriculture, Fisheries and Foods, MAFF 4 
Department of Trade and Industry, DTI 6 
Other government departments 2 
Total 67* 
*UGC specifically allocated £3M for new biotechnology projects. A much larger level 
of funding benefits general funding of biotechnology as part of university R&D. 
The MRC distinguishes between work with a clear intent to produce 
something of commercial value and basic research, but classes it all as 
biotechnology. In contrast, SERC spending by the Biotechnology Directorate is 




The DTI is keen to encourage international collaboration in certain areas 
of biotechnology. The UK plays an active part in the EC Biotechnology Action 
Programme and would like to see this further developed, providing it involves 
industrial collaboration. Things should be better in the EC Framework 
Programme as there are agreed priority sectors, clear objectives for evaluation 
and a relationship between Framework and Eureka. Eureka’s philosophy 
involves the exploitation of advanced technologies with a global sales 
potential best achieved collaboratively within Europe, where companies lead 
in identifying and conducting projects. Biotechnology has had until now a 
rather low profile in Eureka for a number of reasons. Within certain sectors 
such as pharmaceuticals, the notion of near market collaboration is 
countercultural, as the companies have a long tradition of self sufficiency. 
However DTI has come dose to stimulating collaboration in vaccine 
development. There could well be more potential for Eureka in the diagnostics 
area, where technology is changing at a prodigious pace and all European 
companies are threatened by US majors. A particularly important, but hidden, 
aspect of Eureka, relates to its value as a lever for regulatory change. 
There is also scope for bilateral collaboration between companies in 
different countries. Examples include Celltech and the Japanese companies, 
Sumimoto Corporation and Sankyo, as well as Delta Biotechnology and the 
US company Stroh. 
I have outlined UK collaborative programmes covering a wide range 
of biotechnological interests. The UK would be willing to internationalise 
these if other countries would make equal contributions. The areas 
identified as contenders for international involvement include protein 
engineering, the genetic manipulation of plants as well as the industrial use 
of agricultural surpluses. Equally we would be happy to consider other 
countries’ suggestions and help to identify possible industrial participants 
for such collaboration, especially under Eureka. 
Inward Investment 
Many overseas companies are becoming interested in the UK as a 
centre for investment and R&D in biotechnology, not least because of its 
record of a commonsense approach to product regulation, and effective and 
predictable approval processes. US biotechnology companies have already 
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invested in manufacturing facilities for healthcare, biochemicals, biosensors 
and micropropagation. They have been attracted by the same combination 
of excellent manufacturing sites, strength in life science R&D, and high 
quality clinical trials that have made the UK the predominant European 
country for US pharmaceutical investment for many years. Examples are 
Welcome and Schering Plough who both recently obtained UK Government 
approval for the sale of α-interferon, a major event in the development of 
therapeutics through biotechnology. 
The BTU works closely with the Invest in Britain Bureau to attract 
further investment. Seminars have been held in the USA, Japan and other Far 
Eastern countries to persuade companies in those countries that the UK is the 
natural focus for investment to meet the needs of the European market. 
Conclusion 
It is the belief in the UK that the prime motivator of biotechnology is 
industry, although this is complemented by a fair fiscal and regulatory 
regime. The country has a lively and successful biotechnology industry, with 
tariff free access to the European Market of over 400 million people. It is a 
centre for growth in which products can be developed and marketed quickly. 
It has a strong academic base and a large pool of highly trained manpower. 
With its regional investment grants and its highly developed private financial 
sector, the UK is one of the preferred locations for biotechnology. 
There are numerous opportunities for improved international 
collaboration and the UK is ready to do its part in seeking parties for 
projects appropriate for collaborative research. 
Postscript 
Since January 1988 a change in DTI policy has transformed the 
focus of industrial support for technology, including biotechnology. 
The emphasis is away from providing support to individual 
companies and now concentrates on exploitation of technology through 
collaboration. There are several ways in which the DTI, with other 




LINK encourages companies to undertake joint, pre-competitive but 
industrially relevant research with the academic base. Biotechnology 
programmes have been agreed in eukaryotic genetic engineering 
(£4.7M/4 years), biotransformations (£4.0M/4 years), selective drug 
delivery and targeting (£3.0M/5 years) and food processing sciences 
(£14.0M/5 years), whilst a further programme of protein engineering 
is in the pipeline. 
National collaborative/ general industrial reasearch programmes 
encourage collaboration between companies in precompetitive 
research outside the specific focus of LINK, and may or may not 
involve academics. 
EUREKA encourages industrially led projects with EC or other 
European partners. These should both strengthen European 
technological capability in world markets and contribute to the 
completion of the Single European Market (1992) 
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Luis Ramiro Alfonsin 
By His Excellency Mr., Ambassador of Argentina to the EEC 
It is an honour for me to be able to participate in this Seminar on 
Biotechnology in Europe and Latin America’ in the company of a group of 
scientists, industrialists and government officials. 
Some aspects of biotechnology are presented as one of the most 
stimulating sciences of our time. 
In Latin America, one has managed to successfully manipulate some 
of the most traditional aspects of biotechnology, such as the improvement 
of plant and animal species. 
Our progress is not as obvious in other sectors of more recent 
discoveries such as new genetic engineering techniques. 
Some scientists agree that progress in biotechnology will have a 
negative effect on developing countries. Others think that it will be 
difficult for poor countries to benefit from numerous advances which take 
place in this sector. 
I personally think that no futurologist feels at his ease when his 
forecasts do not come true. But whatever the final result, Latin America 
will not be able to remain outside the development of biotechnology. This is 
why I enthusiastically congratulate the organisers of this seminar for their 
idea to gather men and women of both continents showing an interest in 
these themes. 
Many of the businesses created to use genetic engineering for the 
discovery of new processes or products have resulted from the vision and 
enthusiasm of the scientists who have imagined the potential results from 
these recently introduced tools. It seems that it was not very difficult for 
these pioneers to communicate their enthusiasm to investors willing to take 
the risk and to accompany them in their dreams. This was followed by 
hardship, frustrations, and elusive results for which one has had to make an 
effort in order not to be despondent. This is how this young industry has 
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had to mature in a very short time and without giving way to despair, has 
had to learn to be satisfied with more realistic objectives or be more patient, 
but always keeping in mind the possibility of making surprising discoveries. 
One sees today an industry which is starting to move steadily, even if 
this sector is not suitable for people without courage or for those who do 
not want to take risks. 
I imagine that from the point of view of the scientist, the researcher, 
the present climate of biotechnology is something like an ideal 
environment. It appears as an enormous sector presenting great possibilities 
which researchers, as well as entrepreneurs and scientific research policy 
makers, should distance before deciding where to direct the efforts and the 
resources, which are always limited. 
It is certain that Europe will attempt to dedicate itself to highly 
sophisticated small scale productions wherein costs and ingredients coming 
from plants or animals have a relatively small importance. 
I think that there are three different sectors in which biotechnology 
can bring fundamental advances for humanity. 
Undoubtedly what is most important is the pharmaceutical sector 
which appears to present an almost unlimited range of possibilities both for 
medicines as well as for diagnoses. Possible progress in the pharmaceutical 
sector is the one most stimulating our imagination and our hope. Results 
which were hardly envisageable have been obtained this century. This 
brings to mind insulin, tissue plasminogen activator, vaccines against 
malaria or Chagas’ disease which preoccupies us so much, or more efficient 
vaccines against foot and mouth disease and of course, the whole area of 
immunology and fight against cancer. 
A different fundamental sector for biotechnology is the production of 
basic chemical products from material of organic origin. One should start to 
be ready for the time of scarcity of reserves of raw materials. For several 
decades, Argentina has produced acetone, butane and ethane from cereals 
and sugar through fermentation. Brazil produces large quantities of ethane 
through fermentation of sugar. Microbial processes could help to solve 
problems relating to environmental contamination and at the same time 
produce fuel and chemical products. In contradiction to these advances, it is 
surprising to see large projects proposed that are based on European 
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agricultural production which is produced at terribly high cost and which 
requires enormous subsidies in order to be able to be used for these 
industries. It seems to me more reasonable to install these industries in 
countries with a more efficient system of agriculture where the investors 
will not depend on political change, protectionism or to subsidies. 
The other interesting sector for biotechnology is agricultural 
production. Possibilities for improvement are also nearly infinite and the 
needs of humanity are very urgent in this sector. However, Europe also 
needs to correct immediately the expensive inefficiency of its agriculture. It 
would be wrong to continue to produce at exceedingly high costs whilst 
sheltering itself inside a protectionism which causes prejudices. Europe 
needs to start looking for new varieties of cultures which do not require as 
many fertilisers or pesticides to be ready when the time comes to honestly 
compete at a world level. The research in new symbiotic systems has to be 
intensified which will enable the exploitation of atmospheric nitro-gens for 
surface plants reducing costs and water contamination. It is very interesting 
to discover new varieties adaptable to zones of little rainfall or finding 
methods of cultivation which reduce water requirements. The utilisation of 
bacteria in the fight against the effect of frost seems very promising and it 
should be possible to introduce new cultures to areas having short summers. 
Europe could profit from annual cultures producing cellulose at acceptable 
costs. It is also interesting to find saline resistant cultures. 
The European consumer will want many agricultural products to 
regain the flavour and the quality they had in the past and which were lost 
because of technical methods that can be only used in the community 
market which allows high prices independent of quality. 
With so much work to be achieved, it does not seem reasonable to 
devote efforts and scarce funds to try to increase production by high cost 
technical methods which make it impossible to resist honest competition. 
The Latin American technicians want to collaborate in this scientific 
research. Latin American agriculturists are not afraid to compete on an 
equal footing with European agriculturists. It is not possible to compete 
with funds from the North American Treasury or Community budgets. 
This does not mean that Latin America must give up participating in 
the development of sophisticated techniques. On the contrary, we feel 
obliged to reduce the gap which separates us from the industrialised 
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countries in the biotechnological sector, as well as in other scientific and 
industrial sectors, especially if we take into consideration the fact that the 
development of some products, without economic interest for the developed 
countries, may be of vital importance for us. 
Europe and Latin America can collaborate and be complementary in 
this exciting adventure of biotechnology. I think that there will be advances 
in research, development and production which could be realised at a lower 
cost in Latin America than in Europe. 
This first meeting will help to make experts from both continents 
familiar with each other. I expect that this meeting will be successful. 
Interesting ideas for all participants will be brought forward. I hope that at the 
end of the meeting they will already be thinking of the next seminar. Along 
these fines, I allow myself to urge the organisers, enriched by the experience 
gained during this meeting, to continue with the idea of maintaining this kind of 
contact which will certainly be of great interest to both regions. 
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2.0. OVERVIEW OF LATIN AMERICAN  
ACTIVITIES IN BIOTECHNOLOGY 
Karl Simpson 
It has been too easy for Europeans to dismiss Latin America as being 
a collection of underprivileged third world states. It is true that debt 
continues to be a pressing problem for almost all of Latin America’s 
economies, but in 1988 Brazil and Mexico seem to be regaining the 
confidence of the world’s financial centres. Argentina’s recent re-entry into 
democracy is a further cause for optimism and in Chile (ignored in 
SOBELA) there is growing hope of a democratic conclusion to Pinochet’s 
regime. 
Each of the Latin American states, but most notably, Argentina, 
Brazil, Mexico and Venezuela, has a substantial business class, enjoying 
access to European standards of education, health and consumer 
commodities. Industrial output, while largely low-tech, has increasingly 
focused upon new technologies emerging from the R&D based cultures of 
the USA, Japan and Europe. 
In several areas of biotechnology a number of Latin American 
nationals have made substantial contributions. Cesar Milstein (Argentinean 
citizen) gained his Nobel Prize for work on hybridomas. It cannot be 
overlooked that in the event of substantial improvement in living and 
working conditions, Latin America may be able to call upon the skills of 
many technically qualified expatriates working in centres of excellence 
throughout the world. Both Argentina and Brazil have traditions of 
excellence in basic research and have a number of long established and 
internationally recognised laboratories. 
In 1984 the United States Office of Technology Assessment, OTA, 
suggested that the Latin American market for biotechnology would be 
exploited by the USA and Japan. Europe, they reasoned would not be able to 
establish a presence. By 1988 it has become clear that Europe has moved 
and is now establishing a strong position in Latin America, although 
Japan’s involvement is very strong. Paradoxically it is the USA that has 
failed to capitalise upon its proximity to Latin American markets. This has 
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been aggravated by a hostile reaction to Latin America’s generally ‘Laissez 
Faire’ approach to intellectual property protection. 
A growing sense of community is emerging in Latin America and 
this is manifest by an increasing number of joint activities in areas of 
strategic interest such as biotechnology. The states of the Andean Pact have 
effectively devolved national responsibility to the supra national 
responsibility of the Pact. Professional Associations such as Brazil’s 
ABRABI (Associação Brasileira de Empresas de Biotecnologias) are 
spreading throughout the region. 
A sense of realism prevails in most of the states. It is realised that 
commitment to biotechnology is not immediately going to force a dominant 
position in world markets. It seems more likely that the short term 
advantages of developments will be a reduction in foreign imports, such as 
AIDS diagnostic kits or insulin. In the long term it is possible that relatively 
cheap labour costs and a well educated professional class might permit the 
exploitation of world markets on an equal footing with companies in 
Europe, the USA and Japan. 
One of the consequences of SOBELA may well be the establishment of 
joint ventures that realise these hopes in the short term. 
In the following lines we paint a very brief picture of biotechnology 
in the states presented at the SOBELA meeting. 
Argentina 
The election of a civil government in 1984 gave impetus to the 
National Biotechnology Programme, PNB, launched in 1982. Nobel 
Laureate, Dr Luis Federico Leloir, heads the Executive Committee of the 
PNB. With major support from the National Department of Science and 
Technology and the National Council for Scientific and Technical 
Research, as well as significant input from other ministries, the PNB is 
orientated towards servicing the needs of industry. Human health and 
livestock health and improvement have been defined as priorities for the 
PNB. In the period 1984-86 US$1.6 million was divided between 90 projects 
in 70 centres. From a European point of view such expenditure would seem 
to be spread very thinly. 
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Training is a key issue in the Programme and grants are made 
available for scientists to train in foreign countries. The EEC has been 
asked for financial support in this area. The PNB is orientated towards 
international collaboration and links with several countries in Europe exist 
already (Belgium, France, Federal Republic of Germany, Italy and 
Sweden). Internal cooperation and particularly the cementation of strong 
industry/university links are essential if the Programme is to meet its 
goals. Individual entrepreneurs are expected to take the initiative in 
establishing such finks, while the PNB will support the activities of a 
representative body, the Argentine Forum of Biotechnology. Launched in 
1986 its President, Dr Aldo Ferrer is also President of the Bank of the 
Province of Buenos Aires. 
A fiscal package has been agreed which accords credit certificates to 
a value of 60% of the cost of approved projects. This is also available to 
foreign entrepreneurs investing in Argentina. 
Argentina has developed particularly dose links with Brazil, 
manifest in the foundation of a joint centre for biotechnology. On this 
background of activities there is an increase in interest and investment in 
industrial biotechnology. 
Brazil 
With an academic tradition in the biological sciences dating back to 
the mid 19th century Brazil has a commanding lead over its neighbours. São 
Paulo, active from the beginning has become the focus for institutes 
operating in the areas of vaccines, immunology etc. Successful public 
health campaigns are making progress in the control of typhus, 
leishmaniasis and other diseases. Agrobiotechnology has achieved some 
notable successes, using very traditional technologies. Brazil has 
established commercially valuable Maize hybrids. 
There is a strong commercial base for exploiting innovation in 
biotechnology. Agroceres, the seeds company, was founded in the 1940s. 
In the 1960s Brasilsul and Agropecuária were founded. These companies 
can trace their evolution to the work of plant geneticist, Cruz Martins in 




Companies with an interest in biotechnology have guaranteed Brazil 
self sufficiency in insulin production, and are looking closely at the local 
manufacture of products including the interferons. Arable and stock 
farming is served by many universities and institutes, several of which now 
boast competence in gene manipulation. Selection of soya cultivars has 
resulted in an 80% increase in nitrogen use efficiency in the last 20 years. 
Genargen has established germ plasm banks, which will help offer 
protection from North American, Japanese and European companies hoping 
to exploit Brazil’s vast phytochemical resources. 
Biotechnology in Brazil cannot ignore the Proalcohol Programme, 
although this is coming under increasing internal criticism. The programme 
did much to stimulate local biotechnology related industry and incited 
contacts with companies such as Denmark’s Novo, who became interested 
in the prospects of selling starch converting enzymes. Perhaps the long-term 
benefit of the programme will have been the accumulation of know-how in 
all aspects of the sugar complex. 
Although the Ministry of Science and Technology accepts 
responsibility for control and co-ordination of Brazilian biotechnology, the 
government, as in Argentina, looks to entrepreneurs to provide the 
industrial impetus to the programme. More so than anywhere in Latin 
America industrialists have come forward to launch companies in areas 
ranging from micropropagation of plants to AIDS diagnostics. 
Examples of companies include: Biobras, interested in the 
manufacture of genetically engineered insulin. Bio-Planta in association 
with Native Plants have set up an agrobiotechnology research centre. 
Cibran, the antibiotics company is implementing rDNA technology in its 
R&D facility. Embrapa is a public sector company which has a commitment 
to the exploitation of Brazil’s germ plasm resources. 
In the public sector the Oswald Cruz Foundation and the Butantã 
Institute make a major contribution towards biotechnology R&D. Many of 
the new companies will participate in the formation of regional poles of 
biotechnology, where private/public sector integration will be a feature. 
This activity mirrors what is going on in France. 
In Brazil there is a growing concern that biotechnology may threaten 
the future of employment in the agricultural industry. Increased 
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productivity may seriously damage the organisation of society in areas 
removed from major cities. 
Mexico 
Although Mexico has a number of university departments with 
competence in several aspects of biological science it is true to say that 
industrial exploitation of biotechnology is dominated by first generation 
technology. Such technology is manifest in the production of beers and 
spirits. Second generation technology is used for the production of 
antibiotics, amino acids and aspartame sweeteners, but all of this 
technology has been imported from foreign countries. 
Several small scale industrial enterprises have been launched to 
capitalise upon the market for the products of this technology. Enzymology, 
based in Monterrey, is a company manufacturing aspartame, phenylacetic 
acid and related chemicals. Bioenzimas, in Saltillo, Coahuila, is an agro-
biotechnology company with interests in improved grain yields, 
insecticides, giberellic acid and agricultural enzymes. 
Modern biotechnological innovations such as micropropagation are 
being initiated by a small number of firms including: Industrial biogenetics, 
involved in the micropropagation of strawberries, asparagus and violets; 
Genin, who are working on immobilised enzyme bioreactors and the 
Forestal Center of Genetics, dedicated to genetic improvement of forests by 
micropropagation. 
Gene manipulation and hybridoma technology are found only in 
government funded laboratories and universities. In these centres 
biochemistry and related sciences have been established since the 1930s. 
Biochemical engineering degrees are awarded by more than 20 institutions, 
with 7 centres offering postgraduate training. 
The Andean Pact 
Bolivia, Columbia, Ecuador, Peru and Venezuela 
The Andean Pact is a structure similar to the EEC. Most of the 
member states do not have the resources required to fund major 
programmes in high technology. Under the auspices of the Pact central 
facilities and concertation measures optimise those skills and technologies 
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available. An Andean Biotechnology Programme has existed since 1986. 
Within the members of the pact there is considerable variation in wealth 
and scientific competence. The Andean Council for Science and 
Technology has principal responsibility for concertation of biotechnology 
actions within the Andean Pact. 
Bolivia is not advanced, but does have a programme focusing on 
Embryo transfer between species of South American Camelidae. Work is 
carried out in the Instituto de Genetica Humana, where a programme on the 
molecular biology of diarrhoea is also active. In 1985 Peru and Bolivia 
launched the Andean Mining/Metallurgical Programme, PMMA. One aspect 
of this titled, biohydrometallurgy, concentrates upon the extraction of 
metals by microbial leaching. 
Columbia has a very ambitious National Biotechnology Programme, 
but given the present level of trained personnel and appropriate facilities it is 
difficult to see how the programme can be implemented in its present form. 
Ecuador has indulged in some limited biotechnological work since 
1983, but a realistic government cannot contemplate a significant National 
Programme. Training is singled out as the most important requirement in 
the National Plan for biotechnology. Government laboratories are carrying 
out R&D in aquaculture, in collaboration with commercial interests. Inexa 
SA is a small company carrying out meristem culture in collaboration with 
university laboratories. Pronatec SA is studying the commercial exploitation 
of natural extracts. Life SA in collaboration with the Instituto Nacional de 
Higiene is manufacturing vaccines for animals. Levapan is developing 
fermentation technology. There is hope that it may be possible to stimulate 
the pharmaceuticals industry by applying rDNA technology and other 
aspects of modern biotechnology. 
Peru has little infrastructure capable of supporting advanced applications 
of biotechnology. It is the mining industry which has turned to bacterial 
leaching as a possible tool for the extraction of metal from unworkable 
deposits. The government sector has some activities in plant biotechnology. A 
joint programme with Bolivia, supported by the Federal Republic of Germany 
expands upon national competence in microbial leaching. 
Until recently Venezuela has had the privilege of having the highest 
per capita earnings in Latin America. Decline in oil revenues is forcing a re-
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evaluation of national goals. Biotechnology is seen as a tool with 
considerable potential and a programme launched in 1984 concentrates on 
three major areas: Agriculture, Medicine and Industry. In Agriculture the 
focus of effort is upon the production of pathogen free plants through 
somatic hybridisation and tissue culture. The potato and yucca plants are 
the targets for exploitation. Medical priorities include assault upon regional 
diseases and the development of competence in monoclonal and polyclonal 
antibody production to back up a domestic competence in diagnostics 
targeted at cancer, AIDS and epidemiology. rDNA technology is on the 




José La Torre  
Sara B. de Rietti 
Structure and Operation of the National Biotechnology Programme 
The National Programme of Technology (PNB) was created at the end 
of 1982, even if it only became popular in 1984 with the inauguration of the 
constitutional government of Doctor Raul R. Alfonsin. The information 
supplied by this Programme is rich in experience but corresponds to a 
starting phase. Argentina has a long tradition in biosciences (with three 
Nobel Prizes) as well as an important pharmaceutical and biochemical 
industry. In 1984, during the initial phase, there were already numerous high 
quality research centres in areas linked to the development of 
biotechnology. Even if the National Programme of Argentinean 
biotechnology is new, its foundations are solid. The Programme has been 
organised as an advisory, co-ordinating and financing unity with minimal 
administration and wide ranging executive powers. The head of the 
National Department of Science and Technology (SECYT) is directly 
responsible for the PNB and its management is co-ordinated through the 
Secretary of Sciences and Technology. The programme has an Executive 
Committee of four members and an Advisory Committee of twenty 
members headed by the Honorary President, Dr Luis Federico Leloir, Nobel 
Prize for Chemistry. 
The Advisory Committee represents public and private research 
centres and State and University Institutes as well as the body linking the 
industrialists of the biotechnological sector. All the members of the 
Executive Committee, and nearly all of the members of the Advisory 
Committee, are specialists in disciplines finked to biotechnology from the 
various regions of the country. The actual composition of the PNB appears 
in Appendix A of this report. 
R&D Financing in Biotechnology 
One of the basic functions of the PNB is the granting of subsidies for 
R&D related to biotechnology. The word basic is used because R&D 
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administrators know that it is a very powerful instrument in the implementation 
and shaping of policies. The funds are provided from subsidies budgeted by the 
SECYT and by support from the National Council for Scientific and Technical 
Research (CONICET) operating in co-ordination with the Programme. 
This specific financing is an addition to that granted by other 
organisations and sectors of the SECYT with similar aims. One can thus 
mention the support of the CONICET for selective basic and applied research 
which at least doubles the value of the PNB grants, and the role of the 
National Institute of Farming Technology (INTA) which has considerable 
resources and programmes. Other support is offered by National 
Programmes of the SECYT related to biotechnological aspects of Food 
Technologies and Non-Conventional Energies, and subsidies granted by the 
SECYT through ‘Apoyo Institucional’, in the same way as the PNB. 
The financial support of the PNB is mainly directed to the centres and 
laboratories of the public sector. In all its other activities, such as the 
interaction between science and production or international co-operation, 
those depending on private companies and institutions are also included. In 
this way the PNB is a common point for public and private initiatives whose 
realisations very often result from a disinterested collaboration of 
researchers and private industrialists. Subsidies are granted as a function of 
standards and priorities established for each programme. 
Interested parties have to present a Pre-Project for which approval is 
indispensable to allow detailed examination of the Project. It is advisable to 
co-ordinate Pre-Projects with similar topics into an Integrated Research 
Programme. Financial support is organised as far as possible for a 
maximum period of three years subject to a control of academic and 
budgetary administration, which is made by the PNB. 
The priorities established by the Programme for the distribution of 
subsidies are based both on the research topics and their connection with 
the general development of the sector and with the level of technical 
innovation reached including the socio-economic impact of the Project. For 
the productive importance of research it is essential that the results are 
applied in the most direct way to the production of goods or services. 
One of the basic objectives of the Programme is to place the 
scientific work at the service of the productive activities. This is especially 
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so as Argentina, in its present state of development, cannot afford the 
luxury of maintaining expensive, non-productive, basic research in a sector 
such as biotechnology, which historically presents for the country an 
interesting academic development, and that at the same time offers an 
enormous productive potential at an international level. 
As far as the research topics are concerned, their priority has been 
established after many long debates and preference has been given to those 
concerning human health and agricultural livestock production. Productive 
applications rather than specific research topics have been considered as a 
determining condition for the approval of a project but this does not exclude 
a proposal favouring the development of any weakness of the sector. 
In particular, priority topics of research are the following: 1) 
Development of biotechnological processes with special emphasis in the ones 
which concern the application of advanced biochemical engineering; 2) 
Biological fixation of nitrogen; 3) Plant biotechnology with special emphasis in 
molecular biology of plants and cultures of plant tissues; 4) Production of 
vaccines and biopharmaceutical products; 5) Diagnostic reagents. 
Between December 1984 and December 1986, the PNB approved 
subsidies for a value equivalent to more than US$1.6 million distributed 
between more than 90 research projects and various plans for equipment at 
more than 70 centres and research laboratories throughout the country of 
which a substantial number are related to biotechnology. 
Vocational Training 
Argentina has a rich tradition of professional education in bio-
sciences and has trained high level researchers who work on very advanced 
topics in several parts of the world. However, in order to cope with this 
challenge of providing a scientific and technical infrastructure capable of 
supporting the development of production methods incorporating 
biotechnological advances, an effort is required in training and re-education 
which implies a qualitative and quantitative change. The PNB is aware of 
this situation and in co-ordination with the CONICET has developed an 
intensive plan of external grants which will be valid from 1987 onwards. 
The support of the European Community will be sought for the 
development of this plan and the process of promoting an intense horizontal 
co-operation with Latin-American countries has begun. 
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The PNB has given its support to this for the last three years by the 
promotion and financing of various activities directed towards the training 
and re-education of the researchers such as: intensive theoretical courses, 
seminars and conferences organised by research centres, university and 
private institutions which has been able to work with foreign or 
Argentinean specialists living abroad. International co-operation and a 
growing emphasis on the activities of CONICET has channelled support 
towards this goal. The purpose of the programme is to intensify activities 
finked to training in biotechnology in which international co-operation 
plays an important role. All methods such as doctorate or postgraduate 
grants and specialists missions are utilised to gain foreign or external 
support. In the particular case of Argentina the training must reach all levels 
of university lecturers as well as all aspects of administration because of the 
scarcity of specialists capable of dealing with scientific projects of the 
complexity or the extent required for new technologies. 
International Co-operation in Biotechnology 
From its inception, the PNB has given preferential attention to 
everything which is connected to international co-operation in 
biotechnology. With the objective of using offers of co-operation from 
countries of higher scientific technological development, Programmes have 
allowed the realisation of meetings and scientific seminars which officials, 
researchers and foreign entrepreneurs have attended. In particular, the 
French-Argentinean meeting in Buenos Aires in 1986 has brought about an 
important exchange of ideas and created contacts between the 
biotechnological enterprises of both countries. The 1986 cooperation 
agreement with Sweden has included five biotechnological projects which 
have been completed by Argentinean and Swedish Institutes implying an 
important economic and technical contribution. In 1984 an agreement was 
made between the Argentinean Republic and the Kingdom of Belgium 
which foresees the realisation of twelve joint projects including one on 
wheat covering aspects linked to biotechnology. Additionally, Italy and the 
Federal Republic of Germany have expressed intentions for co-operation 
which are expected to be realised before the end of 1987. To promote 
regional co-operation, taking into account the integral complementary 
economic policy of the Argentinean Government, the PNB has allowed joint 
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meetings of officials, researchers and entrepreneurs linked to biotechnology 
with other Latin-American countries, especially Brazil. 
It has actively taken part in setting up the Regional Programme in 
biotechnology for Latin-America and the Caribbean patronized by the 
PNUD, UNESCO and UNIDO and has a large responsibility for 
commercialisation, which is of great importance for the development of 
biotechnology. The first director of the Argentinean-Brazilian Centre in 
Biotechnology (CABBIO) serving a three-year term is a member of the 
Executive Committee of the PNB. 
Models for Internal Co-operation 
The PNB has started a number of interdisciplinary co-operative 
activities inside Argentina to realise policy. 
The fundamental objective of the Programme is to obtain as close a 
contact as possible between the productive sector and the research centre as 
well as the various State run or supported laboratories. This inter-relation is 
established through active participation of representatives of private 
enterprises and activities promoted by the Programme, either in national or 
international meetings or in a Commission or Working Group. The 
Programme also stimulates the activities of the committees of scientific and 
industrial co-operation which are encouraged by the CONICET. These 
committees specify agreements, tasks and results of the R&D Centre and the 
nature and amount of payments made by the company consisting of fixed 
yearly amounts or sales commissions for a fixed period. 
Finally, in order to enlarge the market or to incorporate advanced 
technology which allows the support of large industries the PNB organises 
meetings between Argentinean and foreign industrialists such as those 
bilateral meetings between France and Brazil. An example, involving 
France at the end of 1986, was the mission linked to the biotechnological 
sector of the EUREKA plan, during which co-operation between Argentinean 
and French companies was established. 
The link between universities and enterprises is established through 
agreements created by CONICET when there are R&D centres or university 
laboratories capable of completing such co-operation. In general, the 
national universities, particularly the best ones, have experienced a serious 
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recession because of the political vicissitudes during the decades prior to 
the present Constitutional Government which provoked a reduction of the 
teaching and more qualified scientific staff whose real contribution to the 
development of biotechnology helps consolidate a recuperation process 
with which the SECYT is deeply involved. 
As for the proposed entrepreneurial models, the PNB prefers the 
actual entrepreneurs to take the initiatives required in each case. On the 
contrary it has been concerned with the creation of a representative body 
where both private associations and enterprises as well as public sector 
centres linked to biotechnology have a say. This is how the Argentinean 
Forum of Biotechnology was created in October 1986 whose president is 
also president of one of the main state banks of Argentina and is presently 
part of the Consulting Committee of the PNB. The SECYT has created a law 
promoting development and technological innovation in production. The 
PNB has taken part in these discussions which were presented to the 
Congress of the Nation in 1986 and which establish the basis of an 
institutional rule in this field. Three possible modalities for the execution of 
entrepreneurial technological R&D projects have been established: 1) total 
execution of the project by a national centre of R&D contracted by the 
company; 2) execution of the project by the company and a national R&D 
centre in which each of the parties must realise distinct and complementary 
tasks and 3) total execution of the project by the company under fixed 
conditions determined by the law and subject to a technical and accounting 
verification by the SECYT. The concept of the national R&D centre covers 
laboratories, professor-ships and state institutions (such as the INTA) and 
others allowed by the SECYT. 
The benefit for the company consists of the delivery of fiscal credit 
certificates for the payment of national tax equivalent to 60% of the cost of 
the approved project. This type of benefit is also available to companies of 
foreign capital established in Argentina and the approval for these projects 
is given by the SECYT. This is subject to priority criteria fixed by law which 
takes into consideration the contribution to the national economy and to the 
promotion of exports. 
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Scientific and Technological Co-operation between Europe and Argentina 
As already mentioned, Argentina has realised co-operation 
agreements linked to biotechnology with Belgium, France and Sweden and 
is in a very advanced preparation stage of programmes for which it shows a 
great interest, with Italy, and the Federal Republic of Germany. 
To reinforce the existing co-operation and the permanent how of 
information the following is suggested: 
a) The initiation of intensive training, education and coaching of the 
R&D staff at all levels including the administration of projects 
within the framework of the plans drawn up by the PNB. 
b) The completion of joint R&D projects in biotechnology on topics 
considered as priority ones by the PNB with the exchange of 
specialists and contribution to the technological equipment needed 
by Argentina. 
c) The establishment of industrial plants which bring advanced 
technologies and employ local personnel at all levels. They are 
obliged to dedicate a substantial percentage of profits to R&D for 
which local professionals trained by investors are responsible and a 
substantial percentage of production to export. 
d) Association of European companies with Argentinean companies in 
which the effective transfer of technologies brought by the 
European side is certain. 
e) Establishment of international services of scientific and 
technological data bases related to biotechnology which are 
accessible to public and private entities in Argentina. 
f) Creation of information and documentation committees in 
European cultural diffusion agencies operating in Argentina.  
In particular, support is needed to set up a R&D centre for industrial 
farming production in the rich damp pampa of Argentina equipped with a 
system of enormous productive potentiality. The scientific and 
technological training tasks of the new centre will be closely linked to the 
production activities of the area characterised by the very interesting 
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problems of dealing with the natural environment, plant and animal health 
and productivity. 
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Antonio Paes de Carvalho 
Background to Brazil’s Biotechnology Policy 
Brazilian biotechnology began in the middle of the last century when 
pioneer work was carried out in São Paulo on various specialized fields of 
microbiology, notably bacteriology, mycology, protozoology, phytopathology 
and virology. As a result of the work of these pioneer groups the first institutes 
devoted to research on bacteriology, vaccines, and clinical, pharmacological 
and immunological analyses sprang up in São Paulo. 
Brazil benefited greatly from the results of these early initiatives 
which paved the way for successful public health campaigns against 
epidemics of yellow fever, trypanosomiasis, leishmaniasis, bubonic plague 
and typhus. Important institutes such as Oswaldo Cruz, Adolfo Lutz, 
Butantã and Pasteur were also set up, and these are now fully competent to 
maintain national progress in the field of biotechnologies applied to health. 
In agriculture the technical progress made in the early days of 
biotechnology studies applied to seed production made Brazil the second 
country in the world, after the United States, to obtain uniform and high-
yield hybrid maize from fines developed from local genetic stock. 
As a result of this process of development and consolidation of 
various branches of traditional biotechnology, in particular those related 
to agriculture, the first private enterprises in the seed production markets 
such as Agroceres sprang up in the forties followed, in the sixties, by 
Brasilsul Agropecuária. 
As regards the development of genetics, the basis of modern 
biotechnology, Brazil’s historical development has its roots in the work of 
Cruz Martins, in 1924, together with the Instituto Agronômico de Campinas. 
The development of Brazilian genetics is also connected with international 
names such as Dr Dreyfus, Dr Krüg, Dr Brieger and Dr Dobzhansky who 
were the pillars of Brazilian genetics and left behind many disciples who 
became top-level researchers. 
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Again in the field of health, Brazil is carrying out initiatives in 
diagnosis methods and biopharmaceuticals of high molecular weight; it is 
self-sufficient in insulin and is carrying out research into the production of 
interferon and also has the technology to produce blood derivatives, 
including human albumin and anti-haemophilic factors. 
Arable and Stockfarming 
This represents a great development potential for the country since we 
now have a number of excellent research institutes and universities covering 
various areas such as genetic engineering, cell and tissue culture (USP, IAC, 
UNICAMP, EMBRAPA, IAA, UFRJ, UFVIÇOSA, ESAL, IAPAR), and biological 
fixing of nitrogen and mycorrhiza (inoculants) (UAPNPBSOLO/ EMBRAPA, 
UFRGS, CENA, IPT, IAC, UFV and others). 
The most impressive example of nitrogen fixing is the result obtained 
by the constant research carried out over the past twenty years with soya 
cultivars which, today, can extract 80% more than their nitrogen needs by 
biological fixing. 
Noteworthy Brazilian technological developments in the field of 
plant health, owing to their importance and possible uses, are techniques for 
disease detection, pest control, resistance to herbicides and resistance to 
diseases and weeds, from endogenous technological development. As 
regards pest control in particular, it should be stressed that Brazil is one of 
the first countries in the world to undertake a large-scale project to spray 
nearly 600.000 hectares with bacullovirus. 
Mention should also be made of the experience of Cenargen whose 
work has proved to be of growing importance for the systematic 
identification and establishment of active germplasm banks. 
Bioconversion and Energy 
The example of Proalcool, among others, is a clear demonstration of 
Brazilian potential for making use of its bioclimatic conditions, coupled 
with its technological development, to resolve, using native resources, the 
serious question of alternatives to oil. In this area, the Department of 
Industrial Technology of the Ministry for Industry and Trade is investing 
mainly in the field of alcohol fermentation, aimed at the production of fuel 
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alcohol and the genetic improvement of yeasts (direct fermentation of 
starch to alcohol; this work is being carried out by the Institute of 
Chemistry of the USP). 
This being the case, the Department of Biotechnology of the Ministry of 
Science and Technology sees itself as an agent of integration and co-operation 
and acts as national co-ordinator of the Government’s biotechnology activities. In 
this context it should be private enterprise which acts, with public-sector support. 
The policy proposed by the Department of Biotechnology, leading up 
to 1990, assigns the following roles: 
a) Public sector 
a.1. guidance, co-ordination and stimulation of biotechnology 
activities; 
a.2. supervision of national work in the sector, so as to take account 
of the priority economic- and social-development programmes 
in a long-term strategy; 
a.3. participation in production sectors, on a complementary basis, in 
the national interest and/or in cases where private enterprise is 
unable or unmotivated to act; 
a.4. provision of guarantees for national production; 
a.5. establishment of appropriate conditions for full scientific and 
technological skills to be developed in the sector by the 
strengthening of research centres and training of teams with 
guaranteed resources for these activities; 
a.6. stimulation and guarantees for the development of national 
technology and the economic, financial and commercial 
strengthening of Brazilian enterprise, to ensure that it can 
compete on an open market.  
b) Private sector 
b.1 exploitation of the results obtained from technological research 
in biotechnology, bringing products within reach of society; 
b.2 suggestions to the Government, on an interactive basis, of the 
areas most needing investment for national production; 
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b.3 Raison with areas in which knowledge is generated, with a view 
to providing conditions for the satisfactory assimilation and 
dissemination of knowledge. 
In order to give substance to this proposal for the integration of 
scientific and technological development work, by complementing and 
incorporating the other fields addressed by the Ministry of Science and 
Technology (CNPq and FINEP), the Department of Biotechnology will have to 
allocate some US$60 million for the period 1987-89 over and above the 
biotechnology budgets of the other areas of the Federal and State authorities 
(source: SBIO plan of objectives). Approval was recently given for the 
allocation of resources for the award between now and 1989 of 4 650 grants in 
the country and 2 700 abroad, with the aim of stepping up training of 
researchers and technicians in biotechnology, at home and abroad. 
One of the principal means of distributing the above-mentioned 
resources will undoubtedly be the implementation of the Biotechnology 
Integration System. 
The Biotechnology Integration System (BIS) is a national technical 
and scientific cooperation network which brings together, under a number 
of subject headings, the centres of scientific and technological production, 
devoted to the same line of research or the subsequent development of a 
product or provision of services using biotechnology. 
The system will examine, on the one hand, the critical areas of 
science and technology to be introduced in the country, with a view to 
reducing the present difference in level between the national and 
international contexts and, on the other hand, will have to bring existing 
know-how in science and technology within the reach of the national 
production sector, for the development of goods and products. 
In this system, input data will be taken to be the information and 
requests resulting from scientific and technological production, at national 
and international levels, the production sector, the administrative authorities 
and related institutions and, in particular, the directives issued by the 
national government, as embodied in the state biotechnology programmes, 
which are being implemented in various parts of the country, such as Rio de 
Janeiro, São Paulo, Minas Gerais, Rio Grande do Sul, Parana and Bahia. 
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The input data also include those opportunities offered by inter-
national co-operation programmes, with special emphasis on horizontal co-
operation, the main example of which, to date, is the Brazil-Argentina co-
operation programme. 
At the operational level, the BIS will make use of BICs (biotechnology 
integration centres). 
BICs will be structures for co-ordinating centres of acknowledged 
research capability, organized at state or regional level, intended to support 
biotechnology application projects integrated with the production sector. 
The BICs will take part in the Biotechnology Integration System 
within the context of activities and lines of research of national interest, 
managing their activities entirely independently of the sys-tem as regards 
local and regional integration initiatives. 
The administration of the system will be the responsibility of the 
Department of Biotechnology, and general coordination will involve full 
representation of institutional bodies and the operational sectors. 
The system will have a matrix configuration and will offer as output data 
the products established in its planned objectives, with feedback based on a 
system of continuous assessment, to be implemented by general co-ordination. 
Therefore it is expected that, coupled with the other initiatives taken 
at federal and state level, the biotechnology integration system will be a 
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Rosa Luz Gonzalez Aguirre 
Introduction 
Biotechnology in Mexico is represented by a mixture of research and 
development as well as industrial and promotional activities realised at 
different levels of scientific and technological complexity. To evaluate its 
development and position in the country as well as estimating the potential and 
possibilities of technico-economic multi-lateral co-operation, it is necessary to 
define and delimit this techno-logical sector using the parameters available. 
The definition of biotechnology used in this document is as follows: 
A multidiscipline which has evolved from the initial objective of 
manipulating micro-organisms in the production of goods and ser-vices 
to include the use of enzymes, as well as vegetal or animal cells, 
aggregates or components thus amplifying its practical utilisation and 
now including the modification of superior organisms such as plants 
and animals. All this was made possible thanks to technological 
breakthroughs such as: recombinant DNA, cell fusion, cell and protein 
immobilisation, molecular synthesis with enzymatic characteristics 
which have all reinforced fermentation technology, culture of plant and 
animal cells and enzymatic technology(Quintero, 1985) 
A classification of the different types of biotechnology is shown in 
Table 1 (González and Zermeño, 1986; Quintero, 1985). Based on these 
elements, the first part of this work presents a general view of the situation 
in Mexico describing the biotechnological activity in research and 
development, industry, vocational training and legislation. 
In the second part, some potential options for technico-economic co-
operation between the members of the EEC and Mexico are discussed within 




Table 1. Categories of Biotechnology 
Parameter First generation Second generation Third generation Alternative 
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Source: González and Zermeño, 1986 
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The Present Situation of Biotechnology in Mexico: Research, 
Development and Industry 
FIRST GENERATION INDUSTRIAL BIOTECHNOLOGY 
Industrial biotechnology of the first generation constitutes the most 
important category in Mexico in terms of market size. The main products 
are fermented drinks, milk derivatives, cereal derivatives, industrial yeasts 
for baking, alcohol (for industry or for consumption), acetic acids and 
edible mushrooms (Table 2). The most important application of this type of 
biotechnology is found in the fermented drink sector of which beer is the 
greatest user (González and Zermeño, 1986; Quintero, 1985) 
Research and development in this biotechnological technique is 
scarce and production is oriented towards an internal market. Generally 
speaking, traditional Mexican biotechnology in the last decades has been in 
a state of saturation due to a sustained population growth with a better 
standard of living and because international trade has been of a marginal 
nature (González and Zermeño, 1986). 
Despite the fact that there are different ranges of products, the traditional 
biotechnology industry is of a strongly oligarchical nature. The competition 
between these industries from one point of view and the actual maturity of 
technology from another, has led the stronger enterprises to rationalise and 
standardise production through more and more automated processes. 
The most consolidated industries such as those for fermented drinks 
like beer, wine products and liqueurs are important sources of employment 
not only in production and distribution of these products but also of the raw 
materials, and are factors of economic development of other products. This 
industry has reached a state of prolonged saturation. Part of the industry 
handles high production volumes which helps improve product quality and 
productivity and which represent the most important conditions to maintain 
and improve the internal market as well as to enter into international 




Table 2. Mexican Biotechnological Industry 
Category Products Companies 
 





Wines and brandies 
Derived products  




Yeast for bakeries Acidos Orgánicos, S.A. 




Ethyl alcohol Asociación Nacional de Productores de 
Alcohol 
 Acetic Acid Compañia Beneficiadora Del Coyol, S.A. 
 
Antibiotics Fermic, S.A. de C.V. 
Orsabe, S.A. 
Cyanamid de México, S.A. 




 Centro Industrial Bioquímico, S.A. 
Upjohn, S.A. de C.V. 
Abbot Laboratorios de México, S.A. 
Sinbiotik, Beneficiadora e 
Industrializadora, S.A. 
 
Enzymes Enmex S.A. 
Velfer, S.A. 
Pfizer, S.A. 
*Genín, S.A. de C.V. 
*Enzymóloga, S.A. 




Química Mexicana, S.A. 
Pfizer, S.A. 
Nitragin, S.A. 







Table 2. Continued. 
Category Products Companies 
Second generation 
Biotechnologies 
Vaccines Gerencia General de Biológicos y 
Reactivos 




Micro-propagation Biogenética Industrial, S.A. 




Methane Digestors exist in various parts of 
the country 
 Silage Various parts of the country 
 Cell usage Various parts of the country 
* Dedicated to technological development. 
** Dedicated to the final packaging. 
Source: Quintero, 1985 
Such increments in quality and productivity could be achieved by 
small technological innovations. These are likely to take place in the near 
future since a number of fermented drink manufacturers have shown an 
interest in national research groups working on solutions to service 
problems in the industry. 
The consumption of food products such as edible mushrooms and 
milk derivatives can be increased by encouraging lower cost and smaller 
scale production processes than those predominant in the country. 
The culture of mushrooms and other macro mycological products can 
be developed both for export and internal consumption at production sites 
that make use of favourable climatic conditions and by intensively using 
manpower (Leal, 1985). 
It must be emphasised that the production of edible mushrooms 
constitutes one of the rare possibilities of biotransforming lignocellulosic 
residues without submitting them to a pre-treatment which is presently still 
very expensive. This is of great importance because of the abundance of 
this type of residue in the country (Table 3) (Leal, 1985). 
The production of macro mycological products with this approach 
requires that the culture technology is adapted to the local conditions from 
the point of view of both availability and investment as well as cost and 
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skill of local labour. The same applies to the development of new methods 
for the preparation of substrates from local raw materials, new types of 
materials and locally adapted climatisation (Leal, 1985). 
Table 3. National Agricultural Production in 1978 (NPTSD, 1984) 
Agricultural harvest Production (tons) 
Corn straw 16.613.532 
Sorghum straw 2.492.874 
Wheat straw 1.723.670 
Bean straw 1.320.716 
Sugar cane straw 1.205.557 
Wheat husks and brans 750.172 
Barley straw 534.746 
Oat straw 131.321 
Non-commercial fruit and vegetables 79.855 
Rice husks 59.309 
Peanut straw 43.379 
Chickpea straw 25.134 
Total 24.980.265 
Source: Leal, 1985.  
Milk derivatives such as traditional cheeses can be integrated into the 
production of milk, which in turn forms part of the normal agricultural 
production, through fermentative processes using the subproducts or the excesses 
as forage. This improves the profit of small producers and reduces competition in 
the production of the basic grains which form the popular diet (Viniegra, 1986). 
The above implies the availability of specialised equipment, technical 
assistance and a means of commercialisation for the small cheese co-
operatives. These services are necessary to encourage and sustain the 
production chain at an elementary technological level and include 
information, transport and distribution methods in order to commercialise 
the products in a way adapted to the local conditions (Viniegra, 1986). 
SECOND GENERATION BIOTECHNOLOGY 
This type of biotechnology is actively used in the production of 
antibiotics, amino-acidic enzymes and in the treatment of effluents as 
shown in Table 2. All the technology used comes from abroad (González 
and Zermeño, 1986). 
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A well equilibrated investment in this category of global bioindustries 
does not apply to groups of products in the same way. For this reason foreign 
investment appears to dominate the area of enzymes and certain antibiotics. 
However, there are national and public enterprises which are dedicated to the 
production of amino acids as well as penicillin and some of its derived 
products (Quintero, 1985). 
Because of the international effervescence in biotechnology a number 
of new, mostly small sized, national enterprises have appeared in this 
biotechnical category (Table 4). It must be emphasised that newly created 
enterprises have a more open attitude towards research and development 
contrary to the vast majority of second generation biotechnological 
enterprises in which this type of activity is almost non-existent. 
Table 4. New Biotechnological Organisations in Mexico 
Enzymology (Monterrey, N.L.) Phenylglicina (enzymatic), phenylacetic 
acid, phenylalanine and aspartame (of its 
interest) 
Bioenzimas (Saltillo, Coahuila) Improved grains, insecticides, gibberellic 
acids and other agricultural 
biotechnological products (enzymes) 
Industrial biogenetics (México D.F.) Micropropagation of strawberries, 
aspergus, Violet (tissue cultures) 
Genín (México D.F.) Technological development of 
immobilised enzymes 
Forestal Center of Genetics (Texcoco, 
Edo of México) 
Genetics improvement and forest 
micropropagation 
Source: Quintero, 1985 
Research groups are concentrated in universities, centres and 
institutions of higher education (Table 5). It is in this type of biotechnology 
that the country has the largest and most qualified research group even if most 
of its efforts are devoted to applied research and technological development. 
However, no technological development in this area has been applied to 
production methods (González and Zermeño, 1986; Quintero, 1985). 
In the case of enzymes and new pharmaceutical products the 
internal market is insufficient and the competition in international markets 
is very difficult. With amino acids, the important conditions for 
industrialisation exist but expansion presents problems with economic 
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resources. This type of problem also affects the unicellular proteins and 
the microbial polysaccharides. In the case of xanthans, for example, the 
technology has developed in this country and has reached a semi-
commercial level with a specific application for the product. However, at 
a national level, there are insufficient economic resources to make use of 
it even if it shows a high profitability in the current conditions in Mexico 
(González and Zermeño, 1986; Quintero, 1985). 
Table 5. University Research Centres with Adequate Facilities and 
Experienced Staff 
Genetic and Biotechnological Engineering Research Centre (UNAM), Cuernavaca, 
Mor.; covers an area of 5.000 m². Areas of interest: genetic engineering and 
biotechnology applied to health and food. 
Research Centre for nitrogen fixation, (UNAM), Cuernavaca, Mor.; covers and area 
of 4.000 m². Areas of interest: molecular biology and genetic engineering applied 
to plant cells. 
Research and Advanced Studies Centre, (IPN), Department of Biotechnology and 
Bioengeering, México, D.F.; has an excellent pilot project facility and well 
equipped laboratories. Areas of interest: fermentation and enzymatic engineering. 
Research and Advanced Studies Centre. (IPN), Unit of Modern Plant Biology, 
Guanajuato, Gto; covers and area of 8.000 m². Area of interest: conservation and 
preservation of grains, genetic engineering applied to plant cells. 
Research Institute of Biomedicine, (UNAM), México, D.F.; has an operational pilot 
project and is generally well equipped. Areas of interest: industrial microbiology, 
fermentation and enzymatic engineering. 
Department of Biotechnology, UAM – Iztapalapa, México, D.F., has pilot project 
facilities and good equipment. Areas of interest: food, transformation of substrates 
via solid fermentation, water treatment. 
Source: Quintero, 1985 
Other countries show a great interest in acquiring this technology. This 
could be very positive for national production to increase its confidence in the 
local development and the resources obtained from royalties could be used to 
finance national developments. 
The lack of economic resources is critical within all categories of 
biotechnology but particularly for second generation types as, even if they 
have rapidly restricted themselves, they offer better short term possibilities 
because of the world wide scale of development (González and Zermeño, 
1986; Quintero, 1985). 
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THE NEW OR THIRD GENERATION BIOTECHNOLOGY 
Micro-organism manipulation work is exclusively restricted to 
research in centres and higher educational institutions. It is currently being 
linked with industrial projects especially for the improvement of 
pharmaceutical processes. 
It must be emphasised that pharmaceutical products form the 
objective of the majority of research projects. They are internationally 
highly competitive with high development costs and require a long time 
before commercialisation. Such projects are: human insulin, growth 
hormones, some vaccines, diagnostical tests, interferons, etc. 
There are many qualified research groups in the field of plant cells, 
particularly cultures of plant tissues (CVT), in the country which, although 
they presently work on micro-projects, could devote their work to topics of 
importance in the agricultural sector. Two of the recently created 
enterprises belong to the plant biology area which covers the 
technologically less sophisticated aspects of CVT such as the micro-
propagation (González and Zermeño, 1986; Quintero, 1985). 
The genetic engineering of plants is becoming a well structured 
sector. A centre has just been opened and what is most important is the 
integration of very high level human resources. For animal cells the human 
and technical resources are scarce compared with the previous sectors and 
they are mainly dedicated to the development and industrial production of 
vaccines against measles and poliomyelitis but with some work on embryo 
transplants at a commercial level. 
These elements, even if briefly presented, allow the following 
prospects for third generation biotechnology to be considered. 
MICRO-ORGANISMS 
This sub-category could have an important role in the improvement 
of micro-organisms both for known second generation processes and for 
future modifications to processes used in the manufacture of existing 
products. Both cases link the existing research groups in the country and 
firmly localise their participation in the chain of complete biotechnological 
processes. The second option requires an understanding of the present 
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productive methods and capacity in the technologies which are intended to 
be substituted (González and Zermeño, 1986). 
New products, and particularly pharmaceutics, have greatly reduced 
prospects as the human and economic resources (especially the latter) are 
limited and the risk involved in new developments is very high. 
PLANT CELLS 
Simpler applications such as micro-propagation of ‘cultivares-
valiosos’ have a considerable potential market because highly skilled 
scientists are available to develop the techniques and, if moderately skilled 
technicians are trained, the use of the available climatic conditions, the 
market access and the cost of labour will enable the country to both 
compete with external markets and open new markets. Also, the economic 
resources required to make use of these productive activities are not 
excessively high compared to those required by other types of 
developments (González and Zermeño, 1986; Robert, 1985). 
The production of ‘metabolites secundarios’ using plant cells in 
biological reactors for the processing of raw materials of for agricultural, 
food and pharmaceutical products is a sector in which highly skilled 
scientists are available but in insufficient number to cover all the stages 
necessary for complete technological development. Moreover, an adequate 
infrastructure is needed to allow development to be taken beyond the 
laboratory stage (González and Zermeño, 1986). 
There are, however, important limitations related to the type of 
products. For example: the development of new pharmaceutical products is 
very expensive, very long, and involves many risks. The production of 
natural substances for food use, such as flavours, aromatics and colorants is 
less costly and faster than the previous processes but experiences high 
international competition which demands a very careful selection of 
development projects. 
Without any doubt the most important potential application related to 
plant cells is a genetic improvement. Both in Mexico and internationally, 
agricultural production currently faces a series of limitations which are: a 
lack of cultivable land, environmental stress, sickness and plague (González 
and Zermeño, 1986; Robert, 1985). 
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For each of these limitations, plant biotechnology has an answer 
which could be the development of varieties adapted to ever better 
controlled conditions (which is not much different from the ‘green 
revolution’) or varieties more and more adapted to socio-economic and 
environmental conditions. This type of answer could revolutionise 
agricultural production, have large repercussions on industry and the 
economic and social activity of each country. This would particularly apply 
to those less industrialised countries which, for their development 
requirements and the diffusion of this kind of technology, could have access 
to the benefits that the latter could relatively easily provide (González and 
Zermeño, 1986; Robert, 1985). 
In the particular case of Mexico, the conditions allow both solutions to 
be applicable. There are highly qualified scientists available who can develop 
either of the technological solutions. The food policy adopted will determine 
which solution will be emphasised (González and Zermeño, 1986) 
Before ending this topic, it is very important to note that genetic 
manipulation research groups are aware that they do not replace the 
traditional work of agronomists and botanists. For this reason, a contact 
with them is being sought and mechanisms are being pre-pared to promote 
interdisciplinary research. 
Finally, the existing animal cell groups, even if very scarce, have 
extensive experience in producing vaccines and they have recently 
succeeded in using a national development for the industrial production of 
anti-measles vaccines with diploid cells and are actively working to modify 
the production of polio vaccines (the diploid cells instead of monkey renal 
tissues). The experience of these groups forms an excellent basis for the 
promotion of this sector especially for the improvement of processes. 
ALTERNATIVE BIOTECHNOLOGY 
Less conventional biotechnologies, which try to use residues in order 
to produce biogas or cattle feed, should also try to solve the problems of 
regional contamination caused by specialisation in cattle and agriculture. 
However, the scale of production must be maintained in order to reach 
intermediary dimensions. To presume that these biotechnologies exist in the 
rural environment only at the level of one or several families is very 
optimistic (González and Zermeño, 1986; Quintero, 1985). 
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From this viewpoint, alternative biotechnology is better considered as 
a subcategory of all other biotechnologies rather than a separate category in 
which its scope of application would be very limited and the technological 
content more basic (González and Zermeño, 1986; Quintero, 1985). 
Based upon previous success, the development and growth potential 
of certain biotechnologies applied to aquaculture, the cultivation of 
mushrooms or other species and food processing will be stimulated as 
conventional technology is more compatible and the impact much greater. 
What is most important is to acquire experience and create a basis to be 
able to benefit from the possibilities offered by biotechnology. This also 
means a change in the tendency towards specialisation. As long as diversity 
is increased by more integrated processes which are less intensive in capital 
and energy and more adapted to the environment, the profits related to the 
scale of production will be less and less important and the level of 
development of the country will be raised with less socio-economic and 
environmental costs than the current mode of development (González and 
Zermeño, 1986; Quintero, 1985). 
Vocational Training 
The history of scientific training in biotechnology in this country 
dates back to the second half of the thirties at the time when the studies of 
enzymology and biological chemistry were created and oriented towards 
industrial biological processes. Both studies later became biochemical 
engineering (1957). Nowadays, a degree in biochemical engineering can be 
obtained at more than twenty educational institutions distributed throughout 
the country (Quintero, 1985, 1986). 
Postgraduate training began early in 1970 and the seven institutions 
which offer such courses are fisted in Table 6. All offer master of science 
degrees and, recently, two of them offer doctorates. Most of the 
postgraduate programmes cover the most general sectors of biotechnology 
(fermentation and enzymatic technology, genetics and genetic engineering) 
and two are dedicated to plant biotechnology. At first degree as well as at 
postgraduate level the main subjects are oriented towards the food sector 




Table 6. Postgraduate Biotechnology Programme (Leal, 1985) 
No. Institution Programme Degree 
1. Research and Advanced Studies Centre/D.F. Biotechnology M 
2. Research and Advanced Studies Centre/D.F. Biotechnology M 
3. Research and Advanced Studies Centre/Irapuato Biotechnology M, D 
4. Technological Institute of Mérida/ Scientific 
Centre of Yucatan 
Biotechnology M 
5. Technological Institute of Veracruz Biotechnology M 
6. Technological Institute of Veracruz Biotechnology M 
7. Research Institute of Biomedicine, National 
Autonomous University of México 
Biotechnology E, M, D 
E = Technical training 
M = Master’s degree 
D = Doctorate 
Source: Quintero, June 1986. 
Historically, vocational training in biotechnology has only covered 
biochemical engineering with postgraduate degrees in biotechnology and 
bioengineering but the available number of positions related to biotechnology 
is much higher in the country. In plant related biotechnology there are more 
than 100 higher education establishments for agriculture and biology with an 
equal number of experimental sectors. 
There are several institutions which offer a master’s degree in a 
speciality linked to biotechnology and which have had doctorate 
programmes in biochemistry, cellular and molecular biology, genetics, 
microbiology, chemistry and biology. Moreover, since the Mexican 
government considers biotechnology as a priority sector, it assigned special 
resources for all of the scholarships granted in 1985 for postgraduate study 
abroad by the National Council of Sciences and Technology (NCST) of 
which 17% corresponded to biotechnology. 
The basis of the above indicates that degree level training in 
biotechnology is actually based on the possibilities of absorption by the 
existing biotechnological industry which requires technicians of an average 
level of education. In the case of the first generation, the specialised 
technical assistance is obtained from abroad through suppliers of machinery 
and equipment; in the case of the second, most enterprises are branches of 
multinationals which import this technical assistance and, as far as both the 
 
163 
third and alternative ones are concerned, they are non-existent. (González 
and Zermeño, 1986). 
Finally, at postgraduate level, the system is new and has produced in 
the last ten years more than twenty master’s degrees in sciences and more 
than forty without any degrees. An exhaustive diagnosis was recently 
completed in the food sector in which biotechnology is included for 
practical reasons. As a result of this work, specific recommendations have 
been made for each of the postgraduate programmes in the country relating 
to food with the expected result being a sharp increase or development in 
the short or middle term of this level of biotechnology. Relative to this, it is 
important that scientific training at a national level must be directed towards 
the interdisciplinary work and to the development of integrated 
biotechnological processes through educational programmes and research 
linked to the production sector (VTG, 1985). 
Legal Aspect 
The country’s legal requirements relating to technological and 
economic multilateral cooperation are: patent and trademark laws, laws 
relating to registration and control of technological transfer and those 
concerned with foreign investment. 
The patent and trademark law dates back to 1976 and has recently been 
reformed and expanded partly in dose relationship with biotechnology. 
According to Mexican law the following are not subject to patents: 
1. The plant and animal species, their varieties, and the essentially 
biological processes necessary for their creation, including those of 
a genetic type. 
2. The biotechnological processes for pharmaceutics, general medicines, 
drinks and food for animal consumption, fertilizers, anti-plague 
products, herbicides, fungicides or biologically active products. 
3. Chemical products, chemico-pharmaceutics, general medicines, food 
and drinks, food for animal consumption, fertilizers, herbicides, 
fungicides and biologically active products. 
4. Food and drinks for human consumption as well as processes to 
obtain or modify them. 
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According to the present Mexican legislation, a patent does not cover 
biotechnological processes and products; however, it is possible to obtain a 
certificate of invention for processes and products mentioned in paragraphs 
b) and d). 
The invention certificate is a non-exclusive right granted by the 
Mexican State for a period of 14 years to allow the holder to commercialise 
an invention. Anyone else who is interested in commercialising the product 
pays the certificate holder the corresponding duties. This certificate is used 
when a patent is not granted because the invention is of social benefit where 
a monopoly is not permitted. 
The invention certificate allows royalty payments to be made even if 
it is not possible to practically apply the invention because it does not 
oblige the exploitation of the invention. 
This is not the same with a patent where exploitation of the invention 
should start within three years from the date of it being granted. If it is not 
exploited, the patent becomes invalid and the invention becomes part of the 
public domain. 
Mexican law states that one can register a certificate of invention 
concerning any invention susceptible to be protected as a patent. This has 
been done to give an incentive to individual creativity via advantages and to 
protect the rights of research and development workers who are 
concentrated in universities. If the only means to protect their inventions 
was through patents, they would lose their rights if they did not manage to 
exploit them within a three-year period. 
Technological transfer in Mexico is regulated by laws covering the 
control and registration of the transfer of technologies and the use and 
exploitation of patents and trademarks (LCRTT). The main objective is not 
exclusively to maintain control over technology transfer but also to ensure 
that its own technological work is promoted. The organisation responsible 
for the enforcement of this law is the Secretariat for Commerce and 
Industrial Promotion (SCIP), which controls the National Register of the 
Technological Transfer (NRTT). 
Item 2 of this law catalogues the legislation used within the 
national territory where registration is compulsory. Those related to 
technical and economic multilateral co-operation in biotechnology are 
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presented in Table 7. These acts or agreements are covered by Mexican 
laws, by treaties or international agreements of which Mexico is part and 
which are applicable to the case. 
Table 7. Licences, Contracts and Activities Related to the Multilateral Co-
operation in Biotechnology that have to be registered with the ‘RNTT’. 
– Licence for use or authorization for improvement or exploitation of an invention 
which is patented or covered by an invention certificate. 
– Licence or authorization to use commercial names. 
– Communication of technical knowledge through plans, diagrams, models, 
instructions, specifications, personnel training and education or any other means. 
– Technical assistance of any type. 
–  Provision of basic or detailed technical assistance. 
–  Operational services or company administration. 
– Advising, consulting and supervising services if controlled by foreign nationals, 
or their representatives, independently or their residence. 
– Computer programs. 
The following are required to apply for registration with the NRTT: 
Mexican nationals as well as foreigners living in the country, foreign 
agencies or foreign branches established in Mexico as well as nationals 
residing outside the country but who are involved with agreements or 
contracts which affect the country. 
Registration is necessary to be able to benefit from the profits, the 
encouragements, the assistance or the facilities foreseen in the 
governmental plans and programmes, as well as for the establishment or 
expansion of industrial enterprises. The legislation contained in article 
number 2 which has not been registered with the NRTT (or which has been 
cancelled by the SCIP) is null and void and cannot be made valid in front of 
any authority and its application cannot be requested by the national courts. 
The law also provides a chapter covering the causes allowing the 
NRTT to reject an application for the following reasons: the protection of the 
applicant regarding any detriment to his financial situation, his 
administrative autodetermination or any restriction to his R&D activities. 
Within the legal framework, and in policies directly related to foreign 
investment, the law enforced since 1973, which promotes Mexican 
investment and regulates foreign investment, together with the policy of 
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selective promotion of foreign direct investment, which started in 1984, 
clearly promotes the direct foreign investment in biotechnology. From this 
viewpoint, it is important to note that one of the most regulated foreign 
investment sectors, that of secondary petrochemical derivatives, has 
recently been freed from the restriction of using national capital for the 
majority of investments relating to the expansion of the range of products. 
Current technological advances (including biological technology) have 
made this possible using either different processes or raw materials which 
are not petrochemical. In Figure 1, the percentage participation of foreign 
direct investment is presented according to the country of origin. 
Options for Technico Economic Co-operation 
Biotechnology has direct applications in most of the sectors of economic 
activity and can be used at different scientific and technological levels with a 
variety of raw materials for similar types of products. This results in a group of 
technologies with different characteristics and requirements and with a 
tendency for interchange between them. The countries meeting on this 
occasion are all at different levels of technological advancement. For this 
reason it is important to consider any proposal related to these differences 
and this is why the possibilities of application of the various options are 
closely related to the scientific and technological capacity of the 
participants and to the level at which their political, economic, and social 
interests can merge. 
1984 % 1985 % 
United States 66,0 United States 67.4 
Federal Republic of Germany 8.7 Federal Republic of Germany 8,0 
Japan 6.3 Japan 6.1 
Switzerland 5,0 Switzerland 5.3 
Others 14,0 Others 13.2 
Sources: SCFI, 1986 
Fig. 1. Foreign investment per country of origin (percentage) 
It is important to underline that, in Mexico, studies have been made 
for some time to define the sectors which require efforts to be made to 
develop and diffuse biological technology whilst taking into account the 
requirements, the scientific and technological capacities, the economic 
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resources and the availability of raw materials (González and Zermeño, 
1986; Quintero, 1985, 1986). 
The establishment of priorities was no easy task for a country with 
the population size of Mexico. However, it has become apparent that the 
multitude of applications made possible by biotechnology cannot be coped 
with simultaneously. Accordingly the applications selected for a recent 
study on the evaluation of opportunities in biotechnology, which was 
financed by the National Council of Science and Technology, are: food, 
agriculture and health (Quintero, 1985, 1986). 
Taking into account the above factors and other elements considered 
as important for the scientific and technological policy of the last 15 years 
in order to make sure that research has an economic and social impact, 
(NPTSD, 1984; NPST, 1978) as well as the situation concerning biotechnology, 
(Quintero 1985) we consider that the following types of co-operation are the 
ones which would have the greatest potential for success. 
Vocational Training 
High level technical training is mainly oriented towards interdisciplinary 
education and research programmes which integrally cover the different 
stages of the development process of biological technology. The sectors 
which should be mostly emphasised are: design, sizing and operation of 
biological reactors as well as recuperation and purification of products. This 
type of training should preferably be given in research laboratories of the 
production sector as well as in technological development centres. 
RESEARCH AND DEVELOPMENT 
R&D collaborations should be aimed at the realisation of research 
projects in previously mentioned applications. The possibilities offered by 
biotechnology for the co-existence of differing levels of technology would 
allow different countries to participate in precise activities throughout the 
project according to their respective scientific and technological capacities. 
As a consequence, third generation and alternative biotechnology provide 
several applications in which the processes must be adapted to socio-
economic and environmental conditions, and in which some of the stages of 
the project must be realised at the site of the application. 
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To take care of this, the country has provided research and 
technological development centres with experience in pilot and commercial 
level projects allowing specific agreements of collaboration to be agreed. 
Some of these centres have highly qualified staff who belonged to 
international research groups at the time these groups were realising 
considerable achievements in third generation biotechnology. 
APPLICATIONS IN PRODUCTION 
Establishment of new undertakings in selected applications. The most 
appropriate option for multilateral co-operation is considered to be joint 
ventures as this would imply an intermediate investment level compared to 
the establishment of a branch and the financial risks would be shared. 
This option not only allows the partners to share the technology, but 
also offers the possibility of gathering together human, technical and material 
resources to continue with research and development activities. In our opinion, 
this is very similar to previous statements that multilateral co-operation should 
be founded on shared interests and in a mode of equality of rights and duties. 
Finally, the options for co-operation that have been mentioned in the 
case of Mexico should be based on third generation and alternative 
biotechnology. The advantages and the disadvantages of the analysis of 
some of these options is shown in Table 8. 
Table 8. Types of Associations for the Production Sector. 
Type Advantages Disadvantages 
Association 
via licence 
Cost and risks are low for the 
technological partner. 
Financial profits limited for the 
technologist 
 
Greater control for the financial 
partner 
Risk that the technology is not 
adequate for the socio-economic 
and environmental conditions 
Joint ventures Shared financial risks 
Whatever disadvantages remain 
after defining the following: 
– Proposals 
– Objectives 
– Contribution of each party 
– Adequate methods to evaluate 
tangible and intangible assets 
 
Access to patented technological 
information. 
 
The optimization of resources to 
develop new technologies. 
 
The access to reputation, market 
distribution network and 




Vocational Training Guidance, Conacyt, ‘Evaluatión de programas de pos-
grado del pais, en la área de alimentos’, México, D.F. January 1985. 
González, R. L. and R. Zermeño, ‘El desarrollo tecnológico y su 
promoción’, ‘El caso de la biotecnologia en México, presented to the 
Cuban Seminar II on the interferon, at the Cuban Seminar I on 
Biotechnology, La Havana, February 22, 1986. 
Leal, H., ‘La utilización microbiológica de desperdicios lignocelulósicos. 
Potencialidades y perspectivas’, in R. Quintero (Ed.), Prospects of 
biotechnology in México, Foundation Javier Barros Sierra and the 
National Council of Sciences and Technology, México, 1985, pp. 93-
114. 
National Programme of Sciences and Technology, National Council of 
Sciences and Technology, México, 1978. 
National Programme of Technological and Scientific Development 84-88, 
Federal Power Executive, México, August 1984. 
Quintero, R., ‘Biotechnology in México: Needs and opportunities’, 
presented at the Symposium: Development, Achievements, 
Aspirations and Problems of the Biotechnological Sciences in 
México, organised by The Society for Industrial Microbiology, 43th 
Annual Meeting, San Francisco, California, August 11-15, 1986. 
Quintero, R., ‘El desarrollo de la biotecnologia en México: Evaluación de 
Oportunidades’, National Council of Sciences and Technology (in 
preparation). 
Quintero R., ‘Prospectiva de la biotecnologia en México’, in R. Quintero 
(Ed.), Prospects for biotechnology in México, Foundation Javier 
Barros Sierra and the National Council of Sciences and Technology, 
México, 1985, pp. 461-468. 
Quintero R., ‘Role of Government in food, science and technology in 
México’, presented to the Symposium on Food Sciences in México 
organised by the Institute of Food Technologists, 46th Annual 
Meeting, Dallas, Texas, June 15-18, 1986. 
 
170 
Robert, M. L., ‘El Cultivo de tejidos vegetales en México’, in R. Quintero 
(Ed.), Prospects of biotechnology in México, Foundation Javier 
Barros Sierra and National Council of Sciences and Technology, 
México, 1985, pp. 367-373. 
SCFI, ‘Panorama de la Inversión Extranjera en México’, Department for 
Social Communication, México, 1986. 
Viniegra, G., ‘La biotecnologia en la agroindustria alimentaria’, in R. 
Quintero (Ed.), Prospects for biotechnology in México, Foundation 
Javier Barros Sierra and National Council of Sciences and 
Technology, Méidco, 1986, pp. 115-130. 
 
171 
2.4. THE ANDEAN COUNTRIES 1 
B. Carlos Aguirre 
2.4.1. Andean Technology Policy: Its Nature and Far-Reaching Effects 
The Technological Policy adopted in 1969 by the Andean Group 
(GRAN), was defined to handle the demands generated by the economic 
integration process, whose goals were: the opening of possibilities to link 
technology to the building of a large market, the subordination of foreign 
investments and technology transfer to national and subregional interests 
and to link technology to the very process of production and services as one 
of its main factors. 
The Andean Technological Policy was an essential element of the 
idea which tried to assert a process based on domestic habilities, displaying 
its own capacities and promoting the utilization of local production factors 
as an important component of an independent development model. 
Handling problems related to foreign investment, patent rights, technology 
transfer, information, permitted a step forward to the understanding of the 
matter. It also made possible to enact new rules on these matters allowing 
the definition of the action to stimulate technological development. 
The Andean Programmes for Technological Development (PADT’s) 
are the tools of the Andean Technological Policy and have become a new 
experimental area within the GRAN (Andean Group). Thanks to their 
execution, it was possible to realize that the integration process can take 
upon itself different co-operative forms to reduce the possibilities of 
conflict that can arise because of the complementarity that creates them. 
They lead to the interaction and the union of efforts that outline the Andean 
Group as a new unit of international co-operation. 
                                                     
1 This document was prepared for the European/Latin-American Seminar on Biotechnology 
which, under the auspices of the European Economic Community, held in Brussels, 
Belgium, between the 27th and 29th April 1987. This document represents the opinions of 
the authors and does not necessarily reflect the views or opinions of the Cartagena 
Agreement, nor those of the member countries of the Andean Group. The present document 
is based on works done by experts of each Andean country, propositions by the Cartagena 
Agreement to the Andean Council of Science and Technology, and the results of a co-
operation programme carried out since 1975. 
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This instrument eventually became one of the most typical 
contributions of the Andean Group. As a matter of fact, through their 
execution it was possible: to constitute multinational teams of experts and 
technicians; to obtain external financial resources; to reduce the differences 
among the projects; to exchange specialized information; and, to develop 
new techniques and methods for technology transfer. 
As indicated before, the Andean Technological Policy was steered to 
demand knowledge from an ambitious project of subregional industrialization 
and a growing market. However, the far-reaching effects of a joint 
industrialization were partial and could not cope with the proper 
characteristics of an incomplete industrialization of the Latin-American 
region. The enlarged economic space, a key factor for technological 
development, did not trigger the expected demand of technology. 
The strategic scope established by the Technological Policy of the 
Andean Group intended the combination of many financial, commercial 
and fiscal elements, but there were multiple divergences among the public 
powers, and between them and the private sector – a very common problem 
in the Andean countries. The lack of concertation seriously restrained the 
complete application of the Andean Technological Policy. 
2.4.2. Guidelines for a Reorientation of the Andean Scientific and 
Technological Integration 
NEW CHALLENGES 
The application of the Andean Technological Policy advanced with 
the achievements and limitations already noted. In the meanwhile, and after 
a period of dynamism and growth, the integration process went through 
phases of stagnation and even regression. 
Simultaneously, there is an unprecedented acceleration toward the 
technological change in the more developed countries, favourable to the 
upheaval of a new pattern of industrialization which tends to ignore the 
comparative advantages of developing countries. 
On the other hand, as a counterpart to the crisis, the modernization 
gaps within the countries constitute a great challenge from social, 
productive and technological points of view. 
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In spite of the growing attention placed by the governments of the 
Andean countries on science and technology, the answers are still 
insufficient for a National Policy to face problems such as those cited. The 
new technological elements playing a role deepen the differences between 
the Andean countries and the more developed countries. The intrinsic 
weakness of the existing scientific community, the fiscal crisis and the 
public debt, exacerbates the brain-drain and the dismantlement of the sub-
region’s research centers. 
Reorientation of the Scientific and Technological Integration: Bases for a 
New Concept of Joint Action 
A series of orientations directed to consolidate the obtained results, 
overcome limitations and face the new challenges at national, sub-regional 
and international levels, have occurred over the last three years in the 
Andean Group. 
The ‘Reorientation Programme of the Andean Integration Process’ 
(1983) contains a conceptual basis that should be mentioned. It points out 
that integration should offer the countries new prospects and alternatives for 
their development processes in fields necessitating efforts beyond the 
national boundaries and, therefore, requiring to be approached by a joint 
and concerted action. It also underlines the necessity to work with a flexible 
and pragmatic criterium in order to complete the application of the existing 
tools with all the possible forms of co-operation leading to a major 
interrelation among the countries. 
Science and technology will help the development of this idea of 
reorientation. Two central aims are at the base of the new Andean 
technological strategy: 
a) ‘To create a joint capacity of scientific and technological response 
to the challenges of the countries’ development and subregional 
integration process’ 
The problems, already described, show the advantages of 
association. The current crisis makes it urgent to unite efforts. In the 
technological field, it is more and more obvious that isolated positions 
are insufficient. A joint action is the new support for integration. 
Besides, scientific and technological co-operation is a must for the 
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Andean countries, since none of them can establish an independent and 
viable scientific and technological community. 
It is worthwhile to insist here upon the elements of an Andean 
scientific and technological community. To achieve this, it is imperative to 
combine human, institutional and financial resources, not only those of the 
member countries, but also those of an international cooperation. 
A pragmatic and urgent effort of permanent harmonization must be 
made to identify areas susceptible of integration. 
b) ‘To contribute with science and technology to the carrying out of 
sectorial strategies for the Andean integration process’ 
The sectorial strategies for integration enable to identify scientific and 
technological requirements. From them and through adequate programming 
and planning, the appropriate mechanisms and instruments to them can be 
recognized. Among the strategies, the following should be mentioned: 
Food safety, within it new prospects for research and application of 
biotechnology: improved seeds, production of animal vaccines, nitrogen 
fixation, development of a variety of plants resisting diseases, etc. 
Different political decisions give priority to the necessity to develop, 
appraise and protect renewable and unrenewable natural resources. 
On the other side, the industrial sector strategy points out common 
methods to develop the agro-industry sector. This is due to its potential not 
only in the expansion of the production of existing goods, but also in the 
incorporation of new products responding to the basic needs of 
consumption, and the restriction on imports of final products and basic 
materials which can be substituted by subregional natural products. 
The capital goods sector, a little behind but having a great potential 
for development in the subregion. It must be taken into account because of 
its implications on the use of skilled labour, major autonomy of industrial 
development, commercial potentiality, margin to continue the substitution 
of imports, and beginning exports on an extended market. 
Electronics and telecommunications sector. Because of its numerous 
links to other areas, such as industry when it results in capital goods, it is 
one of the ‘most promising’ themes to work on science and technology. 
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Priority is given to the evaluation of potential partners investing on projects 
for development and production of equipment and the constitution of 
Andean multinational enterprises. 
2.4.3. Fields of Action of the New Andean Technological Policy 
To reach the enumerated goals, the Andean Strategy for Scientific 
and Technological Integration has suggested a series of policies focused on 
fields of action that permit a kind of viable programming, that is to say 
ready to be applied under Andean realities. The carrying out of these 
policies should integrate efforts and resources around key matters, and give 
to the Andean Group a more specific outline when working on science and 
technology, and using for its development the economic space of the five 
member countries. Thus, new opportunities are open because of the 
deliberate utilization of a subregional space for products and sectors – 
carriers of technology. 
Three areas of action have been defined and will permit the 
organisation of the GRAN’s efforts on science and technology: 
A) MANAGEMENT APPLIED TO THE DEVELOPMENT OF TECHNOLOGICAL 
INNOVATION 
The lack of an adequate management makes it difficult to apply 
technology to production. What has been tested is more intuitive than 
systematic. At present, it is clear that to obtain a real benefit from the 
research results, it is necessary to combine commercial, financial, etc. 
market mechanisms, as well as feasibility studies and technology transfer. 
This stage will require higher expenses. ‘The enterprise, in general terms, 
must play the role of a technological innovation promoter and open the 
access to more appropriate and modern technologies’. It must be said that 
without an improvement of the management applied to innovation, no 
concrete results can be obtained. 
B) TECHNICAL AND INFORMATION AREA 
As indicated by the Andean Strategy for Scientific and Technological 
Integration, one of the areas requiring a major emphasis is the one which 
will permit ‘to collect, process, and offer to the countries technical and 
economic information at subregional and international levels’…‘to prospect 
 
176 
on trends of technical and economic change through branches and products’ 
and ‘to support the strategical thought of the subregion’. 
Confronted with technical change, it is necessary nowadays to adopt 
a watchful and prospective attitude, more rigorous, exigent and permanent, 
as part of the subregional strategy, including the setting up of alternative 
models for development, taking into account the new technologies and the 
availability of subregional natural resources. The definition of best elements 
in order to determine a future technological pluralism, must consider the 
improvement of traditional technologies. 
It has been underlined that ‘the creation of information susceptible to 
support the concrete decisional process, in the pre-feasibility studies, is of 
vital importance. It requires the combination of structured information on 
alternative technologies, their economy and their economic conditions of 
access. This information is not spontaneously available. It must be created. 
Data must be organized to produce information, and so to say, likely to 
modify representations and behaviours. The constitution of technical, 
commercial and economic information must be made at the very foundation 
of the new activities. 
C) SCIENCE, RESEARCH AND ADVANCED TECHNOLOGIES AREA 
The present scientific and technological revolution is influencing 
multiple aspects of production, health, education and services, which are 
matters, because of their nature, of great interest for the Andean Group. 
The encouragement given to science in the subregion acquires a 
different perspective. It becomes the condition to assimilate the present 
current of technological advances. There is talk of an industry based on 
science. The development of intellectual factors will be the key of 
competition between countries and group of countries. In the more 
developed countries, the scientific policy is gaining consideration after a 
period of stagnation. 
In the light of a series of new demands that the sectorial strategies of 
the Andean Group would lay on scientific and technological areas, it is easy 
to remark that it is impossible to step forward without a good dose of 
organization, programming and effective support in the field of personnel 
training and its utilization through research activities. 
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The ‘Caracas Programme’, approved by Decision 183 of the 
Cartagena Agreement Commission, claims to fulfill the void on those 
matters, setting up arrangements and compromises through harmonization 
and concertation. 
A proposition of interest consists of structuring around the 
Programme a strong supporting movement to the scientific disciplines that 
serve as a basis for advanced technologies, depending on common needs, 
that is to say, scientific research and training of personnel. 
Therefore, the human resources policy becomes a ruling principle of 
the Andean strategy as announced at the Cartagena Agreement, ‘…the 
unique policy compatible with a shifting future and the dynamics of the 
technical change, is the training of specialists who should be given a solid 
scientific knowledge and good practice in research methods. These are the 
right tools that will enable a fast adaptation to scientific changes, 
technological innovations and exchange of researchers…’ 
2.4.4. The Andean Programme of Biotechnology 
The Cartagena Agreement has promoted since 1986 the programming of 
the Andean Strategy for Scientific and Technological Integration in concertation 
with ruling organisms of scientific and technological policy of the member 
countries, which constitute the Andean Council of Science and Technology. 
The new stage, expected to be started in 1987, proposes to re-appraise 
the meaning of integration, especially its potential economic space, as a 
means to promote technological innovation within the subregion and to use 
this process to fortify the Andean integration. 
The effort displayed till now to structure the Andean Programme of 
Biotechnology is an important part of the framework. To this purpose, there are 
national and community experiences, which will be analyzed in this document. 
In general, the programme will try to organize joint capabilities on 
Biotechnology, especially in areas of social and economic interest to the 
Andean countries, such as the agriculture, health and food safety areas. 
In the management area of biotechnology innovation, the programme 
will include financial incentives and a growing market. These actions allow 
the promotion and establishment of Andean multinational enterprises or 
similar forms of association, with the participation of the private sector and 
 
178 
research institutes. Special attention will be placed on problems such as 
technology transfer and intellectual property. 
The programme must consider the degree of advancement of the 
results already obtained in the Andean countries. Information on 
opportunities and sources, where a subregional action is advisable, will be 
collected and analyzed. The programme’s basic activity is the analysis and 
evaluation of economic, technical and commercial information. 
An immediate requirement is to promote the education and training 
of personnel research techniques. The establishment of networks and 
specific projects of R&D is part of the initial effort to identify requirements 
and common means for training. 
2.4.5. National and Subregional Experiences  
NATIONAL EXPERIENCES 
The outline of the Andean Programme of Biotechnology is based on 
the experience of each member country in the biotechnology field. 
At national level, there is a group of important activities in execution 
or planned at short or middle term, not only to formulate policies but also 
programmes and projects. 
BOLIVIA 
The development of biotechnology in Bolivia has not so far reached the 
level of the other countries of the subregion. However, at the Academia 
Nacional de Ciencias and the Universidad Boliviana, there is a group of 
researchers working together with those of the private sector, which constitute 
the basis on which a short-term nationwide programme is being discussed. 
It is convenient to indicate as background that various efforts have 
already been displayed to establish a critical mass of re-searchers on which 
the programme will be based on. 
Particularly, the activity developed by the National Co-ordination 
Committee for the development of biological sciences, has increased the 
scientific level of experts on biology through national and international 
courses and lectures, fellowships and training. At present, there are in 
Bolivia experts concentrated mainly at Instituto de Genética Humana, 
founded in 1972, Instituto de Investigaciones Biológicas of the Academia 
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Nacional de Ciencias, founded in 1961, Department of Biology of the 
Universidad Mayor de San Simón and at the Facultad de Bioquímica y 
Farmacia of the Universidad Mayor de San Andrés. 
At the industrial sector level, the pharmaceutical industry, although 
in the initial phase of formation has an important potential within a reduced 
number of national laboratories: INTI, VITA, ALCO, SIGMA and others, which 
have a high technological level. In the pharmaceutical field, Bolivia can 
develop biotechnology for the production of antibiotics through available 
natural resources. 
There is also an important potential for biotechnology development 
and its application on farming. On the other hand, within the framework of a 
subregional project, Bolivia acquired important experience in the application 
of biotechnology to the mining and metallurgical sector. 
Within the framework of policies and strategies for the development 
of the biotechnology programme, the Academia Nacional de Ciencias of 
Bolivia proposes to prepare the right ground for the management of a larger 
international co-operation, both regional and North/South, according to the 
programmes previously developed by CONDECIB and enlarged with new 
specific projects, which will integrate the scientific development sectors to 
productive areas of the nation. 
The specific projects will constitute a coherent whole through which 
products and services of national and subregional interest will be obtained. 
They will contribute to the development and strengthening of science in the 
country and the Subregion. 
The basic activity of these programmes or subprogrammes will be 
made up of specific projects for research and development of products and 
services. The programmes will be carried out by means of subcontracts 
between both the ruling and the executive organisms. 
In its initial phase, the programme will analyze the establishment of 
an information network, the development of legal tools permit-ting the 
protection of the obtained results, and the organization of biotechnology 
laboratories so as to increase the interactions among them. 
The general goals of the programme will be: 
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a) To promote integration and links among the activities to be 
developed on biotechnology in the country, allowing the techno-
logical advance for development, implementing the definition and 
execution of biotechnologies and supporting the definition and 
execution of joint actions in order to find solutions to local and 
regional priority problems, through the obtainment of process 
products and services. 
b) To generate projects of regional interest, which will permit the 
obtainment of international funds in order to try to solve the 
problems which action will have to face within the national borders, 
giving a remarkable social and economic impact enabling to clear 
up and solve problems through biotechnology techniques. 
c) To develop diffusion and demonstration mechanisms directed to 
both state-controlled and private companies in order to promote 
investments. 
d) To fortify the scientific and technological infrastructure of the country 
in order to carry out the programme for the benefit of Bolivia. 
Regarding present research work in Bolivia, the Instituto de Genética 
Humana is carrying out a research programme, sponsored by the O.E.A., on 
Americanae Camelidae with the objective to implant vicuna embryos in 
llama uterus. 
Another programme, in execution at the present time, is molecular 
biotechnology on diarrhoea diseases (enteropathy) and the transmission of 
viruses; to combat the drug resistance of the pathogenic strains through plasmids. 
The Instituto de Biologia of the Academia Nacional de Ciencias, is 
carrying out a study on the neurobiological effects of snake venoms, and 
later, will prepare serums and vaccines. 
COLOMBIA 
The National Programme of Biotechnology set up by COLCIENCIAS 
endeavors the creation of a working mechanism with a high degree of 
participation and consultation with both the scientific community and the 
national productive sector. It also attempts the establishment of relations of 
active exchange and co-ordination with other countries of the region which 
have similar problems as those of Colombia, and also with countries in 
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which biotechnology is well developed, marking the international trends 
whose social and economic impact must be analyzed and made known at 
the right time. 
The basic activity is the permanent evaluation of the programme’s 
progress, the redefinition of its objectives and priorities in accordance with 
the results, new trends, identification of needs, studies of feasibility and 
new opportunities. 
The programme’s basic activity as well as the whole series of 
necessary and essential activities for its perfect development, must rely on 
sufficient financial and human resources besides a definitive planning in 
order to reach the objectives. For this reason, each one of the essential 
activities has been structured as a subprogramme defined with concrete and 
specific goals and its proper order of priorities to give an answer to the 
needs of the Nationa1 Programme. 
Another of the Programme’s essential actions, already structured as 
subprogramme, is the establishment of an interaction between the 
productive sector and the scientific and technological sector. To fulfill this 
requirement it is necessary to undertake an aggressive policy of reciprocal 
diffusion between both sectors by means of a series of seminars attended by 
international experts, and later on, to promote activities resulting in an 
effective transfer of knowledge, technique, methods and services between 
the sectors above mentioned. 
Concerning the international relations, the corresponding sub-
programme promotes the exchange with outstanding centres, binational and 
multinational projects which encourage the national research activity, 
courses, congresses, and any other scientific meeting in order to satisfy 
specific needs of the research groups; organizes and diffuses any 
information received from abroad and from international organisms to the 
scientific community of the country; establishes contacts with technical 
missions of the embassies and, through them with other science and 
technology organisations of the countries represented; and keeps an active 
relation with regional and international programmes on biotechnology. 
Up to now, the following activities have been considered as 
necessary for the efficient execution of the research projects: 
a) Training of human resources. 
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b) Establishment of a scientific and technological information and 
documentation network. 
c) Setting up and running of a system of evaluation and control of the 
programme’s development and other projects. 
d) Monitoring and analysis of world-wide development trends of 
biotechnology, and anticipation of its economic impact. 
e) International relationships and regional integration. Co-ordination 
with other national programmes. 
f) Setting up and running of communication mechanisms between 
both the scientific and technological and the production sectors. 
Encouragement of a university/industry co-operation. 
g) Enterprise management and development. 
h) Projects for scientific and technological development. 
i) Economic projects. 
Each one of the activities mentioned above will give their support to 
research projects. The activities have been chosen after consultation with 
the scientific community and some representatives of the national 
productive sector according to the country’s needs and priorities and the 
presence of active groups in the different areas (see Chart 1). 
The establishment of priorities for the development of biotechnology 
products and their production at commercial level, should be based on detailed 
economic surveys and on the predominating needs of the country and region. 
Studies envisaged by the National Programme will start soon. 
However, there are certain product lines and services unquestionably 
essential because of their strong demand or immediate application and, 
therefore, receiving financial support from COLCIENCIAS through specific 
projects for development and research, which will be at short and middle term 
the object of negotiations for technology transfer and adaptation. 
These lines are: development of vaccines; production of antigens, 
monoclonal antibodies, diagnostic kits for tropical diseases; plant 
micropropagation through tissue or cell culture; improvement of the 
symbiotic and asymbiotic fixation process of nitrogen in plants; 
biodegradation of organic polluants; recovery of biogas and biofertilizers; 
production of single-cell proteins for animal feed; production of enzymes 
for industrial use, lactic starters, organic acids and antibiotics. 
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In the middle-term, there are also, at nation-wide level, projects with 
significant economic prospects such as: the animal reproduction through genetic 
techniques; the production of hormones, diagnostic kits for plant viral diseases, 
secondary metabolites from plant cell cultures, biopesticides for the biological 
control of epidemics, and bacterial leaching processes of certain metals. 




The National Council of Science and Technology (CONACYT) has 
promoted activities on biotechnology since 1983. At the very beginning an 
advisory group was created, composed of researchers of institutions 
working in biotechnology fields. 
This group has helped to define priority areas and research projects 
which need to be developed. On the other side, it has supported the analysis 
of propositions made by international organisations, which have urged the 
country to adhere to development programmes on biotechnology. In the 
policy guidelines proposed by CONACYT, biotechnology is considered as a 
scientific and technological priority to solve some of the serious problems 
the country is facing, taking into account the unprecedented development of 
this sector at international level. 
The policy guidelines will be concretized in a National Plan which, 
on the one hand, will gather the activities developed in the ‘Grupo 
Ecuatoriano de Biotecnologia’ and, on the other hand, will determine 
actions directed to the production, application, adaptation and diffusion of 
biotechnology in the agro-food and industrial production; and will also 
attach health and environment preservation problems. 
The National Plan for Biotechnology Development will contain 
harmonized programmes as part of the actions to be carried out in order to 
reach objectives and goals. 
Among the planned programmes, the following ones can be mentioned: 
a) Manpower Training Programme, through which a review and 
harmonization of the study plans on the basic sciences will be done at 
medium and high levels. It will support and fortify the disciplines of 
basic sciences in order to provide a basis for the training of human 
resources in biotechnology, such as: cellular biology, molecular 
biology, biochemistry, biophysics, virology, enzymology, genetics, 
microbiology and immunology, at postgraduate level. It will permit the 
identification of Master and Ph.D. programmes on biotechnology, 
which will be followed by Ecuadorian experts, in the countries of the 
region and in the developed countries. 
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b) Research and Development Programme, through which the following 
points will be carried out: the evaluation of scientific and 
technological potential; the survey of research needs on biotechnology, 
giving priority to research Unes; identification of research projects on 
biotechnology which could be carried out by combined action of both 
the university and the industry; backing the foundation of a 
Biotechnology Research Centre whose objective will be, on the one 
hand, to stimulate the execution of research projects on problems of 
social interest, encouraging sectorial biotechnology production, and, 
on the other hand, to enrich the manpower training programmes and 
provide technical advice on governmental decisions; supporting 
research projects planned by institutions and research centres, which 
are presently developing surveys. 
c) Programme to encourage international and technical co-operation, 
aimed to fortify the participation of the country in research projects 
on biotechnology, at regional and international levels. 
From a strategical point of view, CONACYT intends to defineate the 
scientific and technological policies in the sector and the National Plan, 
suitable for being applied to the country’s conditions and according to the 
evaluation of the scientific and technological potential, in co-ordination 
with the ‘Grupo Ecuatoriano de Biotecnologia’, which should be changed 
into a Technical Committee. 
Concerning the research at present on execution, see Chart 2. Besides, 
the following institutions of public and private sectors are developing research, 
some of them at industrial and semi-industrial levels: 
 Instituto Ecuatoriano de Investigaciones Agropecuarias: Merismatic 
Culture. 
 Instituto Nacional de Higiene: production of human vaccines. 
 INEXA S.A.: merismatic cultures. 
 LATIN-RECO S.A.: food production. 
 PRONATEC S.A.: Natural extracts. 
 Centro de Adiestramiento Lechero S.A.: Lacteal fermentations. 
 LEVAPAN S.A.: Development of fermentation processes. 
 Laboratorios farmaceuticos Ecuatorianos (LIFE) S.A.: Production of 
animal vaccines. 
 ALCOLESA S.A.: Alcoholic fermentation of molasses. 
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Chart 2. Current Projects 
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In order to accelerate the biotechnology development, it is required, on 
the one hand, to encourage the training of human resources, strengthening in 
this way the country’s scientific level through postgraduate courses in the 
countries of the region and the developed countries, and, on the other hand, to 
set up a teaching and permanent research programme at under- and 
postgraduate levels for the education and training of national researchers. 
On that account, it is expected in Ecuador to initiate in 1988 the 
postgraduate programme on molecular and cellular biology as basic 
sciences in order to develop biotechnology. 
At last, research projects to be carried out in the middle term are: 
 Pharmaceutical products: Nation-wide development of the industrial 
production of pharmaceuticals; study of plant active principles and 
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their application in the pharmaceutical industry; ‘in vitro’ production 
of antibodies from hydridoma to determinate: a) bacterial and viral 
antigens through etiopathogenic studies in animals; b) vaccine 
production from characterization of surface antigens; c) detection of 
blood markers of malignity for diagnosis of tumoral diseases; d) 
therapy methods using monoclonal antibodies finked covalently to 
drugs in order to attach malignant cells. 
 Food products: Liquid and solid fermentations for the production and 
industrial transformation of food; in high-protein food, it is planned to 
carry out genetic modifications of the quinoa to increase its nutritive 
value; microbial culture collections: implementation of a microbial 
culture collection for the maintenance and distribution of strains of 
industrial interest; aquaculture: culture of sea organisms to improve 
production and nutritive value of shrimps, oysters and fish; biomass 
processes: production of biomass to obtain animal feeding-stuff 
biological control of insect vectors: studies of molecular biology, 
cellular biology and cytogenetics for the control of the life cycle of 
insect transmitters of malaria, oncocercosis, trypanosomiasis; plant 
culture: production of vegetable clones to obtain plants with high 
productivity and higher resistance to diseases. 
 Genetic engineering: Interferon production for the treatment of 
cancerous diseases. Diagnosis of hereditary diseases through 
recombinant DNA techniques. 
 Environment pollution: Treatment of industrial wastes, especially 
waste waters. 
PERU 
In 1986, the Peruvian National Council of Science and Technology 
(CONCYTEC) created the Consulting Commission of Biotechnology to analyze 
and propose activities for the application of biotechnology in the country. 
Peru is far away from having a critical mass of researchers in this 
field. The country requires an adequate co-ordination of the international 
organization and the existing research activities for the development of this 
field allowing it to reach the phase of goods and services production and to 
improve the standard of living of the population. 
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In Peru, there is a deep gap between the industry sector and the 
universities; that is why initial actions of mutual benefit should be started, 
and whose quality and quantity would be gradually improved and increased. 
On that account, the teaching centres could offer quality control and 
advisory services, permitting an ever growing exchange and a real activity 
of co-operation in the future. A possible form of this co-operation is the 
establishment of industries which, rooted in academic institutions, can 
benefit from the human resources, equipment international advisory and 
consultancy available for those institutions, and contribute to their entire 
work on teaching, research and services. 
An important aspect to be considered for the development of 
biotechnology in the country is the manpower training. In this direction, the 
National Programme must first contemplate the strengthening of different 
systems of advanced education (postgraduate courses, professional 
specialization, training, etc.), as well as trainee researcher exchange and the 
utilization of international and regional co-operation for that purpose. 
The Consulting Commission of Biotechnology considers four sectors 
in which the application of biotechnology in Peru is of great importance: 
Biomedical and Veterinary Sector. There are good reasons to back the 
biotechnology development in the health sector. The programme embraces 
promising technologies, of fast development, not requiring large investments 
for their implementation, depending on the existence of a critical mass of 
skilled specialists, and could be established in the present centres wherein 
biologists, chemists, pharmacists, veterinarians, biochemical physicians, 
microbiologists, immunologists and other researchers are educated and 
further trained. 
It is likely to aim to a nation-wide production of diagnostic elements 
of biotechnological origin that will substitute, more or less quickly, 
expensive culture techniques and for which basic material is still imported. 
With regard to therapeutic products, agreements could probably be 
concluded to ask national companies to take upon themselves the production 
and commercialization of bioproducts and to assume the development and 
production of products according to the needs in the near future. 
Concerning vaccines, the World Health Organization and the Pan-
American Health Organization, working jointly with National Institutes of 
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other American countries, will probably offer consulting services, support 
the technological development, set up production lines, quality control, etc. 
The areas of major interest are the following: 
 Diagnosis of enteropathy, tuberculosis, acute respiratory diseases, 
transmitted by vectors and parasites; 
 Thermostable vaccines and new vaccines; 
 Other biological products such as antidotes, insulin and 
plasminogen activator. 
Agro-Food Sector. This is a prior-right sector because of the 
agricultural situation of the country. 
In several points of this sector, the in situ application of 
biotechnological processes is feasible, which could incite the development 
of rural industries, with a very large social impact. The application of these 
processes would also increase the production and productivity of the land. 
However, the promotion of a biotechnological agriculture will require a 
good control of its production and an appropriately expanded work from the 
corresponding governmental organisms. 
In the agro-food sector, there are already some experiences and 
preliminary results which should be encouraged for obtaining short-term 
success, including their transfer to other countries of the region. 
Experiences and results within the following areas: 
1. in vitro cultures; 
2. micropropagation and genetic stabilization of plants; 
3. production of basic seeds; 
4. bioconversion of materials and agro-industrial wastes into animal 
5. feeding stuff, enzyme production, alcohols and other chemical 
substances; 
6. production of biogas and biofertilizers; 
7. nitrogen-fixing micro-organisms and mycorrhyzal fungi; 
8. production of diagnostic systems for plant viruses. 
Chemical and Pharmaceutical Industry Sector. Considering the import 
balance of basic materials for the chemical and pharmaceutical industries, it is 
essential to substitute imports and to develop the following areas: 
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1. alcohol production as raw material for chemical industries 
(chemistry of alcohols); 
2. production of solvents (butanol, isopropanol, acetone, etc.); 
3. production of antibiotics through fermentation and biosynthetic methods 
(penicillins and semi-synthetic cephalosporins, aminoglycosides and 
rifampicin); 
4. production of organic acids (citric, acetic, lactic, fumaric and others); 
5. production of essential amino acids (lysine, methionine and 
glutamic acid) and vitamins (riboflavin and ascorbic acid); 
6. production of steroids (cortisone, prednisone) and other molecules 
obtained from yams; 
7. production of alkaloids and other substances through vegetable cell 
cultures. 
Other Sectors. The following four areas are important: 
1. metal extraction from metallic sulphates through bacterial 
2. leaching; 
3. tertiary recovery of petroleum; 
4. biodegradation of pollutants; 
5. monitoring of environmental pollution. 
Generally speaking, it is extremely important to carry out in these 
sectors a national evaluation of economic, political and technical nature. 
In order to set up a programme, the Consulting Commission has proposed: 
a) To carry out an evaluation of the national biotechnology, developing 
its prospects. 
b) To analyze biotechnology abroad at three levels: Developed 
Countries, Third World Countries, the Andean Countries. 
c) The elaboration and regulation of a policy responding to a national 
demand and adjusted to the situation of the country, in order to 
reach results enabling the improvement of the standard of life of 
the Peruvian consumer. The regulations must include a ‘Patent 
Register’ for the protection of biotechnological processes which do 
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not have a directly human and social incidence, and, of course, 
underline the priority of working areas. 
Besides the Commission has proposed: 
 To create a National Network of Biotechnology as an institutionalized 
system of co-ordination and intercommunication, in accordance with the 
existing national laboratories. 
 To recommend the creation of a special fund for biotechnology 
research and development, giving to the ITINTEC a part (2%) of the 
resources provided by the industry, and thus harmonize research teams, 
activate the laboratories of the National Network and encourage 
researchers. This fund would be managed by the CONCYTEC. 
 To promote meetings and communication among entrepreneurs, 
researchers and users of biotechnology to make effective the 
utilization of the National Network. 
 It is necessary to clarify to what extent basic materials and scientific 
equipment, essential for the development of biotechnology, represent 
a significant point in the Peruvian import balance. A strategy must be 
planned to put an end to this dependency in order to develop the 
national production of these basic materials and scientific equipment. 
 The permanent problem of imports has also been discussed. By 
general consent, CONCYTEC should try to speed up the regulations 
concerning customs clearance so as to be able, at least, to receive 
radioactive materials with preserved good specific capacity, really 
fresh biochemical supplies, laboratory reactives, biologically active 
and special strains. 
VENEZUELA 
The National Programme of Biotechnology was set up in 1984, after the 
President of the Republic created by Presidential Decree No. 240 the National 
Commission for Genetic Engineering and Biotechnology, within the National 
Council for Scientific and Technological Research, to act as an advisory 
organism to the presidency of the Republic and to define policies and elaborate 
plans for the development of genetic engineering and biotechnology. 
The Programme’s main objectives are the following: 
 
192 
a) To promote scientific and technological research in genetic 
engineering and biotechnology areas. 
b) To formulate and co-ordinate the National Plan for Genetic 
Engineering and Biotechnology. 
c) To co-operate with organisms whose task is to promote, plan and 
finance the scientific and technological development of the country 
in this area. 
d) To attempt the establishment of scientific and technological 
networks of information on genetic engineering and biotechnology. 
e) To spur the training of human resources in this area. 
f) To co-operate with organisations which represent the Republic on 
international matters; especially when relationships in the 
biotechnology area are concerned. 
With the aim to get the Programme started, a strategy has been 
adopted to sort out projects, including the establishment of research co-
operative groups in agriculture, agro-industry, and medicine areas, in which 
the participation of the teaching and the industry sectors is expected. 
The principal projects of the biotechnology Programme, already 
selected, are the following: 
Agriculture. Production of potato and yucca mother plants and other 
products, through tissue culture techniques, somatic hybridization, 
induction and selection of mutants. 
Obtainment of pathogen-free plants using tissue culture techniques, 
followed by massive clonal propagation and development of diagnostic 
reactives for pathogen detection. 
Industry. Purification technology of glucose and fructose syrups. 
Design and evaluation of processes for the production of fructose syrups. 
Agro-industrial waste recovery for the production of protein-rich 
animal feed. 
Enzymatic degradation of lignocellulose wastes. 
Biomedicine. Studies of diagnosis, prophylaxis and epidemiology of 
diseases such as: leishmaniasis, trypanosomiasis and leprosy. Research in 
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this field will include pathogen isolation and culture, cloning and antigen 
identification, obtainment of monoclonal and polyclonal antibodies, etc. 
Biochemistry and immunology studies are also planned. 
Another group of studies in this area are: Cancer and AIDS diagnosis, 
therapeutics and epidemiology. Research in this area could be aimed to 
gene isolation, recombination, production of RNA and DNA probes, 
oncogens, transformation factors, etc. 
SUBREGIONAL EXPERIENCES: PADT-COBRE AND THE MINING-
METALLURGICAL PROGRAMME 
The Commission of the Cartagena Agreement, by Decisions 86 and 
87, approved the Andean Projects for Technological Development in the 
Copper area (PADT-Cobre), whose activities started in 1973 and came to an 
end in 1981. The general objectives of PADT-Cobre were the following; 
a) To form specialists teams, competent enough to generate and improve 
technologies applied in the area, from laboratory level to the planning, 
design, maintenance and operation of industrial plants. 
b) To create in Bolivia and Peru laboratory facilities for the analysis, 
evaluation and development of existing studies on leaching of 
copper ore. 
The projects executed within the PADT-Cobre framework, in which 
Peru and Bolivia participated, were: 
Project I: Copper-oxide ore treatment through leaching with sulphuric acid 
and cementation with scrap iron. 
Project II: Bacterial-acid leaching of copper ore in columns or wastes. 
Project III: Copper recovery from copper sulphate solutions through ion-
exchange electro-deposition. 
NOTEWORTHY RESULTS IN BOLIVIA 
a) Equipment, fitting up, and operation of the laboratory belonging to 
the Department of Special Metallurgical Projects of the Sub-
Direction of Projects of COMIBOL, in Oruro. 
b) Fitting up of the Krupp pilot plant type 11 for copper recovery 
through ion-exchange electro-deposition. 
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c) Education and training of 23 specialists, among them engineers and 
technicians on acid-leaching technologies; and, on the planning, 
design, building and operation of pilot and industrial plants for copper 
treatment through hydrometallurgical methods. This technical team has 
up-to-now elaborated two studies of feasibility ‘Corocoro’ and 
Solivar’, and two of pre-feasibility ‘San Miguel’ and ‘Telemayu’. 
NOTEWORTHY RESULTS IN PERU 
a) Equipment, fitting up and operation of the laboratory of the 
Department of Metallurgy Research of CENTROMIN, in La Oroya. 
b) Plan, design, fitting up and operation of the Pilot Complex of 
Toromocho which is composed of 8 copper ore columns with more 
than 150,000 MT, reaching, some of them, an extraction rate of 88% 
and a throughput of 3.5% per month; a cementation plant of nearly 
15 MT per month; and a Krupp plant for ion-exchange electro-
deposition with a capacity of 14 MT of electrolytical copper per 
year. Approximately 400 MT of copper cement (worth US$470,000) 
were produced in the cementation plant. 
c) Education and training of 35 specialists, among them engineers and 
technicians, of CENTROMIN Peru, Ingemmet and Minero Peru. 
In general, the following concluding remarks can be mentioned: 
a) The development of PADT-Cobre has permitted the utilization of 
technologies in the copper hydrometallurgical area applied to the 
benefit of lower-grade copper ore in the following areas: chemical 
leaching, ferro-bacterial leaching, extraction by solvents, 
cementation, electro-deposition and crystallization. 
b) As a result of the above mentioned development, technical and 
economic studies have been worked out, such as the planning, 
design, building and operation of the Pilot Complex of Toromocho 
in Centromin Peru. 
c) The mastering of the technologies developed in Bolivia and Peru 
will enable their incorporation to the industrial and productive 
sector of both countries. 
 
195 
d) The utilization of technologies developed in the subregion in the near 
future will allow the incorporation and development of new sources of 
foreign exchange. At the same time, they will have a growing effect, 
which will permit a larger industrial activity and the creation of 
‘satellite’ services parallel to the establishment of new technologies. 
e) The technological achievements attained through the concerted effort of 
the Cartagena Agreement and the Member Countries, in the present case 
Bolivia and Peru, are a clear example of what can be reached by means 
of a clearly defined technological integration policy provided with 
mechanisms and tools for its efficient application. 
f) The adopted technologies open the way to recover copper and other 
valuable metals from lower-grade ore constituted by out-falls, 
effluent residues, wastes, etc. Two million tons of lower-grade ore 
has been estimated in Peru and Bolivia. The acquired technological 
knowledge will permit not only a more important income for both 
countries, but also a great contribution to fight environmental 
pollution provoked by traditional mining methods. 
On basis of the experience above described, the Cartagena 
Agreement began in 1985 the development of the Andean Mining-
Metallurgical Programme (PMMA), whose general objective is to strengthen 
the technical and economic integration of the mining-metallurgical sector of 
the Andean subregion. 
Particularly in the bio-hydrometallurgical area, work is at present 
carried out on technology transfer of bacterial leaching, obtained during the 
PADT-Cobre, and its application for polymetallic extraction. On the other 
side, research on the application of other hydro-metallurgical technologies, 
which will permit the recovery of other metals, is on the way. 
These activities are possible because of the consolidation of the 
research and application centres for this technology in the Member 
Countries, and of course the training of human resources. 
The technologies constituting this programme, will be applied in 
deposits chosen by the Member Countries. 
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With regard to financing, it is necessary to indicate the support for 
technical co-operation, not refundable, from the government of the Federal 
Republic of Germany, thanks to an accord with the Cartagena Agreement. 
THE ANDEAN COUNCIL FOR SCIENCE AND TECHNOLOGY AND THE 
CONCERTATION OF ACTION ON BIOTECHNOLOGY 
The Andean Council for Science and Technology (CACYT) strives to 
promote, at subregional level, an adequate scientific and technological 
capacity to satisfy the demands for economic and social development of the 
Member Countries (Decision 213). 
The CACYT is composed of top authorities responsible, in each one of 
the countries, for the scientific and technological system and the orientation 
of activities considered in the ‘Caracas Programme for Co-operation on 
Research and Scientific and Technological Education and Training’ 
(Decision 183). 
During its second meeting (La Paz, 1984) the CACYT recommended to 
enter upon biotechnology all together, and also sup-ported the creation of a 
work team composed of Colombia and Venezuela in order to elaborate 
preliminary actions, initiating a process of concertation and programming. 
To achieve its goal, this task took form at the ‘Cucuta Meeting’, 
celebrated between both countries in September 1986; further details will be 
given in the next section. 
Another source of discussion for concertation on biotechnology 
during the Fourth CACYT (Caracas, 1986) were the topics identified in the 
national plans for Science and Technology, by means of a document 
prepared by the Cartagena Agreement. 
The Fourth CACYT adopted the idea of ‘problem-areas’ in order to 
identify action lines and to programme, at the first phase, joint activities on 
biotechnology. 
In the health area: Tropical diseases, malaria, Chagas’ disease and 
leishmaniasis were considered as targets for biotechnology applications. 
In the agriculture area: The improvement of productivity through 
nitrogen fixation and micropropagation of pathogen-free plants were 
considered as priority lines. 
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In the agro-industry area, priority was given to the improvement of 
nutrition through the production of protein-rich food. 
In the natural resources area, an adequate utilization of natural 
resources will allow work on biotechnological research, and especially in 
fields related to promising products, treatment of waters and wastes. 
In the energy area, the development of new sources, such as those 
generated by biomass, was considered as a priority for the first stage. 
The Fourth CACYT recommended that the programming of scientific 
and technological activities on action lines above mentioned, must arise 
from the necessity to link research and production, and to take advantage of 
the Andean growing market to boost intensive products in technology, and 
fixing the financial mechanisms to obtain them. 
THE COLOMBO-VENEZUELAN MEETING ON BIOTECHNOLOGY IN HEALTH 
AND AGRICULTURE AREAS 
The Colombo-Venezuelan Meeting on Biotechnology in the health 
and agriculture areas, sponsored by the CACYT, was held between the 18th 
and 20th September 1986. Delegations of each Member Country presided by 
the top governmental authorities on scientific and technological policy, the 
Ministry of Science and Technology of Venezuela and the Director of 
Colciencias. Representatives of the Cartagena Agreement, EEC and BID 
attended the meeting too. 
The participants contributed to the elaboration of specific project 
outlines intended to apply biotechnology in the health and agriculture areas 
through the creation and support of a series of co-operative networks to which 
other Member Countries would be later invited to participate in (see Chart 3). 
The Programme’s main objectives will be the expansion of the 
scientific and technological capacity on biotechnology and the potential 
market for the products resulting from its application; obtainment of 
products and services of significant economic and health interest for the 
subregion; and the co-operation on education and training of human 




Chart 3. The Cucuta Meeting: outlines for specific projects 
Biotechnology on Health 
Project I Leishmaniasis 
Utilization of biotechnology for the development of detection techniques of leishmaniasis. 
Subprojects 
1. Standardization and production of leishmania for diagnosis and prognosis of leishmaniasis. 
2. Employment of DNA probes for identification and classification of leishmaniasis in 
vectors, for epidemiological control. 
3. Use of monoclonal antibodies for identification, diagnosis and prognosis of leishmaniasis. 
4. Isolation and characterization of specific antigens of leishmaniasis for diagnosis 
Project II Creation of New Techniques for Diagnosis of the Chagas’ Disease 
Project III Diagnosis of Malaria 
Subproject A: Entomological diagnosis. 
Subproject B: Human blood cell screening. 
Project IV. Animal Health 
Subprojects 
1. Bacterial and viral agents affecting bovine reproduction, brucellosis, bovine viral 
diarrhoea, bovine rhinotracheitis. 
2. Hemoparasites, babesia and anaplasm. 
3. Vesicular diseases, vesicular stomatitis and foot-and-mouth disease. 
4. Viral agents provoking diarrhoea in porcines, bovines (rotavirus, reovirus). 
5. Viral agents affecting poultry raising. 
Biotechnology on Agriculture 
Project I Tissue Culture 
Subprojects 
1. Selection and programming of promising banana clones of regional interest for Colombia 
and Venezuela. 
2. Production of healthy potato plants for sowing. 
3. Development of methodologies for clonal propagation of cacao. 
4. Development of a technology for pelleting embryos produced ‘in vitro’. 
Project II Diagnosis and Prevention of Viral Diseases in Food and Industrial 
Cultures 
To that effect, it has been suggested the creation of an integrative 
programme embracing the different aspects of co-operation in the area, and 
precluding the arise of a package of independent specific projects. A two-
fold objective is in mind to face mutual deficiencies which would hinder the 
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success on the intended projects, and allow the introduction of new 
products as soon as areas of interest for regional concertation are detected. 
The programme will probably last four years in order to enable the 
harmonization of the goals fixed in projects initially chosen and those 
which could be introduced in the programme’s first stage. 
The programme is subdivided in three subprogrammes: (a) human 
health; (b) animal health; (c) education and training of human resources and 
scientific exchange. The first two subprogrammes embrace a series of 
specific projects in their respective areas. Priority was given to these 
projects because of the available information in the First Colombo-
Venezuelan Meeting on Biotechnology, but the introduction of projects for 
co-operation by well-known laboratories in both countries in areas not 
considered within the first stage, will be accelerated. 
Every financed project will be directed by a co-ordinator appointed by 
the heads of the participant laboratories, and its execution will be periodically 
evaluated according to international rules, employing as far as possible 
technical commissions and the mechanisms established to follow up 
programmes for international co-operation by CONICIT and COLCIENCIAS, 
including the help, if necessary, of international experts. 
The manpower training and scientific exchange programme will 
embrace the usual activities in this area trying to harmonize the respective 
needs of the specific projects and, in more general terms, the goals of a 
programme for integrative development of biotechnology. To that effect, 
mechanisms to ease the research exchange between Colombia and 
Venezuela will be established, and also the use of courses and training 
programmes of common interest. 
The three subprogrammes will be run by an ‘ad hoc’ sharing 
Committee created by CONICIT and COLCIENCIAS and will oversee the 
accomplishment of objectives and the attribution to each sub-programme of 
the necessary resources. 
THE BIOTECHNOLOGY PROGRAMME OF THE ANDEAN CORPORATION FOR 
DEVELOPMENT (CAF) 
In order to contribute to the development of biotechnology in the 
countries of the Andean Group, through support to the research areas and 
spurring the creation of structures which will permit to link research results 
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to the producing activity, the Andean Corporation for Development adopted 
a programme that will enable: 
a) To promote communication among specialized research centres and to 
stimulate the exchange and harmonization of research and information. 
b) To back the development of specific projects of applied research with 
the purpose to settle the ground for a more self-sustained development. 
c) To support the constitution of operative structures that will bridge 
research sectors and users. (For instance, facilitating the association 
of research groups, farming centres and private enterprises.) 
d) To support the establishment of enterprises specialized in the 
culture, propagation and commercialization of plants obtained by 
biotechnology applications. 
e) To organize programmes for the education and training of the 
personnel, to ease technology transfer and advisory. 
In the first phase, the programme will concentrate on the tissue 
culture area. 
Selected research centres or companies carrying out or conceiving 
biotechnology projects will be supported. Choice or selection of projects 
will basically depend on the degree of their practical use. 
Support will include personnel training and specialization, as well as 
technical assistance and consulting services. It will also include the 
equipment and the supply of research material. Concerning training and 
equipment areas, an important task has been planned: the search of support of 
international organisms in order to reinforce the CAF possible contributions. 
At later stages, and after evaluation of the initial actions, new areas of 
biotechnology and genetic engineering will be introduced according to 
applicability and utility criteria. 
The programme is expected to carry out the following main activities: 
1. The establishment of an inventory of the subregional capacity in 
biotechnology, including: 
a) Research areas. 
b) Availability of laboratories. 
 
201 
c) Availability and needs of skilled personnel. 
d) Degree of application and present and potential use of biotechnology 
in the productive sector. 
2. Selection or choice of programmes or projects, actual or in course 
of preparation. 
3. Organization and outset of the projects. 
4. Organization of a specialized seminar at subregional level. 
5. Intervention before international organisations to obtain support on 
personnel training, consulting services and equipment. 
6. Evaluation of the programme’s results after the first year of operation. 
The program will last two years and cost US$1.0 million that will 
finance the following activities: 
a) Inventory of the subregional capacity in the biotechnological sector. 
b) Further development and identification of biotechnology 
programmes or projects. 
c) Organization of meetings and specialized seminars at subregional 
level. 
d) Promotion of participation of specialized international agencies 
in the programme. 
e) Budget support to specialized centres on biotechnology in each 
country of the subregion. 
The programme will be financed with resources of the Fund for 
Development of Genetic Engineering and Biotechnology in the Andean 
Group. The Assembly of Shareholders of the Andean Council for 
Development (CAF) has been urged to create the above mentioned fund, and 
to grant it US$1.0 million from the accumulated net income of the CAF on 
the 31st December 1986. 
The programme will be conducted by a unit specially created to that 
effect and composed of the Head of the Programme, one or several 
consultants, according to needs, supplied without any cost for CAF by 
specialized governmental or international agencies, and a secretariat. 
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2.4.6. Andean-European Co-operation on Biotechnology 
A future Andean-European Co-operation in the biotechnology sec-tor 
may rely on the Agreement for Co-operation signed by both integration 
groups. To that effect, it is convenient to identify the main points of the 
above mentioned Agreement. 
The Agreement has a global and integrative conception of co-
operation which is defined as ‘a broad economic co-operation to 
contribute to the development of the Parties respective economies and to 
raising their standards of living’. It is no longer something as punctual as 
the supports the EEC was offering to certain sectors in the past. The 
Agreement’s global task is to spur more adequate stages according to the 
degree of maturity of both integration processes: it opens an ambitious 
outlook with far-reaching effects. 
A ‘more equitable distribution’ of development potentials encloses a 
redistributive criterium maintained by the Andean Group and must lead to 
the planning of operation in which science and technology transfer would 
play an important role; and this because of the arrangements and 
commitments for teaching and transmission stated in the Agreement. The 
Agreement must therefore serve as an ambitious instrument for 
redistribution at subregional level. 
To recognize that the Andean Group is made up of developing 
countries, and within it of less-developed countries, is to give to Bolivia and 
Ecuador a special treatment, above all in the education and training. 
The co-operation for development enunciated in the GRAN/EEC 
Agreement recognizes the necessity to co-ordinate EEC member states 
efforts to back integration projects, in the present case scientific and 
technological. For the Andean Group it implies a larger capacity of 
harmonization and concertation so as to enable the integration projects to 
seize major opportunities which will probably be carried out by means of 
the European effort for co-ordination. The resulting rationalization should 
be considered as a growing and profitable potential which will depend on a 
more active and efficient position of the Andean Group during the 
execution of the Agreement. 
Scientific and technological co-operation was sometimes confined 
to certain activities with detriment to others, to public agents 
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disadvantaging the private sector. The Agreement explicitly embraces 
co-operation in the fields of science and technology, industrial 
development, agro-industry and farming, mining, fisheries, infra-
structure, transport and communications, energy and tourism. The 
possibility to form joint ventures was not considered by the GRAN/EEC 
co-operation in the past. This leads to the necessity of seeking synergetic 
effects. Science and technology, as proposed by the An-dean strategy, 
must be the common denominator to all the sectors affected by 
modernization processes within the framework of the Andean Strategies 
for Science and Technology. Knowledge becomes the key to the whole 
integration process in various areas. 
Concluding Remarks 
a) We face an Agreement whose potential must be ambitious in its 
far-reaching effects. It may be used, within the present crisis, to 
transfer of knowledge and capacity necessary for the Andean 
Group for a more self-sustained development. 
b) It is important to point out mechanisms or tools from the 
GRAN/EEC Agreement to make viable the knowledge and 
capacity transfer, and realized through the co-operation above 
indicated or in exclusively detailed activities. 
c) The Agreement requires an explicit and feasible action frame-
work for scientific and technological co-operation. 
d) Completing this idea, a strong support would be given to the 
relationship of horizontal co-operation among the GRAN member 
countries in order to create a joint action through resources, 
capacities and abilities from the EEC. 
The GRAN and EEC Member States must come to understand each 
other’s experiences in science and technology. Priority is placed on the 
better understanding of the rationalization and canalization of recent 
resources in order to create a new and more integrative cooperation scheme. 
GRAN is stepping towards a scheme of harmonization and concertation 
of needs and will, soon be ready to initiate this task. The subregion’s 
‘harmonized’ demands are already known, particularly in the subregional 
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personnel education and training area which could become one of the most 
important channels for capacity transfer from the EEC to GRAN. 
An unavoidable subject which has been discussed for a certain time 
by the GRAN member countries and in consequence has been approved as a 
Special Fund by Decision 183, is the organization and setting up of a 
financial mechanism to support joint actions. The precise identification of 
mechanisms for co-operation will come to light from the experiences and 
opinions exchanged during the European/Latin-American Seminar. 
 
205 
HEALTH IN THE THIRD WORLD: 
THE ROLE OF INTERNATIONAL CO-OPERATION 
Luiz Pereira da Silva 
Expectations of the benefits from the introduction of new 
biotechnologies on the health of people in the third world is reflected in the 
immense publicity given to them not only in the specialized press but also 
in the mass media. 
Therefore, it is not necessary here to re-emphasize the new possible 
applications to health sciences provided by DNA recombinant techniques, 
molecular genetics, monoclonal antibodies and other modern techniques for 
the diagnosis, prevention and treatment of human diseases. 
Taking for granted that most if not all of the people in the audience 
are aware of these potential benefits, the speaker is more inclined to discuss 
a few general points related to the introduction of new biotechnologies in 
the third world. By assuming an ‘against the stream’ attitude, the speaker is 
conscious of the fact that he will probably be considered as having 
conservative views. He accepts this blame and asks for the comprehension 
of his younger colleagues. 
The speaker will try to define some problems which he thinks are 
specific to third world conditions, to raise some questions on the 
introduction of new biotechnologies and to develop arguments in favour of 
particular policies he thinks must be followed by govern-mental agencies, 
either national or international to provide a rational basis for the use and 
development of biotechnologies. Finally, he will try to define the type of 
international co-operation that he thinks could contribute to accelerate 
socio-cultural progress in the third world and would lead to an improvement 
in the infra-structure necessary for the development of health policies. 
Specificity of Third World Problems 
The first thing to define is the existence of specific problems of 
health in the third world. They consist first in the nature of the health 
problems: malnutrition, high incidence of infectious and parasitic diseases, 
high rates of maternal, neonatal and infantile mortality, low quality and 
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insecurity of housing and working conditions, with high incidence of 
accidents. Most of these problems, which drastically decrease the 
expectation of life and seriously deteriorate the living standards are 
determined by social and economical structures. Medical care measures are 
only of limited effect and correspond to the use of traditional products like 
antibiotics and chemical drugs. 
The second important feature of health problems in the third world is 
the inadequacy or absence of the structures necessary to provide health 
care: hospitals, welfare centres, and the low (or insufficient) qualification of 
the staff responsible for health care. In respect to the subject discussed here, 
namely the introduction of modern biotechnology in health sciences and in 
medical practice, one important deficiency is the absence of national 
pharmaceutical and chemical industries for drugs and pesticides in most 
countries of the third world and the weakness or absence of a biological 
industry for vaccines, sera and blood products and derivates. As a 
consequence, all the medical measures of the health policies in the third 
world, from the public health level to the private clinical medicine are 
entirely dependent on the importation of technology in the form of drugs, 
products, machines and equipment. 
A Rational Policy for the Introduction of New Biotechnologies 
With this picture of the health problems in the third world we will try 
first to describe some errors and illustrate how they can be avoided. 
1. New biotechnologies cannot, in any case, replace measures at the 
social-economical level responsible for the basic problems of health. 
2. New biotechnologies are not obligatorily giving the best solutions 
for health problems in substitution to traditional biotechnology. 
3. New biotechnologies cannot (or are difficult to) be introduced 
independently of the complex economical and technological infra-
structures necessary for their functioning. 
4. New biotechnologies cannot be employed out of context of a solid 
scientific environment and a precise evaluation of interdisciplinary 
and technological interactions. 
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5. New biotechnologies will not be an area in which can proliferate 
small new enterprises full of original ideas and opening fantastic 
opportunities for imaginative young people. 
6. New biotechnologies applied to health will not be an area of 
activity from which important financial benefits are to be expected. 
After having considered all of these negative views on the use of new 
biotechnologies in the third world, the speaker will discuss some positive 
ones which are important: 
1. Some of the important problems of public health in the third world 
would benefit enormously from the introduction of new 
biotechnologies, like for the diagnosis and prevention of hepatitis, 
malaria, AIDS and other diseases. 
2. Most of the countries in the third world, in addition to a majority of 
poor people, have also a fraction of the population with relatively 
high socio-economic conditions, and consequently health problems, 
equivalent to those of developed countries. 
3. The absence of strong local industry occupying areas of economical 
activity and using traditional technology liberate countries of the 
third world from conservative pressure of lobbies. 
A rational policy on the introduction of modern biotechnologies in 
health sciences and in medical care in the third world must take into 
consideration both the positive and negative constraints discussed above. 
According to the speaker’s point of view it must respect some basic points: 
 Development of scientific and technological education, scientific 
and technological research without any dicotomy but looking for 
equilibrium and association of both activities; 
 Acurate planning of investments to provide, through the 
development of economical and technological backgrounds, the 
opportunity for the flowering of different innovation; 
 Stimulate the participation of the scientific community through an 




 Define social priorities and integrate public health programs in a 
general project of socio-economic development. 
International Co-operation 
The difficulty in defining a rational model for the development of 
international co-operation in the area of new biotechnologies is the 
difficulty in defining the protagonists. Since technologies are finally to 
produce goods and since the production of goods is a function of Industry, 
‘new biotechnological products’ are as result produced by the different 
branches of the ‘Industrie de pointe’ in Pharmacy, Chemistry, Mechanics, 
Electronics, etc. As we know these industries are nowadays developing a 
tremendous international commercial war for conquering markets. To create 
artificial needs is often more important than to satisfy a real necessity. 
Marketing is more decisive than scientific accuracy. 
The past experience of the third world of co-operation in Industry is 
quite negative. The example of what happened with the pharmaceutical 
industry in Latin America in the 1960s is illustrative. During the Second 
World War, and in the years just after, many Latin American countries had 
developed a promising pharmaceutical industry. This, however, collapsed 
when confronted with the multinational enterprises invading the market 
during the economical ‘boom’ of the 1960’s which offered a series of new 
products like antibiotics, neuroleptics, tranquillizers, etc. (which, of course, 
were all covered by patents). 
If we wish to avoid the repetition of this phenomenon with new 
biotechnologies we need to have very clear ideas on the mechanisms by 
which international co-operation and technological and commercial 
exchange must be oriented. For the moment there is no reason for an excess 
of optimism, since all the available indicators point to an undesirable 
evolution and this for a series of reasons: 
 New biotechnologies and their derived products applied to health 
sciences and medical care are more and more the ‘affaire’ of giant 
chemical-pharmaceutical enterprises, which are normally more 
interested in selling products than in transferring know-how. In 
the 1970s we observed the creation of a large number of new small 
enterprises dealing with biotechnology, especially in the USA but 
also in Europe, nowadays most of them have disappeared or have 
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been absorbed by the giant industrial conglomerates either 
national or multinational. 
 To regulate the exchange of technologies between developed 
countries and to conciliate conflicts arising from the industrial and 
commercial activities of national and multinational giant 
enterprises, European countries have created structures at the 
supranational level, like the EEC, which have all the political 
support from national governments and which are provided with 
the necessary social, political and economical authority to 
guarantee and support their role. 
 Apart from some political tribunes in United Nations, there is no 
equivalent international organisations to regulate the interactions 
and exchanges among developed and underdeveloped countries 
with the exception of those in charge of the police supervision at 
the financial level like IMF. 
 In these conditions it is easy to realize that free direct interactions 
between industrial protagonists, bringing together, on the one side 
experienced giant enterprises and on the other inexperienced small 
and poor companies will more often generate good business for 
the first than useful technological transfer for the second. 
 Therefore, the natural tendency of trade, interactions and ‘co-
operation’ will be (and already is in many respects) the invasion of 
nascent markets in the third world countries by commercialized 
products, either imported or produced by local subsidiaries of 
multinational enterprises. They will satisfy the needs (real or 
artificial) of the fraction of the population referred to above as being 
similar to the consumer society present in developed countries. 
If following this model, transfer of new biotechnologies will 
reinforce economical and technological dependence, create artificial social 
needs, create foreign commercial exchange imbalance and deform the 
priorities of national health policies. 
The only way that third world countries have to protect them-selves 
against all these negative consequences of ‘free exchanges’ and ‘open 
borders’ is to refuse them and to regulate the international co-operation 




The speaker has already defined some of the main principles he 
thinks must be followed by third world countries in order to favour a 
rational introduction of modern technology obtained from developed 
countries. 
If we assume that all men are alike and that all of them would benefit 
from a general improvement in the health of the third world, then it is 
possible perhaps to express some wishes concerning practical 
recommendations that could be addressed to the EEC to favour know-how 
transfer in the area of new biotechnologies. 
 Creation of permanent bilateral structures between EEC and the 
equivalent regional inter-governmental organizations, for the 
study, regulation, financial support and control of technological 
transfer projects. 
 Developing and amplifying the already existing programmes of 
scientific co-operation between third world and European 
laboratories. Give priority to institutions of the third world directly 
involved in research in health sciences to allow them to elaborate 
new adapted techniques and products. 
 Developing programmes of scientific and technological training for 
third world students giving preference to projects conducted in local 
laboratories and institutions. The organization of permanent 
summer schools with a minimum of permanent administration and 
the participation of relevant European technicians and scientists 
would be a welcome formula. 
 Elaborate programmes to drain the surplus of trained people in 
Europe to work for periods of one to a few years in laboratories of 
the third world with financial support from the EEC or international 
agencies. In this respect, a welcome initiative would be to stimulate 
well-trained young Europeans, during their military service, to go to 
work in third world laboratories. 
All these and other possible initiatives might be developed in co-
ordination with WHO and their regional agencies. A dose interaction with 
parallel projects related to agriculture would certainly increase their impact. 
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CONCLUSIONS AND ANALYSIS 
Bernardo Sorj 
The three days of discussion confirmed the importance of 
biotechnology for Latin America not only in such fields as tropical 
medicine and nutrition which are vital to basic welfare, but also in areas 
directly contributing to economic growth and development. 
Biotechnology has a role to play in strengthening Latin America’s 
growth prospects and trade performance by: 
 improving crop yields; 
 favouring import substitution in agriculture and industry; 
 extending the pharmaceutical industry into new areas; 
 and, perhaps above all, capturing the creativeness and 
entrepreneurship of Latin America’s smaller technology-based firms. 
If these hopes are realised biotechnology will feed into structural 
adjustment efforts and so contribute to relaunching growth, and overcoming 
the debt problem. 
But these hopes will not be realised overnight: 
 there is a shortage of scientists able to place the necessary expertise 
at the service of Latin American industry; 
 research institutes and universities cannot keep pace with the 
demand; 
 information concerning available technologies which could be 
adapted to the needs of Latin American industry and agriculture is 
lacking; 
 smaller firms possessing such technologies in Europe and else-
where may, because of their size, lack the means to establish 
contacts with counter-part firms in Latin America. 
This situation poses a challenge to research institutes, industry, 
governments, regional organisations in Latin America and to the European 
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Community. SOBELA was an impressive demonstration of the will of all 
parties concerned to meet this challenge. 
Where do we go from here, now that a certain number of contacts 
have been made? What can Europe and Latin America do, working together 
as partners, to further co-operation in the field of biotechnology? How in 
particular can the Community, by virtue of its own experience in promoting 
cross-national research on biotechnology and more generally of economic 
co-operation help assure a follow-up which is worthy of the many valuable 
interventions made at the seminar? 
There are at least three fields which call for immediate action: 
A. Information. The improvement of the two-way flow of information 
between Europe and Latin America on new developments in 
biotechnology: the Commission is ready to explore possibilities for 
improving data bases, facilitating exchanges between research 
institutes, organising specialised seminars and conferences to 
ensure that researchers in our two continents are informed of each 
others efforts, within the normal constraints imposed by 
commercial considerations; 
B. Training. Latin America is producing an increasing number of 
scientists but their number falls short of that required by the rapid 
growth of biotechnology. 
The Community and its Member States can help overcome this 
problem by: 
 making available experts to work with Latin American research 
institutes and biotechnology-based enterprises; 
 arranging traineeships for Latin American scientists with 
Community firms and research institutes; 
 providing assistance for Latin American biologists to pursue 
advanced studies in Europe; 
 improving information on training possibilities throughout the 
Community. 
C. Industrial Co-operation. These three days’ discussion have shown 
that both sides have an interest in joint ventures and other forms of 
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collaboration between firms and research institutes on either side 
of the Atlantic. Such arrangements are among the most effective 
instruments for technology transfer. 
The Commission has recently proposed to the Council that hence-
forth the Community should do more to promote industrial co-operation 
with enterprises in our partner countries in Latin America and elsewhere in 
the developing world. 
We will examine together in the coming months how best these ideas 
can be applied to the field of biotechnology. 
You can rest assured that the European Commission will do whatever 
is within its power to support those efforts which you, who are dose to the 
reality of industry and research, decide jointly to undertake. 
Together we will examine the kind of instruments by which we could 
develop and implement joint initiatives in the fields covered by this seminar. 
For us this seminar has served as a valuable learning experience, an 
example of the kind of initiative which can help bring researchers and 
industrialists in Europe and Latin America closer together. 
The many suggestions put forward will help us to develop new forms 
of co-operation not only in biotechnology but also in other advanced fields 
where Europe and Latin America can learn from each others’ experience. 
SOBELA Analysis 
Advanced technologies pose new challenges for developing countries 
and their relationships with the developed world. How can high technology 
be integrated into a development strategy? What is the best basis for co-
operation between Europe and Latin America in the context of a global 
market challenged by Japan and the USA? 
It is the belief of the Editors that the SOBELA seminar and this volume 
provide some valuable indications of how the preceding questions might be 
addressed. 
SOBELA was organised in two parts: the meeting itself and a number 
of satellite visits to European countries by members of the Latin American 
delegations. Proposals for possible co- operation were evaluated by a 
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questionnaire distributed to Latin American delegates both before and after 
SOBELA. The following table shows the level of response. 
Table 1. Questionnaire replies. 
Country Delegates Replies Percentage 
Andean Pact 9 (11)* 4 45 
Argentina 10 6 60 
Brazil 17 (26)* 11 65 
Mexico 5 3 60 
Totals 41 (52)* 24 59 
* The number in parentheses includes journalists and governmental representatives, not 
directly involved in biotechnology. 
The number of co-operation proposals advanced by each delegation 
attests to a broadly similar level of interest. If numbers are extrapolated to 
include all delegates from Latin America some 200 proposals for co-
operation may have been initiated. 
Table 2. Co-operation proposals by delegation. 
Country Total Extrapolated total* Average proposals per delegate 
Andean Pact 28 58 6.4 
Argentina 23 38 3.8 
Brazil 36 56 3.3 
Mexico 10 17 3.4 
Totals 97 169 4.1 
*extrapolation to 100% rate of reply for each delegation. 
The following table summarizes proposals on a country by country 
basis. 
Table 3. Co-operation proposals, synopsis. 
Countries B F GR NL IRL I P E GB D LA Total 
Andean Pact 6 4 – 2 1 4 – 2 1 5 2 27 
Argentina 6 7 – 1 – – – 1 7 2 – 24 
Brazil 12 11 1 7 – – 2 1 1 2 – 36 
Mexico 2 – 1 2 – – – 2 1 1 1 10 
Totals 26 22 2 12 1 4 2 6 10 10 3 98 
The above figures reflect the special efforts made by Belgium, France 
and the Netherlands who organised visits within their countries for 
members of the Latin American delegations. Although the United Kingdom 
did not host any visits it is notable that a strong tradition of co-operation 
served as the basis for a number of proposals. 
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Table 4. A sectorial analysis of replies. 
Countries Health Agro Energy Others* Total 
Andean Pact 8 6 – 13 27 
Argentina 10 4 – 10 24 
Brazil 4 24 1 7 37 
Mexico 1 4 – 5 10 
Totals 23 38 1 35 38 
* Refers essentially to training programmes in relevant fields. 
There is a clear division of interest among the Latin American states, 
with Argentina and the Andean Pact focusing on Health Care and Brazil 
and Mexico focusing on Agriculture. Almost half of the proposals related to 
agriculture and a quarter to health care. 
The type of European institution interested in co-operation with Latin 
America is indicated in the following table. 
Table 5. European Institutions interested in proposals. 
Countries Private Public Total 
Andean Pact 3 24 27 
Argentina 11 13 24 
Brazil 21 16 37 
Mexico 4 6 10 
Totals 39 59 98 
Overall there was a balance between private and public sector 
proposals for co-operation. The Brazilian delegation, which included a 
significant number of entrepreneurs showed the greatest tendency to private 
industrial co-operation. 
It is still unclear how many of these early overtures of interest will 
ultimately become manifest as contractual agreements. This will depend in 
some measure on the active involvement of states and individuals in 
initiatives discussed in the concluding remarks. 
A most important consequence of SOBELA was the stimulation of an 
identity amongst those Latin American institutions involved in 
biotechnology. Strong institutions, both public and private, are of 
fundamental importance in promoting and sustaining European/ Latin 
American co-operation. It is important to note that the timing of SOBELA in 
April 1987 was critical, coming just as Latin American countries were 
taking the first steps in the establishment of private and governmental 
enterprises in the field of biotechnology. Brazil had just launched the 
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Association of Biotechnology Enterprises (ABRABI). The National 
Secretariat of Biotechnology of the Ministry of Science and Technology, in 
its second year, was defining its programme of activity. Argentina, with a 
lesser degree of institutionalisation, had a government body responsible for 
promoting biotechnology, and a forum for encouraging the interaction of 
entrepreneurs. Mexico has long had government sponsored activities in 
biotechnology, but no private industrial sector of note. The Andean Pact 
countries are only now formulating their biotechnology programme. 
The first important, and unforeseen, role of SOBELA was to crystallise 
the institutionalisation of Latin American biotechnology. The seminar 
functioned both as a Latin America/Europe meeting and as a rare Latin 
American forum, where representatives from the differing Latin American 
states were together able to discuss strategy. Thus SOBELA stimulated not 
only inter-continental co-operation, but also intra-continental co-operation. 
The massive Brazilian delegation probably had a stimulating effect on the 
other Latin American delegates, especially in the sense of emulating the 
Brazilian association of enterprises with its large private sector representation. 
SOBELA fulfilled a second role in indicating a ‘modus operandi’ for 
European/Latin American co-operation that may surmount many of the 
problems encountered in such international co-operative ventures. The 
inclusion of representatives from government, industry and research 
institutions allowed the different influences to counterbalance and 
complement each other. Too often there is a tendency for policy makers to be 
rhetorical, entrepreneurs narrow minded and academics unrealistic. In Latin 
America, political instability and sometimes ideological pressures, can 
increase those tendencies. It is fundamental that all sectors work together to 
ensure the continuity and efficacity of international co-operation. 
As an exercise in awareness SOBELA filled a third role, allowing 
Latin American and European delegates to evaluate the advantages of co-
operation. Latin American delegates were most enthusiastic as exemplified 
by the following comments: 
 ‘We felt that Europe is capable of confronting America and Japan 
at the scientific and technological level’ 




 ‘European-Latin American relations should be based on a fair 
exchange by which the first receive technology, and the second an 
important consumer market’ 
 ‘The formation of human resources is a central interest for Latin 
America and a precondition for the effective absorption of 
European technology’ 
 ‘We need to create direct links between European and Latin 
American entrepreneurs’ 
 ‘We need greater selectivity in the field of industrial co-operation, 
taking into consideration existing infrastructure, markets, 
technical capacity and patent laws’ 
 ‘We need to study the mechanisms by which Europe increases the 
links between enterprises and universities’ 
 ‘We need to consolidate realistically our national programmes of 
biotechnology in order to make clearer what we need and have 
to offer’ 
 ‘We need to discuss negotiation models capable of satisfying the 
expectations of both sides’ 
 ‘We discovered that Europe has technologies that will find their 
ideal application in Latin America’ 
 ‘European documents related to legal problems, regulation and 
promotion of biotechnology should be diffused and a workshop 
organised on specific topics of common interest’ 
 ‘I was impressed by the diversity of interest and idiosyncrasies of 
the various European countries, and at the same time by their 
conviviality within a common framework’ 
 ‘SOBELA was important for us (Andean Pact) because we are in a 
stage of definition of our national programme and priorities’ 
 ‘The interpersonal relations established during SOBELA will be 
central to our future co-operation with Europe. SOBELA expressed 
the will of the Commission to increase links with Latin America. 
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These efforts should have continuity through open communication 
channels, and the realisation of new meetings’ 
The Challenges 
The quality and quantity of contacts that were established between 
Latin American and European biotechnology entrepreneurs, and the facility 
with which they were set up indicate that the biotechnology sector is 
particularly well placed for the development of economic co-operation 
between the two continents, especially between small and medium scale 
enterprises (SMEs). The reasons for this lie in the special nature of 
biotechnology based SMEs. Relatively small amounts of capital are needed to 
launch a joint venture operation, and importantly company directors often 
have an academic back-ground with international languages and experience. 
In a sector where industrial and academic skills are highly integrated 
it is possible to exploit the well established international programmes in 
scientific training and research to the benefit of science based commercial 
development. SOBELA raised the prospect of using biotechnology as a tool 
for promoting international co-operation. Many problems still exist and will 
need to be resolved if effective inter-continental partnerships are to be 
effected. It will be critical that in such relationships a fair exchange is 
effected: for European firms, a reasonable return on investment and 
presence in a developing world market, and for Latin American countries 
and organisations, the production of essential goods within the framework 
of a favourable technology transfer and co-operation environment. 
In order to advance the interests of both sides further exchange and 
experience is required. The controversial topic of patent legislation must be 
confronted. This topic is a subject of debate in Latin America, and indeed 
the world press. The USA has recently adopted a most hostile stance towards 
Latin American latitude on the patents issue. Internal debate is moving 
towards a consolidation of opinion and in some states, Mexico for example, 
legislation is being enacted to give full patent protection to pharmaceuticals 
and food products. Europe should seek active participation in these 
discussions, at European Commission, national governmental and industrial 
levels, thus shaping Latin American positions for the future. This will not 
be achieved by confrontation and polarisation, but by exchanges of opinion 
and political concertation. 
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Europe’s presence in Latin America is mediated predominantly by 
large companies. There is however much scope for the active participation 
of European SMEs, which are usually more open to the technology transfer 
schemes expected by Latin American countries. 
Increasing co-operation between European and Latin American SMEs 
is a difficult objective to realise, not least because of limited information, 
provincial attitudes, and simple ignorance of the scope of possibilities for 
international co-operation. On the basis of arguments presented in drafts of 
this volume the European Commission will explore ways to make available 
the information, interface operational units and concertation activities needed 
to transform the spirit of SOBELA into a permanent and expanding reality. 
SOBELA was not simply a seminar on biotechnology in Europe and 
Latin America held in April 1987. It is an ongoing activity, in which Europe 
is demonstrating its capacity to be the active partner and focal point for the 
constant effort needed to turn around the economies of developing countries 
through the medium of high technology. 
